[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 33693
1. Andrle J, Schartinger VH, Schwentner I, Deibl M, Sprinzl GM: Initial staging examinations for head and neck squamous cell carcinoma: are they appropriate? J Laryngol Otol; 2009 Aug;123(8):885-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial staging examinations for head and neck squamous cell carcinoma: are they appropriate?
  • OBJECTIVES: The presence of distant metastases affects the therapeutic regime in patients with head and neck squamous cell carcinoma.
  • This study evaluated the necessity to undertake bone scanning, chest computed tomography and abdominal ultrasonography in patients presenting with primary advanced head and neck squamous cell carcinoma.
  • METHODS: One hundred and sixty-three patients with head and neck squamous cell carcinoma who were scheduled for major surgery underwent screening for distant metastases.
  • CONCLUSIONS: Computed tomography of the thorax is the most important technique for screening patients with head and neck squamous cell carcinoma.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Squamous Cell / secondary. Head and Neck Neoplasms. Lung Neoplasms / secondary. Neoplasms, Second Primary / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone and Bones / radionuclide imaging. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Retrospective Studies. Tomography, X-Ray Computed / methods


2. Xiao YJ, Zheng SB, Tan WL, Chen T, Qi H, Shao ZQ, Jiang YD, Wu P, Zhang HJ: [Nephron-sparing surgery for small renal cell carcinoma: clinical analysis of 21 cases]. Di Yi Jun Yi Da Xue Xue Bao; 2005 Mar;25(3):357-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nephron-sparing surgery for small renal cell carcinoma: clinical analysis of 21 cases].
  • OBJECTIVE: To evaluate the clinical effects of nephron-sparing surgery in patients with early-stage small renal cell carcinoma.
  • METHODS: Nephron-sparing surgery was performed in 21 patients with renal cell carcinoma including 1 with solitary kidney, 3 with unilateral tumor and contralateral renal compromise, and 17 with unilateral tumor and normal contralateral kidney.
  • CONCLUSION: As a safe and effective therapy for early-stage small renal cell carcinoma, nephron-sparing surgery can be considered as the gold-standard therapy for patients with lesions less than 4 cm in T(1) and T(2) stages of localized unilateral tumor with normal contralateral kidney.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Nephrectomy / methods
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15772014.001).
  • [ISSN] 1000-2588
  • [Journal-full-title] Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA
  • [ISO-abbreviation] Di Yi Jun Yi Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


3. Soumier A, Banasr M, Kerkerian-Le Goff L, Daszuta A: Region- and phase-dependent effects of 5-HT(1A) and 5-HT(2C) receptor activation on adult neurogenesis. Eur Neuropsychopharmacol; 2010 May;20(5):336-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Region- and phase-dependent effects of 5-HT(1A) and 5-HT(2C) receptor activation on adult neurogenesis.
  • Adult neurogenesis and serotoninergic transmission are associated to mood disorders and their treatments.
  • The present study focused on the effects of chronic activation of 5-HT(1A) and 5-HT(2C) receptors on newborn cell survival in the dentate gyrus (DG) and olfactory bulb (OB), and examined whether potential neurogenic zones as the prefrontal cortex (PFC) and striatum (ST) are reactive to these treatments.
  • Both 8-OH-DPAT and RO600,175 increase neurogenesis in the OB, but only 8-OH-DPAT affected cell survival, inducing a parallel decrease in the number of BrdU cells in the OB and increase in the SVZ, which suggests an impaired migration.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier B.V. and ECNP. All rights reserved.
  • (PMID = 20022222.001).
  • [ISSN] 0924-977X
  • [Journal-full-title] European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
  • [ISO-abbreviation] Eur Neuropsychopharmacol
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Receptor, Serotonin, 5-HT2C; 0 / Serotonin Receptor Agonists; 112692-38-3 / Receptor, Serotonin, 5-HT1A; 78950-78-4 / 8-Hydroxy-2-(di-n-propylamino)tetralin
  •  go-up   go-down


Advertisement
4. Looi A, Gascoyne RD, Chhanabhai M, Connors JM, Rootman J, White VA: Mantle cell lymphoma in the ocular adnexal region. Ophthalmology; 2005 Jan;112(1):114-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mantle cell lymphoma in the ocular adnexal region.
  • PURPOSE: To study the clinicopathologic features of mantle cell lymphoma (MCL) in the ocular adnexal region.
  • Three cases were CD5-negative, and 2 other cases showed composite histologic findings (MCL and follicular lymphoma and MCL and a plasma cell neoplasm).
  • CONCLUSIONS: Mantle cell lymphoma presenting in the ocular adnexal region has a male predominance and tends to affect an elderly age group, as is typical of MCL involving nodal sites.
  • Mantle cell lymphoma presenting in the ocular adnexal region is associated with advanced-stage disease and short PFS but an OS similar to MCL at other sites.
  • [MeSH-major] Eye Neoplasms / pathology. Eyelid Neoplasms / pathology. Lacrimal Apparatus Diseases / pathology. Lymphoma, Mantle-Cell / pathology. Orbital Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Combined Modality Therapy. Cyclin D1 / metabolism. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Retrospective Studies. Survival Rate. Tumor Suppressor Protein p53 / metabolism


5. Li W, Deng F, Wang H, Zhen Y, Xiang F, Sui Y, Li J: Germ cell-less expression in zebrafish embryos. Dev Growth Differ; 2006 Jun;48(5):333-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germ cell-less expression in zebrafish embryos.
  • The gene of germ cell-less (gcl) has been shown to be important in early differentiation of germ cells in Drosophila.
  • In this research, real-time quantitative reverse transcription-polymerase chain reaction showed that the level of gcl mRNA expression rapidly decreases from the 4-cell stage to the sphere stage at which it reaches a minimum, gradually increases from the 50%-epiboly stage, and then remains stable during the posterior stages.
  • Results of in situ hybridization indicated that the transcripts of zebrafish gcl are evenly distributed in all blastomeres from the 2-cell stage to the blastula period, different from that of vasa, nonas1 and dead end mRNA, and condense into some clusters of cells located along the blastoderm margin from the gastrulation period.
  • In the adult, gcl mRNA was widely expressed in developing germ cells of both ovary and testis.
  • [MeSH-minor] Animals. Cell Lineage. Cleavage Stage, Ovum. DEAD-box RNA Helicases. Embryo, Nonmammalian / physiology. Embryonic Development. Female. In Situ Hybridization. Male. Ovary / embryology. RNA Helicases / genetics. RNA Stability. Reverse Transcriptase Polymerase Chain Reaction. Testis / embryology. Zebrafish Proteins / genetics

  • ZFIN. ZFIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16759283.001).
  • [ISSN] 0012-1592
  • [Journal-full-title] Development, growth & differentiation
  • [ISO-abbreviation] Dev. Growth Differ.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Zebrafish Proteins; EC 3.6.1.- / vasa protein, zebrafish; EC 3.6.4.13 / DEAD-box RNA Helicases; EC 3.6.4.13 / RNA Helicases
  •  go-up   go-down


6. Hu GX, Lin H, Chen GR, Chen BB, Lian QQ, Hardy DO, Zirkin BR, Ge RS: Deletion of the Igf1 gene: suppressive effects on adult Leydig cell development. J Androl; 2010 Jul-Aug;31(4):379-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deletion of the Igf1 gene: suppressive effects on adult Leydig cell development.
  • In the current study, we asked whether deletion of the Igf1 gene affects the number, proliferation, and/or steroidogenic function of some or all of the precursor cell types in the developmental sequence that leads to the establishment of adult Leydig cells (ALCs).
  • Decreased numbers of cells in the Leydig cell lineage (ie, 3β-hydroxysteroid dehydrogenase-positive cells) were seen in testes of postnatal day (PND) 14-90 Igf1(-/-) mice compared with age-matched Igf1(+/+) controls.
  • The increased expression of the gene for 5α-reductase (Srd5a1) in adult Igf1(-/-) testes suggests that the depletion of Igf1 might suppress or delay Leydig cell maturation.
  • These observations, taken together, indicate that the reduced numbers of Leydig cells in the adult testes of Igf1(-/-) mice result at least in part from altered proliferation and differentiation of ALC precursor cells, but not of the stem cells that give rise to these cells.
  • [MeSH-minor] Animals. Cell Differentiation. Cell Proliferation. Male. Mice. Mice, Knockout

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2000 May 29;149(5):1019-26 [10831606.001]
  • [Cites] J Endocrinol. 2007 Sep;194(3):557-68 [17761895.001]
  • [Cites] Endocrinology. 2003 Nov;144(11):5058-64 [12959969.001]
  • [Cites] Biol Reprod. 2004 Mar;70(3):632-9 [14585811.001]
  • [Cites] Invest Urol. 1981 Nov;19(3):142-7 [6170603.001]
  • [Cites] Acta Endocrinol (Copenh). 1985 Aug;109(4):543-9 [2994333.001]
  • [Cites] Biochem Biophys Res Commun. 1986 Jun 30;137(3):950-6 [3488061.001]
  • [Cites] Endocrinology. 1986 Oct;119(4):1641-7 [2944738.001]
  • [Cites] Fertil Steril. 1988 Apr;49(4):666-9 [2965033.001]
  • [Cites] Endocrinology. 1988 Jul;123(1):134-9 [2968236.001]
  • [Cites] Endocrinology. 1989 Feb;124(2):762-70 [2912699.001]
  • [Cites] J Endocrinol. 1989 Jan;120(1):97-106 [2493065.001]
  • [Cites] Mol Cell Endocrinol. 1990 Feb 12;69(1):79-89 [2157618.001]
  • [Cites] Endocrinology. 1991 Dec;129(6):2820-6 [1659515.001]
  • [Cites] Biol Reprod. 1992 Mar;46(3):335-41 [1617007.001]
  • [Cites] Arch Int Physiol Biochim Biophys. 1992 Sep-Oct;100(5):303-8 [1282380.001]
  • [Cites] Mol Endocrinol. 1996 Jul;10(7):903-18 [8813730.001]
  • [Cites] Endocrinology. 1997 Sep;138(9):3719-26 [9275057.001]
  • [Cites] Endocrinology. 1998 Sep;139(9):3787-95 [9724031.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2719-24 [16467141.001]
  • [Cites] Endocrinology. 2007 Jan;148(1):128-39 [17023532.001]
  • [Cites] J Androl. 2007 Jul-Aug;28(4):513-20 [17287459.001]
  • [Cites] Biol Reprod. 2000 Dec;63(6):1825-38 [11090455.001]
  • (PMID = 20203337.001).
  • [ISSN] 1939-4640
  • [Journal-full-title] Journal of andrology
  • [ISO-abbreviation] J. Androl.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD050570; United States / NIA NIH HHS / AG / AG030598; United States / NIA NIH HHS / AG / R37 AG021092; United States / NIA NIH HHS / AG / R01 AG021092; United States / NICHD NIH HHS / HD / R01 HD050570-03; United States / NIA NIH HHS / AG / R01 AG030598; United States / NIA NIH HHS / AG / R01 AG030598-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / insulin-like growth factor-1, mouse; 67763-96-6 / Insulin-Like Growth Factor I
  • [Other-IDs] NLM/ NIHMS599856; NLM/ PMC4103413
  •  go-up   go-down


7. Puente LG, Borris DJ, Carrière JF, Kelly JF, Megeney LA: Identification of candidate regulators of embryonic stem cell differentiation by comparative phosphoprotein affinity profiling. Mol Cell Proteomics; 2006 Jan;5(1):57-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of candidate regulators of embryonic stem cell differentiation by comparative phosphoprotein affinity profiling.
  • Embryonic stem cells are a unique cell population capable both of self-renewal and of differentiation into all tissues in the adult organism.
  • Embryonic stem cell growth and differentiation correlates with kinase activities, but with the exception of the JAK/STAT3 pathway, the relevant substrates are unknown.
  • To identify candidate phosphoproteins with potential relevance to embryonic stem cell differentiation, a systems biology approach was used.
  • This set of candidate phosphoprotein regulators of stem cell differentiation includes products of genes previously noted to be enriched in embryonic stem cells at the mRNA expression level as well as proteins not associated previously with stem cell differentiation status.
  • [MeSH-major] Cell Differentiation. Embryo, Mammalian / cytology. Embryo, Mammalian / metabolism. Gene Expression Profiling. Phosphoproteins / metabolism. Stem Cells / metabolism

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16188873.001).
  • [ISSN] 1535-9476
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Phosphoproteins; 0 / Proteome
  •  go-up   go-down


8. Turin I, Pedrazzoli P, Tullio C, Montini E, La Grotteria MC, Schiavo R, Perotti C, Locatelli F, Carretto E, Maccario R, Siena S, Montagna D: GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia. Cytotherapy; 2007;9(5):499-507
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
  • BACKGROUND: The adoptive transfer of ex vivo-induced tumor-specific T-cell lines provides a promising approach for cancer immunotherapy.
  • We have demonstrated previously the feasibility of inducing in vitro long-term anti-tumor cytotoxic T-cell (CTL) lines directed against different types of solid tumors derived from both autologous and allogeneic PBMC.
  • METHODS: Four patients with advanced solid tumors (two sarcoma, one renal cell cancer and one ovarian cancer), who had received several lines of anticancer therapy, were enrolled.
  • [MeSH-minor] Adult. Antigens, CD8 / immunology. Cell Culture Techniques / methods. Cell Culture Techniques / standards. Cell Line. Cell Proliferation. Cytotoxicity Tests, Immunologic. HLA Antigens / immunology. Humans. Immunophenotyping. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17786611.001).
  • [ISSN] 1465-3249
  • [Journal-full-title] Cytotherapy
  • [ISO-abbreviation] Cytotherapy
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD8; 0 / HLA Antigens
  •  go-up   go-down


9. Daridon C, Pers JO, Devauchelle V, Martins-Carvalho C, Hutin P, Pennec YL, Saraux A, Youinou P: Identification of transitional type II B cells in the salivary glands of patients with Sjögren's syndrome. Arthritis Rheum; 2006 Jul;54(7):2280-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To identify B cell subpopulations participating in the lymphocyte infiltrate of salivary glands from patients with primary Sjögren's syndrome.
  • The results obtained in tissue sections were confirmed by fluorescence-activated cell sorting analysis of B cells eluted from salivary glands, and these findings were compared with those in tonsils.
  • [MeSH-minor] Adult. Aged. Antigens, CD20 / immunology. Antigens, CD27 / immunology. Autoantibodies. B-Cell Activating Factor. B-Cell Activation Factor Receptor. Female. Germinal Center / immunology. Germinal Center / pathology. Humans. Lymphocyte Activation / immunology. Male. Membrane Proteins / metabolism. Middle Aged. Palatine Tonsil / pathology. Phenotype. Receptors, Tumor Necrosis Factor / metabolism. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Sjogren's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arthritis Rheum. 2007 Mar;56(3):1035-6 [17330259.001]
  • (PMID = 16802367.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD27; 0 / Autoantibodies; 0 / B-Cell Activating Factor; 0 / B-Cell Activation Factor Receptor; 0 / Membrane Proteins; 0 / Receptors, Tumor Necrosis Factor; 0 / TNFRSF13C protein, human; 0 / TNFSF13B protein, human; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


10. Burmeister T, Meyer C, Schwartz S, Hofmann J, Molkentin M, Kowarz E, Schneider B, Raff T, Reinhardt R, Gökbuget N, Hoelzer D, Thiel E, Marschalek R: The MLL recombinome of adult CD10-negative B-cell precursor acute lymphoblastic leukemia: results from the GMALL study group. Blood; 2009 Apr 23;113(17):4011-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The MLL recombinome of adult CD10-negative B-cell precursor acute lymphoblastic leukemia: results from the GMALL study group.
  • MLL translocations in adult B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) are largely restricted to the immature CD10(-) immunophenotypes.
  • MLL-AF4 is known to be the most frequent fusion transcript, but the exact frequencies of MLL aberrations in CD10(-) adult BCP-ALL are unknown.
  • We present a genetic characterization of 184 BCR-ABL(-) CD10(-) adult ALL cases (156 cyIg(-), 28 cyIg(+)) diagnosed between 2001 and 2007 at the central diagnostic laboratory of the GMALL study group.
  • [MeSH-major] Myeloid-Lymphoid Leukemia Protein / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Recombinant Fusion Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chromosomes, Human / genetics. Female. Histone-Lysine N-Methyltransferase. Humans. Male. Middle Aged. Neprilysin / metabolism. Societies, Medical

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19144982.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00198991/ NCT00199056
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 0 / Recombinant Fusion Proteins; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


11. Wu Q, Ma Q, Shehadeh LA, Wilson A, Xia L, Yu H, Webster KA: Expression of the Argonaute protein PiwiL2 and piRNAs in adult mouse mesenchymal stem cells. Biochem Biophys Res Commun; 2010 Jun 11;396(4):915-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the Argonaute protein PiwiL2 and piRNAs in adult mouse mesenchymal stem cells.
  • Piwi (P-element-induced wimpy testis) first discovered in Drosophila is a member of the Argonaute family of micro-RNA binding proteins with essential roles in germ-cell development.
  • Here, we report that PiwiL2 and associated piRNAs (piRs) may play similar roles in adult mouse mesenchymal stem cells.
  • We found that PiwiL2 is expressed in the cytoplasm of metaphase mesenchymal stem cells from the bone marrow of adult and aged mice.
  • Knockdown of PiwiL2 with a specific siRNA enhanced cell proliferation, significantly increased the number of cells in G1/S and G2/M cell cycle phases and was associated with increased expression of cell cycle genes CCND1, CDK8, microtubule regulation genes, and decreased expression of tumor suppressors Cables 1, LATS, and Cxxc4.
  • The results suggest broader roles for Piwi in genome surveillance beyond the germ line and a possible role in regulating the cell cycle of mesenchymal stem cells.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier Inc. All rights reserved.
  • [Cites] Curr Biol. 2007 Apr 3;17(7):637-42 [17363252.001]
  • [Cites] BMC Genomics. 2010;11:229 [20374652.001]
  • [Cites] Mol Cell. 2007 Jun 8;26(5):603-9 [17560367.001]
  • [Cites] Mol Cell. 2007 Jun 8;26(5):611-23 [17560368.001]
  • [Cites] J Clin Pathol. 2008 Feb;61(2):164-71 [17468295.001]
  • [Cites] Cancer Biol Ther. 2008 Feb;7(2):180-88 [18059193.001]
  • [Cites] Oncogene. 2009 Jan 15;28(2):297-305 [18931698.001]
  • [Cites] J Biol Chem. 2009 Mar 6;284(10):6507-19 [19114715.001]
  • [Cites] Annu Rev Cell Dev Biol. 2009;25:355-76 [19575643.001]
  • [Cites] Curr Biol. 2009 Nov 3;19(20):1712-7 [19818619.001]
  • [Cites] Oncogene. 2009 Dec 17;28(50):4469-79 [19855428.001]
  • [Cites] Biochem Soc Trans. 2010 Feb;38(Pt 1):217-22 [20074063.001]
  • [Cites] Expert Opin Biol Ther. 2010 Feb;10(2):215-30 [20088716.001]
  • [Cites] Mol Cells. 2009 Dec 31;28(6):521-7 [19937137.001]
  • [Cites] J Cell Biochem. 2010 Feb 1;109(2):277-82 [19950205.001]
  • [Cites] Blood. 2001 Jan 15;97(2):426-34 [11154219.001]
  • [Cites] Science. 2001 Aug 10;293(5532):1146-50 [11498593.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7325-32 [11585773.001]
  • [Cites] Science. 2001 Oct 26;294(5543):862-4 [11679672.001]
  • [Cites] Oncogene. 2002 Jun 6;21(25):3988-99 [12037681.001]
  • [Cites] Dev Cell. 2002 Jun;2(6):819-30 [12062093.001]
  • [Cites] Cell. 2002 Sep 6;110(5):563-74 [12230974.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12825-30 [12226479.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):202-8 [14729625.001]
  • [Cites] Development. 2004 Feb;131(4):839-49 [14736746.001]
  • [Cites] Cell. 2004 Jan 23;116(2 Suppl):S89-92, 1 p following S96 [15055592.001]
  • [Cites] Cell. 2004 Jul 9;118(1):57-68 [15242644.001]
  • [Cites] Nature. 2004 Sep 16;431(7006):343-9 [15372041.001]
  • [Cites] Nature. 2004 Sep 16;431(7006):350-5 [15372042.001]
  • [Cites] Cancer Biol Ther. 2005 Jan;4(1):103-7 [15662117.001]
  • [Cites] Hum Mol Genet. 2006 Jan 15;15(2):201-11 [16377660.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1922-9 [16287078.001]
  • [Cites] J Cell Sci. 2006 Jun 1;119(Pt 11):2204-13 [16684817.001]
  • [Cites] Dev Cell. 2007 Jan;12(1):45-55 [17199040.001]
  • [Cites] Dev Cell. 2007 Apr;12(4):503-14 [17395546.001]
  • (PMID = 20460113.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL044578-06A2; United States / NHLBI NIH HHS / HL / HL072924; United States / NHLBI NIH HHS / HL / HL44578; United States / NHLBI NIH HHS / HL / R01 HL072924; United States / NHLBI NIH HHS / HL / R01 HL044578; United States / NHLBI NIH HHS / HL / R01 HL072924-01; United States / NHLBI NIH HHS / HL / HL044578-06A2; United States / NHLBI NIH HHS / HL / HL072924-01; United States / NHLBI NIH HHS / HL / F32 HL083673
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Argonaute Proteins; 0 / Cables1 protein, mouse; 0 / Carrier Proteins; 0 / Ccnd1 protein, mouse; 0 / Cyclins; 0 / MicroRNAs; 0 / Phosphoproteins; 0 / Piwil2 protein, mouse; 0 / Proteins; 0 / RNA, Small Interfering; 0 / RNA-Binding Proteins; 136601-57-5 / Cyclin D1; EC 2.7.1.- / Lats1 protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.22 / Cdk8 protein, mouse; EC 2.7.11.22 / Cyclin-Dependent Kinase 8
  • [Other-IDs] NLM/ NIHMS210946; NLM/ PMC3151571
  •  go-up   go-down


12. Fuller CL, Yettaw HK, Byrd CA: Mitral cells in the olfactory bulb of adult zebrafish (Danio rerio): morphology and distribution. J Comp Neurol; 2006 Nov 10;499(2):218-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitral cells in the olfactory bulb of adult zebrafish (Danio rerio): morphology and distribution.
  • The mitral cell is the primary output neuron and central relay in the olfactory bulb of vertebrates.
  • This study uses retrograde tract tracing and other techniques to characterize the morphology and distribution of mitral cells in the olfactory bulb of adult zebrafish, Danio rerio.
  • These output neurons, located primarily in the glomerular layer and superficial internal cell layer, had variable-shaped somata that ranged in size from 4-18 microm in diameter and 31-96 microm2 in cross-sectional area.
  • The axons of these cells projected to either the medial or the lateral olfactory tract and, in general, the location of the cell on the medial or lateral side of the bulb was indicative of the tract to which it would project.
  • [MeSH-minor] Animals. Biotin / analogs & derivatives. Biotin / metabolism. Cell Count / methods. Cell Size. Dextrans / metabolism. FMRFamide / metabolism. Female. Functional Laterality. Immunohistochemistry / methods. Male. Models, Anatomic. Nerve Net / ultrastructure. Pyridinium Compounds / metabolism. Silver Staining / methods. Tyrosine 3-Monooxygenase / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BIOTIN .
  • SciCrunch. The Antibody Registry: Reagent: Antibodies .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • (PMID = 16977629.001).
  • [ISSN] 0021-9967
  • [Journal-full-title] The Journal of comparative neurology
  • [ISO-abbreviation] J. Comp. Neurol.
  • [Language] eng
  • [Grant] United States / PHS HHS / / NIDCD 04262
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pyridinium Compounds; 0 / biotinylated dextran amine; 114041-00-8 / 4-(4-dihexadecylaminostyryl)-N-methylpyridium; 64190-70-1 / FMRFamide; 6SO6U10H04 / Biotin; EC 1.14.16.2 / Tyrosine 3-Monooxygenase; K3R6ZDH4DU / Dextrans
  •  go-up   go-down


13. Alhamdan NA, Almazrou YY, Alswaidi FM, Choudhry AJ: Premarital screening for thalassemia and sickle cell disease in Saudi Arabia. Genet Med; 2007 Jun;9(6):372-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Premarital screening for thalassemia and sickle cell disease in Saudi Arabia.
  • PURPOSE: To estimate the prevalence of sickle cell disorders and beta thalassemia, with their regional distribution, in the adult population screened as part of the Saudi Premarital Screening Program.
  • RESULTS: Of a total of 488,315 individuals screened, 4.20% had sickle cell trait, 0.26% had sickle cell disease, 3.22% had thalassemia trait, and 0.07% had thalassemia disease.
  • [MeSH-major] Anemia, Sickle Cell / genetics. Genetic Testing. Premarital Examinations. Thalassemia / genetics


14. Azad NS, Aziz AB, Pervez S, Kayani N: Uterine perivascular epithelioid cell tumour presenting as a cervical mass. J Pak Med Assoc; 2006 Feb;56(2):83-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine perivascular epithelioid cell tumour presenting as a cervical mass.
  • Perivascular Epithelioid Cell Tumour (PEComa) also known as myelomelanocytic tumours are uncommon, recently described mesenchymal tumours that include angiomyolipoma, clear cell "sugar" tumour of the lung, lymphangioleiomyoma and tumours composed predominantly of epithelioid cell morphology.
  • All of these were seen in adult females in the peri and post menopausal age group (from 40-75years), and almost all were located in the region of body of uterus.
  • Occurrence of this tumor in a young female as seen in our case warrants inclusion of PEComa in the diferential diagnosis of all epithelioid and clear cell neoplasms of uterus irrespective of age.
  • [MeSH-minor] Adult. Antigens, Neoplasm. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Melanoma-Specific Antigens. Neoplasm Proteins / metabolism. Perimenopause. Vimentin / metabolism


15. Patrick ML, Aimanova K, Sanders HR, Gill SS: P-type Na+/K+-ATPase and V-type H+-ATPase expression patterns in the osmoregulatory organs of larval and adult mosquito Aedes aegypti. J Exp Biol; 2006 Dec;209(Pt 23):4638-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P-type Na+/K+-ATPase and V-type H+-ATPase expression patterns in the osmoregulatory organs of larval and adult mosquito Aedes aegypti.
  • This study describes the expression patterns of P-type Na(+)/K(+)-ATPase and V-type H(+)-ATPase in the larval and adult forms of the mosquito Aedes aegypti and provides insight into their relative importance in ion transport function of key osmoregulatory organs.
  • The two ATPases switch membrane location along the length of the larval midgut, indicating three possible regionalizations, whereas the adult stomach has uniform expression of basolateral P-type Na(+)/K(+)-ATPase and apical V-type H(+)-ATPase in each cell.
  • In both larval and adult Malpighian tubules, the distal principal cells exhibit high expression levels of V-type H(+)-ATPase (apically and cytoplasmically) whereas P-type Na(+)/K(+)-ATPase is highly expressed in stellate cells found only in the distal two-thirds of each tubule.
  • These results suggest a functional segregation along the length of the Malpighian tubules based on cell type and region.
  • P-type Na(+)/K(+)-ATPase is the only pump apparent in the larval rectum whereas in the larval anal papillae and the adult hindgut (including the anterior hindgut and rectum with rectal pads), P-type Na(+)/K(+)-ATPase and V-type H(+)-ATPase localize to the basal and apical membranes, respectively.

  • MedlinePlus Health Information. consumer health - Fluid and Electrolyte Balance.
  • COS Scholar Universe. author profiles.
  • SciCrunch. The Antibody Registry: Reagent: Antibodies .
  • eagle-i research resources. PMID 17114398 (Special Collections) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17114398.001).
  • [ISSN] 0022-0949
  • [Journal-full-title] The Journal of experimental biology
  • [ISO-abbreviation] J. Exp. Biol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI032572; United States / NIAID NIH HHS / AI / R01 AI048049; United States / NIAID NIH HHS / AI / AI 32572; United States / NIAID NIH HHS / AI / AI 48049
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.6.3.14 / Proton-Translocating ATPases; EC 3.6.3.9 / Sodium-Potassium-Exchanging ATPase
  •  go-up   go-down


16. Mourouzis C, Pratt C, Brennan PA: Squamous cell carcinoma of the maxillary gingiva, alveolus, and hard palate: is there a need for elective neck dissection? Br J Oral Maxillofac Surg; 2010 Jul;48(5):345-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the maxillary gingiva, alveolus, and hard palate: is there a need for elective neck dissection?
  • We retrospectively studied 17 patients with squamous cell carcinoma (SCC) of the maxillary gingiva, alveolus, and hard palate who were treated over a 7-year period (2000-2007) to investigate whether selective neck dissection is justified at an early stage.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Gingival Neoplasms / surgery. Maxillary Neoplasms / surgery. Neck Dissection / utilization. Palatal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alveolar Process / pathology. Alveolar Process / surgery. Elective Surgical Procedures / utilization. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / prevention & control. Neoplasm Staging. Palate, Hard / pathology. Palate, Hard / surgery. Prognosis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19665264.001).
  • [ISSN] 1532-1940
  • [Journal-full-title] The British journal of oral & maxillofacial surgery
  • [ISO-abbreviation] Br J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


17. Yang CZ, Zhang HT, Wang GS, Zhou HQ, Ma C, Hu DH: [Mechanism underlying the inhibitory effects of peroxisome proliferator-activated receptor γ agonists on transforming growth factor β1 in adult skin fibroblasts]. Zhonghua Shao Shang Za Zhi; 2010 Dec;26(6):448-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mechanism underlying the inhibitory effects of peroxisome proliferator-activated receptor γ agonists on transforming growth factor β1 in adult skin fibroblasts].
  • METHODS: Fibroblasts isolated from healthy adult skin were cultured in vitro and divided into blank control group (serum-free DMEM culture), TGF-β(1) group (with stimulation of 10 ng/mL TGF-β(1) for 48 hours), troglitazone group (with the same treatment as in TGF-β(1) group after stimulation of 10 µmol/L troglitazone for 2 hours), and 15-dioxygen prostaglandin J2 (15d-PGJ2) group (with the same treatment as in TGF-β(1) group after stimulation of 10 µmol/L 15d-PGJ2 for 2 hours) according to the stimulation added into DMEM.
  • [MeSH-minor] Cell Line. Connective Tissue Growth Factor / metabolism. Humans. Matrix Metalloproteinase 1 / metabolism. Receptors, Platelet-Derived Growth Factor / metabolism. Signal Transduction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21223655.001).
  • [ISSN] 1009-2587
  • [Journal-full-title] Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns
  • [ISO-abbreviation] Zhonghua Shao Shang Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / PPAR gamma; 0 / TGFB1 protein, human; 0 / Transforming Growth Factor beta1; 139568-91-5 / Connective Tissue Growth Factor; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor; EC 3.4.24.7 / MMP1 protein, human; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


18. Wagner B, Burton A, Ainsworth D: Interferon-gamma, interleukin-4 and interleukin-10 production by T helper cells reveals intact Th1 and regulatory TR1 cell activation and a delay of the Th2 cell response in equine neonates and foals. Vet Res; 2010 Jul-Aug;41(4):47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon-gamma, interleukin-4 and interleukin-10 production by T helper cells reveals intact Th1 and regulatory TR1 cell activation and a delay of the Th2 cell response in equine neonates and foals.
  • Recent reports indicated that cytokine mRNA expression in foals is often quantitatively lower than that of adult horses suggesting that foal T cells are not fully mature.
  • Here, peripheral blood mononuclear cells from foals and adult horses were stimulated with phorbol 12-myristate 13-acetate and analyzed for intracellular interferon-gamma (IFN-gamma), interleukin-4 (IL-4) and IL-10 production, representing the Th1, Th2 and regulatory TR1 cell phenotypes respectively, by flow cytometry.
  • However, the balance between Th1 and Th2 cytokines (IFN-gamma/IL-4 ratio) showed a clear Th1-biased response in foals by 6 and 12 weeks of life, while similar IFN-gamma/IL-10 ratios were found in foals and adult horses.
  • The data suggested that equine neonates and young foals have an impaired Th2 response, that the immune response of foals is Th1 biased, that IFN-gamma production by Th and cytotoxic T cells is qualitatively similar to adult horses, and regulatory IL-10 production by T cells is developmentally mature in foals during the first three months of life.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) INRA, EDP Sciences, 2010.
  • [Cites] Blood. 2007 Apr 1;109(7):2921-7 [17132717.001]
  • [Cites] Clin Vaccine Immunol. 2007 Jun;14(6):669-77 [17409222.001]
  • [Cites] J Comp Pathol. 2007 Jul;137 Suppl 1:S27-31 [17548093.001]
  • [Cites] Nat Immunol. 2007 Sep;8(9):942-9 [17676045.001]
  • [Cites] Vaccine. 2007 Oct 23;25(43):7582-97 [17889970.001]
  • [Cites] Nat Immunol. 2008 Mar;9(3):310-8 [18300366.001]
  • [Cites] Vet Immunol Immunopathol. 2008 Mar 15;122(1-2):57-64 [18061278.001]
  • [Cites] Nat Rev Immunol. 2008 Jul;8(7):523-32 [18566595.001]
  • [Cites] Vet Immunol Immunopathol. 2009 Jan 15;127(1-2):167-73 [18976818.001]
  • [Cites] Vaccine. 2009 Jan 29;27(5):674-83 [19056444.001]
  • [Cites] Am J Vet Res. 2000 Sep;61(9):1099-105 [10976743.001]
  • [Cites] Annu Rev Immunol. 2001;19:683-765 [11244051.001]
  • [Cites] Immunol Res. 2000;22(2-3):177-90 [11339354.001]
  • [Cites] J Exp Med. 2001 Nov 19;194(10):F53-7 [11714761.001]
  • [Cites] Vet Immunol Immunopathol. 2002 Sep 25;88(3-4):111-22 [12127410.001]
  • [Cites] Nat Rev Immunol. 2003 Feb;3(2):133-46 [12563297.001]
  • [Cites] Annu Rev Immunol. 2003;21:713-58 [12500979.001]
  • [Cites] Clin Diagn Lab Immunol. 2003 Mar;10(2):208-15 [12626444.001]
  • [Cites] Vet Immunol Immunopathol. 2003 Mar 20;92(1-2):45-60 [12628763.001]
  • [Cites] Vet Immunol Immunopathol. 2003 Mar 20;92(1-2):75-85 [12628765.001]
  • [Cites] Vet Immunol Immunopathol. 2003 Dec 15;96(3-4):207-17 [14592733.001]
  • [Cites] J Exp Med. 2004 Aug 16;200(4):507-17 [15314076.001]
  • [Cites] J Immunol. 1984 Jul;133(1):123-8 [6327821.001]
  • [Cites] Annu Rev Immunol. 1989;7:145-73 [2523712.001]
  • [Cites] Vet Immunol Immunopathol. 1994 Jul;42(1):3-60 [7975180.001]
  • [Cites] J Virol. 1995 Jan;69(1):606-12 [7983765.001]
  • [Cites] Science. 1996 Mar 22;271(5256):1728-30 [8596934.001]
  • [Cites] Eur J Immunol. 1996 Nov;26(11):2666-70 [8921953.001]
  • [Cites] Vet Immunol Immunopathol. 1998 Mar 31;62(2):101-43 [9638857.001]
  • [Cites] Vaccine. 1998 Aug-Sep;16(14-15):1415-9 [9711781.001]
  • [Cites] Immunol Today. 1999 Jul;20(7):330-5 [10379052.001]
  • [Cites] J Immunol. 1999 Aug 15;163(4):2249-55 [10438968.001]
  • [Cites] Vet Immunol Immunopathol. 2005 Feb 10;103(3-4):207-15 [15621307.001]
  • [Cites] Vet Immunol Immunopathol. 2005 May 1;105(1-2):1-14 [15797470.001]
  • [Cites] Nat Rev Immunol. 2005 Apr;5(4):271-83 [15775993.001]
  • [Cites] Vaccine. 2005 Aug 22;23(36):4541-51 [15913852.001]
  • [Cites] Vet Immunol Immunopathol. 2006 Apr 15;110(3-4):363-7 [16480777.001]
  • [Cites] Vet Immunol Immunopathol. 2006 Aug 15;112(3-4):225-33 [16621023.001]
  • [Cites] Vet Immunol Immunopathol. 2006 Aug 15;112(3-4):199-209 [16621024.001]
  • [Cites] Exp Dermatol. 2006 Nov;15(11):855-64 [17002682.001]
  • [Cites] Dev Comp Immunol. 2007;31(2):202-14 [16824599.001]
  • [Cites] Clin Vaccine Immunol. 2009 Feb;16(2):176-83 [19109450.001]
  • [Cites] Annu Rev Immunol. 2009;27:485-517 [19132915.001]
  • [Cites] Int J Dev Biol. 2010;54(2-3):445-55 [19876828.001]
  • [Cites] Dev Comp Immunol. 2010 Apr;34(4):436-44 [19995577.001]
  • (PMID = 20374696.001).
  • [ISSN] 0928-4249
  • [Journal-full-title] Veterinary research
  • [ISO-abbreviation] Vet. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 130068-27-8 / Interleukin-10; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


19. Quartu M, Serra MP, Manca A, Mascia F, Follesa P, Del Fiacco M: Neurturin, persephin, and artemin in the human pre- and full-term newborn and adult hippocampus and fascia dentata. Brain Res; 2005 Apr 18;1041(2):157-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurturin, persephin, and artemin in the human pre- and full-term newborn and adult hippocampus and fascia dentata.
  • The immunochemical occurrence and localization of the Glial cell line-derived neurotrophic factor (GDNF) family ligands neurturin (NTN), persephin (PSP), and artemin (ART) is described in the human postmortem hippocampus and fascia dentata from subjects aged 21 weeks of gestation to 88 years.
  • In the adult subjects, punctate elements were also present.
  • Comparison of the pattern of immunoreactive structures among young and adult subjects suggests that intracellular distribution and/or trafficking of the GDNF family ligands may undergo age-related changes.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aging / metabolism. Animals. Female. Fetus. Humans. Immunohistochemistry. Infant, Newborn. Male. Middle Aged. Neuroglia / metabolism. Neurturin. Postmortem Changes. Pregnancy. Pyramidal Cells / metabolism. Rats. Rats, Sprague-Dawley. Species Specificity

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15829225.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / ARTN protein, human; 0 / NRTN protein, human; 0 / Nerve Growth Factors; 0 / Nerve Tissue Proteins; 0 / Neurturin; 0 / Nrtn protein, rat; 0 / persephin
  •  go-up   go-down


20. Murray MJ, Saini HK, van Dongen S, Palmer RD, Muralidhar B, Pett MR, Piipari M, Thornton CM, Nicholson JC, Enright AJ, Coleman N: The two most common histological subtypes of malignant germ cell tumour are distinguished by global microRNA profiles, associated with differential transcription factor expression. Mol Cancer; 2010 Nov 08;9:290
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The two most common histological subtypes of malignant germ cell tumour are distinguished by global microRNA profiles, associated with differential transcription factor expression.
  • BACKGROUND: We hypothesised that differences in microRNA expression profiles contribute to the contrasting natural history and clinical outcome of the two most common types of malignant germ cell tumour (GCT), yolk sac tumours (YSTs) and germinomas.
  • RESULTS: By direct comparison, using microarray data for paediatric GCT samples and published qRT-PCR data for adult samples, we identified microRNAs significantly up-regulated in YSTs (n = 29 paediatric, 26 adult, 11 overlapping) or germinomas (n = 37 paediatric).
  • Interestingly, the miR-302 cluster, which is over-expressed in all malignant GCTs, showed further over-expression in YSTs versus germinomas, representing six of the top eight microRNAs over-expressed in paediatric YSTs and seven of the top 11 in adult YSTs.
  • To explain this observation, we used mRNA expression profiles of paediatric and adult malignant GCTs to identify 10 transcription factors (TFs) consistently over-expressed in YSTs versus germinomas, followed by linear regression to confirm associations between TF and miR-302 cluster expression levels.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. MicroRNAs / genetics. Neoplasms, Germ Cell and Embryonal / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Gene Expression Profiling. Humans. Infant. Male. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Biol. 2004 Jun 15;270(2):488-98 [15183728.001]
  • [Cites] J Neurosurg. 1991 Apr;74(4):545-51 [1848284.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):594-603 [9053482.001]
  • [Cites] Am J Hum Genet. 2005 Jan;76(1):8-32 [15549674.001]
  • [Cites] Nature. 2005 Feb 17;433(7027):769-73 [15685193.001]
  • [Cites] Neuropediatrics. 2005 Apr;36(2):71-7 [15822019.001]
  • [Cites] PLoS Comput Biol. 2007 Jan 19;3(1):e7 [17238282.001]
  • [Cites] Bioinformatics. 2006 Jan 15;22(2):134-41 [16287941.001]
  • [Cites] J Pathol. 2007 Nov;213(3):319-28 [17893849.001]
  • [Cites] PLoS Comput Biol. 2007 Nov;3(11):e243 [18052544.001]
  • [Cites] Genome Biol. 2007;8(10):R214 [17922911.001]
  • [Cites] Nat Cell Biol. 2008 May;10(5):593-601 [18376396.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4239-47 [18519683.001]
  • [Cites] Cell. 2008 Aug 8;134(3):521-33 [18692474.001]
  • [Cites] Mol Hum Reprod. 2008 Sep;14(9):521-9 [18697907.001]
  • [Cites] Mol Cell Biol. 2008 Oct;28(20):6426-38 [18710938.001]
  • [Cites] Mol Cell Biol. 2008 Nov;28(21):6609-19 [18725401.001]
  • [Cites] Cell Cycle. 2008 Oct;7(20):3112-8 [18927505.001]
  • [Cites] RNA Biol. 2008 Jul-Sep;5(3):115-9 [19182522.001]
  • [Cites] Cell Cycle. 2009 Mar 15;8(6):843-52 [19221491.001]
  • [Cites] J Pathol. 2009 Jun;218(2):146-62 [19253916.001]
  • [Cites] Am J Surg Pathol. 2009 Jun;33(6):894-904 [19295406.001]
  • [Cites] Cancer. 2009 Jun 15;115(12):2640-51 [19365862.001]
  • [Cites] Genes Dev. 2009 Sep 15;23(18):2152-65 [19759263.001]
  • [Cites] Nucleic Acids Res. 2010 Jan;38(Database issue):D557-62 [19906699.001]
  • [Cites] Am J Surg Pathol. 2009 Jul;33(7):1065-77 [19390421.001]
  • [Cites] Bioinformatics. 2010 Mar 15;26(6):843-4 [20106815.001]
  • [Cites] BMC Genomics. 2010;11:132 [20178649.001]
  • [Cites] Cancer Res. 2010 Apr 1;70(7):2911-23 [20332240.001]
  • [Cites] Mol Syst Biol. 2010 Apr 20;6:363 [20404830.001]
  • [Cites] Stem Cells Dev. 2010 Jul;19(7):935-50 [20128659.001]
  • [Cites] Int J Cancer. 2010 Dec 15;127(12):2859-69 [21351265.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1212 [10561181.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2585-92 [10561326.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D108-10 [16381825.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):820-7 [16424014.001]
  • [Cites] J Pathol. 2007 Aug;212(4):368-77 [17471471.001]
  • [Cites] Science. 2001 Oct 26;294(5543):853-8 [11679670.001]
  • [Cites] Science. 2001 Oct 26;294(5543):858-62 [11679671.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2244-50 [12727846.001]
  • (PMID = 21059207.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105359875; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC2993676
  •  go-up   go-down


21. Bhanja S, Mohanakumar KP: Early-life treatment of antiserotonin antibodies alters sensitivity to serotonin receptors, nociceptive stimulus and serotonin metabolism in adult rats. Int J Dev Neurosci; 2010 Jun;28(4):317-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early-life treatment of antiserotonin antibodies alters sensitivity to serotonin receptors, nociceptive stimulus and serotonin metabolism in adult rats.
  • A single systemic administration of serotonin (5-HT) antibodies on day-1 of the life of rat has been investigated for neurotransmitter contents in nucleus raphe, and several discrete brain regions, as well as for serotoninergic syndromes and nociceptive responses in adult animals.

  • Hazardous Substances Data Bank. Norepinephrine .
  • Hazardous Substances Data Bank. DOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 ISDN. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20188813.001).
  • [ISSN] 1873-474X
  • [Journal-full-title] International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience
  • [ISO-abbreviation] Int. J. Dev. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / Receptors, Serotonin; 333DO1RDJY / Serotonin; VTD58H1Z2X / Dopamine; X4W3ENH1CV / Norepinephrine
  •  go-up   go-down


22. Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, Paty PB, Weiser MR, Neuman HB, Shia J, Schrag D, Temple LK: Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum; 2008 Feb;51(2):147-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous-cell carcinoma of the anal canal: predictors of treatment outcome.
  • PURPOSE: The incidence of anal canal squamous-cell carcinoma is increasing.
  • METHODS: Using one database, we identified 131 Stages I-III patients treated for primary anal canal squamous-cell carcinoma at our institution from December 1986 to August 2006, with minimum six-month follow-up.
  • Effective therapies with less acute toxicity must be identified.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Combined Modality Therapy / methods. Disease-Free Survival. Endosonography. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. New York / epidemiology. Retrospective Studies. Survival Rate. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Dis Colon Rectum. 2008 May;51(5):620
  • (PMID = 18180997.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. Shet T, Ghodke R, Kane S, Chinoy RN: Cytomorphologic patterns in papillary cystic variant of acinic cell carcinoma of the salivary gland. Acta Cytol; 2006 Jul-Aug;50(4):388-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomorphologic patterns in papillary cystic variant of acinic cell carcinoma of the salivary gland.
  • OBJECTIVE: To study the cytomorphologic profile of the papillary and cystic variant of acinic cell carcinoma (ACC-PCV) of the salivary glands.
  • The granular cells were similar to those seen in the usual acinic cell carcinoma but were smaller.
  • CONCLUSION: ACC-PCV is papillary and cystic and hence is often not recognized as acinic cell carcinoma.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Cysts / pathology. Salivary Glands / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Female. Histiocytes / pathology. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16901000.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Xu JF, Zhou CC, Li AW: [Gefitinib in the treatment of refractory non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi; 2007 Dec;29(12):938-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gefitinib in the treatment of refractory non-small cell lung cancer].
  • OBJECTIVE: To observe the efficacy, median survival time, time to progression, quality of life and adverse effect of gefitinib (IRESSA) in the treatment for refractory advanced non-small cell lung cancer (NSCLC).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Brain Neoplasms / secondary. Diarrhea / chemically induced. Disease-Free Survival. Exanthema / chemically induced. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Quality of Life. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Remission Induction. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18478936.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


25. Edelman MJ, Watson D, Wang X, Morrison C, Kratzke RA, Jewell S, Hodgson L, Mauer AM, Gajra A, Masters GA, Bedor M, Vokes EE, Green MJ: Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. J Clin Oncol; 2008 Feb 20;26(6):848-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
  • We performed a randomized phase II trial to test the hypothesis that inhibitors of two eicosanoid pathways (cyclooxygenase-2 [COX-2], celecoxib and 5-lipoxygenase [5-LOX], zileuton) added to chemotherapy would improve outcome in advanced non-small-cell lung cancer (NSCLC).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / drug therapy. Cyclooxygenase 2 / metabolism. Cyclooxygenase 2 Inhibitors / therapeutic use. Eicosanoids / antagonists & inhibitors. Hydroxyurea / analogs & derivatives. Lipoxygenase Inhibitors / therapeutic use. Lung Neoplasms / drug therapy. Pyrazoles / therapeutic use. Sulfonamides / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Celecoxib. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Drug Administration Schedule. Female. Gene Expression Regulation, Enzymologic / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Humans. Immunohistochemistry. Logistic Models. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Prospective Studies. Up-Regulation

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Feb 20;26(6):825-7 [18281650.001]
  • (PMID = 18281656.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA16450; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA31983; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA45389; United States / NCI NIH HHS / CA / CA45418; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA77658
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclooxygenase 2 Inhibitors; 0 / Eicosanoids; 0 / Lipoxygenase Inhibitors; 0 / Pyrazoles; 0 / Sulfonamides; 0W860991D6 / Deoxycytidine; 132880-11-6 / zileuton; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; EC 1.14.99.1 / Cyclooxygenase 2; JCX84Q7J1L / Celecoxib; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


26. Austin H, Key NS, Benson JM, Lally C, Dowling NF, Whitsett C, Hooper WC: Sickle cell trait and the risk of venous thromboembolism among blacks. Blood; 2007 Aug 1;110(3):908-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sickle cell trait and the risk of venous thromboembolism among blacks.
  • People with sickle cell disease have a chronically activated coagulation system and display hemostatic perturbations, but it is unknown whether they experience an increased risk of venous thromboembolism.
  • The odds that a patient had sickle cell trait were approximately twice that of a control, indicating that the risk of venous thromboembolism is increased approximately 2-fold among blacks with sickle cell trait compared with those with the wild-type genotype (odds ratio = 1.8 with 95% confidence interval, 1.2-2.9).
  • The odds ratio for pulmonary embolism and sickle cell trait was higher, 3.9 (2.2-6.9).
  • The prevalence of sickle cell disease was also increased among case patients compared with controls.
  • We conclude that sickle cell trait is a risk factor for venous thromboembolism and that the proportion of venous thromboembolism among blacks attributable to the mutation is approximately 7%.
  • [MeSH-major] African Americans. Sickle Cell Trait / complications. Thromboembolism / etiology. Venous Thrombosis / etiology
  • [MeSH-minor] Adult. Aged. Blood Coagulation. Genotype. Hemoglobin C / analysis. Hemoglobin C / genetics. Hemoglobin, Sickle / analysis. Hemoglobin, Sickle / genetics. Humans. Male. Middle Aged. Mutation. Prevalence. Risk Factors


27. Cebeci AR, Gülşahi A, Kamburoglu K, Orhan BK, Oztaş B: Prevalence and distribution of oral mucosal lesions in an adult Turkish population. Med Oral Patol Oral Cir Bucal; 2009 Jun;14(6):E272-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and distribution of oral mucosal lesions in an adult Turkish population.
  • OBJECTIVES: The purpose of this study was to assess the prevalence and distribution of oral mucosal lesions in a Turkish adult population.
  • In addition, 3 patients (0.06%) were diagnosed as having squamous cell carcinoma, and 1 patient (0.02%) was diagnosed as having adenocarcinoma.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prevalence. Turkey / epidemiology. Young Adult

  • MedlinePlus Health Information. consumer health - Mouth Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19300376.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


28. Shea KL, Xiang W, LaPorta VS, Licht JD, Keller C, Basson MA, Brack AS: Sprouty1 regulates reversible quiescence of a self-renewing adult muscle stem cell pool during regeneration. Cell Stem Cell; 2010 Feb 05;6(2):117-29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sprouty1 regulates reversible quiescence of a self-renewing adult muscle stem cell pool during regeneration.
  • The transcription factor Pax7 marks satellite cells and is critical for establishing the adult satellite cell pool.
  • By using a lineage tracing approach, we show that after injury, quiescent adult Pax7(+) cells enter the cell cycle; a subpopulation returns to quiescence to replenish the satellite cell compartment, while others contribute to muscle fiber formation.
  • We show that Spry1 is required for the return to quiescence and homeostasis of the satellite cell pool during repair.
  • Our results therefore define a role for Spry1 in adult muscle stem cell biology and tissue repair.
  • [MeSH-major] Adult Stem Cells / cytology. Adult Stem Cells / physiology. Cellular Reprogramming. Membrane Proteins / metabolism. Phosphoproteins / metabolism. Regeneration. Satellite Cells, Skeletal Muscle / cytology. Satellite Cells, Skeletal Muscle / physiology
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Animals. Apoptosis. Cell Differentiation. Cell Lineage. Cells, Cultured. Homeostasis. Mice. Mice, Transgenic. PAX7 Transcription Factor / metabolism

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] J Cell Physiol. 2001 Jan;186(1):104-15 [11147804.001]
  • [Cites] FASEB J. 2009 Aug;23(8):2681-90 [19332644.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Jun;5(6):441-50 [15173823.001]
  • [Cites] J Cell Biol. 2004 Aug 2;166(3):347-57 [15277541.001]
  • [Cites] EMBO J. 2004 Aug 18;23(16):3430-9 [15282552.001]
  • [Cites] Exp Cell Res. 1984 May;152(1):154-60 [6714317.001]
  • [Cites] J Cell Biol. 1987 Aug;105(2):949-56 [3624313.001]
  • [Cites] Curr Opin Genet Dev. 1994 Aug;4(4):535-42 [7950321.001]
  • [Cites] Muscle Nerve. 1998 Feb;21(2):173-83 [9466592.001]
  • [Cites] J Cell Sci. 1998 Mar;111 ( Pt 6):769-79 [9472005.001]
  • [Cites] Mol Cell Biol. 1998 Oct;18(10):5780-7 [9742095.001]
  • [Cites] Trends Cell Biol. 2006 Jan;16(1):45-54 [16337795.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):945-50 [16418263.001]
  • [Cites] Cell. 2007 Jun 1;129(5):999-1010 [17540178.001]
  • [Cites] Cell Signal. 2007 Aug;19(8):1671-80 [17481856.001]
  • [Cites] Science. 2007 Aug 10;317(5839):807-10 [17690295.001]
  • [Cites] Stem Cells. 2007 Oct;25(10):2448-59 [17600112.001]
  • [Cites] Growth Factors. 2007 Jun;25(3):151-9 [18049951.001]
  • [Cites] PLoS Biol. 2007 May;5(5):e102 [17439301.001]
  • [Cites] Cell Stem Cell. 2009 Sep 4;5(3):298-309 [19733541.001]
  • [Cites] Dev Biol. 2009 Nov 1;335(1):93-105 [19699733.001]
  • [Cites] J Cell Biol. 2006 Jan 2;172(1):103-13 [16391000.001]
  • [Cites] J Histochem Cytochem. 1999 Jan;47(1):23-42 [9857210.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):70-1 [9916792.001]
  • [Cites] Cell. 1999 Mar 5;96(5):655-65 [10089881.001]
  • [Cites] Development. 1999 Jun;126(11):2515-25 [10226010.001]
  • [Cites] Development. 1999 Sep;126(18):4139-47 [10457022.001]
  • [Cites] J Cell Physiol. 1999 Dec;181(3):499-506 [10528236.001]
  • [Cites] Dev Cell. 2005 Feb;8(2):229-39 [15691764.001]
  • [Cites] J Cell Biol. 2005 Apr 11;169(1):105-16 [15824134.001]
  • [Cites] Cell. 2005 Jul 29;122(2):289-301 [16051152.001]
  • [Cites] Science. 2005 Sep 23;309(5743):2064-7 [16141372.001]
  • [Cites] Development. 2005 Dec;132(23):5173-83 [16251209.001]
  • [Cites] J Cell Biol. 2006 Jan 2;172(1):91-102 [16380438.001]
  • [Cites] Dev Biol. 2000 Jun 15;222(2):347-58 [10837124.001]
  • [Cites] Cell. 2000 Sep 15;102(6):777-86 [11030621.001]
  • [Cites] Nat Rev Genet. 2008 Feb;9(2):115-28 [18202695.001]
  • [Cites] Cell Stem Cell. 2008 Jan 10;2(1):50-9 [18371421.001]
  • [Cites] J Cell Sci. 2008 May 1;121(Pt 9):1373-82 [18397993.001]
  • [Cites] Genes Dev. 2008 Jul 1;22(13):1828-37 [18593883.001]
  • [Cites] Cell. 2008 Jul 11;134(1):37-47 [18614009.001]
  • [Cites] Science. 2008 Aug 22;321(5892):1095-100 [18719287.001]
  • [Cites] Nature. 2008 Nov 27;456(7221):502-6 [18806774.001]
  • [Cites] Methods Mol Biol. 2009;482:295-317 [19089364.001]
  • [Cites] Nature. 2008 Dec 18;456(7224):980-4 [19043405.001]
  • [Cites] Biochem Pharmacol. 2009 Jun 15;77(12):1827-34 [19428337.001]
  • [Cites] Cell Stem Cell. 2009 Jun 5;4(6):535-47 [19497282.001]
  • [Cites] Dev Biol. 2009 Aug 1;332(1):131-41 [19464281.001]
  • [Cites] Nature. 2009 Jul 30;460(7255):627-31 [19554048.001]
  • [Cites] Nat Cell Biol. 2002 Nov;4(11):850-8 [12402043.001]
  • (PMID = 20144785.001).
  • [ISSN] 1875-9777
  • [Journal-full-title] Cell stem cell
  • [ISO-abbreviation] Cell Stem Cell
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K08 CA090438; United States / NCI NIH HHS / CA / R01CA059998; United States / NCI NIH HHS / CA / 1K08CA90438; United States / NCI NIH HHS / CA / R01 CA059998-17; United States / NCI NIH HHS / CA / R01 CA059998; United Kingdom / Medical Research Council / / G0601104; United Kingdom / Department of Health / / G0601104; United Kingdom / Wellcome Trust / / WT080470
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Membrane Proteins; 0 / PAX7 Transcription Factor; 0 / Pax7 protein, mouse; 0 / Phosphoproteins; 0 / Spry1 protein, mouse
  • [Other-IDs] NLM/ NIHMS168182; NLM/ PMC2846417
  •  go-up   go-down


29. Paul A, Ge Y, Prakash S, Shum-Tim D: Microencapsulated stem cells for tissue repairing: implications in cell-based myocardial therapy. Regen Med; 2009 Sep;4(5):733-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microencapsulated stem cells for tissue repairing: implications in cell-based myocardial therapy.
  • Hence, these cells act as a useful source for acquiring renewable adult cell lines.
  • However, a major problem that must be overcome before it can be effectively implemented into the clinical setting is a suitable delivery system that can retain an optimal quantity of the cells at the targeted site for a maximal clinical benefit; a system that will give a mechanical as well as an immune protection to the foreign cells, while at the same time enhancing the yields of differentiated cells, maintaining cell microenvironments and sustaining the differentiated cell functions.
  • [MeSH-major] Stem Cell Transplantation / methods. Stem Cells
  • [MeSH-minor] Animals. Cardiac Surgical Procedures. Cell Culture Techniques. Drug Compounding. Humans. Myocardial Infarction / surgery. Myocardium / cytology. Rats

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19761398.001).
  • [ISSN] 1746-076X
  • [Journal-full-title] Regenerative medicine
  • [ISO-abbreviation] Regen Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


30. Foster RA, Carlring J, McKendrick MW, Lees A, Borrow R, Read RC, Heath AW: Evidence of a functional B-cell immunodeficiency in adults who experience serogroup C meningococcal disease. Clin Vaccine Immunol; 2009 May;16(5):692-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence of a functional B-cell immunodeficiency in adults who experience serogroup C meningococcal disease.
  • Peripheral blood lymphocytes derived from survivors of serogroup C meningococcal disease and from age- and sex-matched controls were incubated with a polyclonal B-cell activator containing anti-immunoglobulin D (alpha-delta-dex) employed to mimic antigen-specific stimuli encountered during immune responses to bacterial polysaccharides, with and without T-cell activation (using anti-CD3/anti-CD28).
  • In patients, T-cell responses to polyclonal stimuli and the delivery of T-cell help to B cells were unimpaired.
  • Levels of B-cell proliferation in response to alpha-delta-dex stimulation alone were low in all samples but were significantly lower in patients than in controls, and these differences were more pronounced with the addition of T-cell help.
  • This defect is manifested as an impaired B-cell response to T-cell-independent type 2 antigens analogous to bacterial capsular polysaccharide.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunol Cell Biol. 1999 Dec;77(6):516-22 [10571672.001]
  • [Cites] Infect Immun. 2006 Nov;74(11):6348-55 [16966413.001]
  • [Cites] Nature. 2002 Jan 3;415(6867):8-9 [11780081.001]
  • [Cites] Infect Immun. 2002 Mar;70(3):1301-9 [11854214.001]
  • [Cites] Lancet. 2002 May 25;359(9320):1829-31 [12044380.001]
  • [Cites] Clin Diagn Lab Immunol. 2002 Jul;9(4):872-6 [12093688.001]
  • [Cites] J Immunol. 2004 Jan 1;172(1):532-9 [14688364.001]
  • [Cites] Clin Diagn Lab Immunol. 2004 Mar;11(2):272-9 [15013975.001]
  • [Cites] Infect Immun. 2004 Oct;72(10):5903-9 [15385492.001]
  • [Cites] J Exp Med. 1969 Jun 1;129(6):1307-26 [4977280.001]
  • [Cites] J Exp Med. 1969 Jun 1;129(6):1327-48 [4977281.001]
  • [Cites] Br Med J. 1976 May 22;1(6020):1247-50 [817771.001]
  • [Cites] N Engl J Med. 1986 Dec 18;315(25):1584-90 [3491315.001]
  • [Cites] Epidemiol Infect. 1987 Dec;99(3):591-601 [3123263.001]
  • [Cites] J Allergy Clin Immunol. 1988 Jun;81(6):1175-9 [3259962.001]
  • [Cites] Curr Top Microbiol Immunol. 1989;146:169-80 [2659266.001]
  • [Cites] J Immunol. 1991 Feb 1;146(3):833-9 [1703179.001]
  • [Cites] J Exp Med. 1992 May 1;175(5):1367-71 [1373759.001]
  • [Cites] Immunol Today. 1992 Nov;13(11):462 [1476602.001]
  • [Cites] J Immunol. 1993 Apr 15;150(8 Pt 1):3215-23 [8468466.001]
  • [Cites] Annu Rev Immunol. 1995;13:655-92 [7612238.001]
  • [Cites] Infect Immun. 1995 Dec;63(12):4642-52 [7591118.001]
  • [Cites] Clin Diagn Lab Immunol. 1997 Mar;4(2):156-67 [9067649.001]
  • [Cites] J Investig Med. 1997 Feb;45(2):57-68 [9084576.001]
  • [Cites] Eur J Immunol. 1998 Mar;28(3):1040-51 [9541600.001]
  • [Cites] Vaccine. 2005 Mar 18;23(17-18):2222-7 [15755600.001]
  • [Cites] Epidemiol Infect. 2006 Jun;134(3):556-66 [16238823.001]
  • [Cites] Methods Cell Biol. 2001;63:375-98 [11060850.001]
  • (PMID = 19279166.001).
  • [ISSN] 1556-679X
  • [Journal-full-title] Clinical and vaccine immunology : CVI
  • [ISO-abbreviation] Clin. Vaccine Immunol.
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / / 061268
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2681599
  •  go-up   go-down


31. Nemeth MJ, Bodine DM: Regulation of hematopoiesis and the hematopoietic stem cell niche by Wnt signaling pathways. Cell Res; 2007 Sep;17(9):746-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of hematopoiesis and the hematopoietic stem cell niche by Wnt signaling pathways.
  • In order to maintain their numbers, HSCs must establish a balance between the opposing cell fates of self-renewal (in which the ability to function as HSCs is retained) and initiation of hematopoietic differentiation.
  • Multiple signaling pathways have been implicated in the regulation of HSC cell fate.
  • In this review, we will discuss the basic characteristics of the adult HSC and its regulatory microenvironment, the "niche", focusing on the regulation of the HSC and its niche by the Wnt signaling pathways.
  • [MeSH-minor] Animals. Cell Differentiation / physiology. Cell Lineage. Humans. Leukemia / physiopathology. Osteoblasts / cytology. Osteoblasts / physiology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17768401.001).
  • [ISSN] 1748-7838
  • [Journal-full-title] Cell research
  • [ISO-abbreviation] Cell Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Wnt Proteins
  • [Number-of-references] 159
  •  go-up   go-down


32. Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR: Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood; 2008 Mar 01;111(5):2563-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study.
  • We examined the prognostic impact of cytogenetics on the outcome of 200 acute lymphoblastic leukemia (ALL) patients 15 to 65 years of age enrolled in Southwest Oncology Group (SWOG)-9400 study.
  • After accounting for the variation among karyotype groups, age was not a significant prognostic factor for OS or RFS, highlighting cytogenetics as the most important prognostic factor in adult ALL.
  • [MeSH-major] Cytogenetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Female. Humans. Karyotyping. Male. Middle Aged. Ploidies. Recurrence. Remission Induction. Risk Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] Oncogene. 2007 Jun 21;26(29):4306-18 [17237825.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1536-43 [11861265.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1337-54 [14508819.001]
  • [Cites] Leuk Lymphoma. 2003 Dec;44(12):2039-53 [14959846.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2444-51 [15039281.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):606-13 [1548523.001]
  • [Cites] Blood. 1992 Sep 1;80(5):1316-23 [1381244.001]
  • [Cites] Leukemia. 1993 Jul;7(7):1000-4 [7686600.001]
  • [Cites] Br J Haematol. 1995 Sep;91(1):93-100 [7577660.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3135-42 [8605327.001]
  • [Cites] Br J Haematol. 1997 Mar;96(3):601-10 [9054669.001]
  • [Cites] Leukemia. 1998 Apr;12(4):463-73 [9557602.001]
  • [Cites] Blood. 1999 Jan 1;93(1):315-20 [9864176.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3983-93 [10339508.001]
  • [Cites] Blood. 2005 May 1;105(9):3434-41 [15650057.001]
  • [Cites] Haematologica. 2005 Sep;90(9):1179-85 [16154840.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Genet Med. 2006 Jan;8(1):16-23 [16418595.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1496-510 [16826225.001]
  • [Cites] Leukemia. 2006 Nov;20(11):2002-7 [16990785.001]
  • [Cites] Blood. 2007 Feb 1;109(3):926-35 [17003380.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Blood. 2007 Apr 1;109(7):3080-3 [17170128.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • (PMID = 18156492.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00002665
  • [Grant] United States / NCI NIH HHS / CA / CA 35176; United States / NCI NIH HHS / CA / N01 CA004919; United States / NCI NIH HHS / CA / CA 63844; United States / NCI NIH HHS / CA / CA 74647; United States / NCI NIH HHS / CA / CA 38926; United States / NCI NIH HHS / CA / N01 CA035176; United States / NCI NIH HHS / CA / CA 20319; United States / NCI NIH HHS / CA / U10 CA004919; United States / NCI NIH HHS / CA / N01 CA035431; United States / NCI NIH HHS / CA / U10 CA063845; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / U10 CA035192; United States / NCI NIH HHS / CA / CA 35119; United States / NCI NIH HHS / CA / CA 33572; United States / NCI NIH HHS / CA / CA 52654; United States / NCI NIH HHS / CA / U10 CA014028; United States / NCI NIH HHS / CA / N01 CA035119; United States / NCI NIH HHS / CA / CA 46441; United States / NCI NIH HHS / CA / N01 CA046441; United States / NCI NIH HHS / CA / CA 63845; United States / NCI NIH HHS / CA / U10 CA074647; United States / NCI NIH HHS / CA / CA 46368; United States / NCI NIH HHS / CA / CA 35178; United States / NCI NIH HHS / CA / CA 04919; United States / NCI NIH HHS / CA / CA 35090; United States / NCI NIH HHS / CA / N01 CA063844; United States / NCI NIH HHS / CA / U10 CA035261; United States / NCI NIH HHS / CA / U10 CA035178; United States / NCI NIH HHS / CA / CA 35431; United States / NCI NIH HHS / CA / CA 35192; United States / NCI NIH HHS / CA / U10 CA045450; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / U10 CA046282; United States / NCI NIH HHS / CA / CA 32102; United States / NCI NIH HHS / CA / N01 CA035178; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / U10 CA067575; United States / NCI NIH HHS / CA / U10 CA046441; United States / NCI NIH HHS / CA / U10 CA045377; United States / NCI NIH HHS / CA / U10 CA058882; United States / NCI NIH HHS / CA / CA 67575; United States / NCI NIH HHS / CA / U10 CA020319; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / U10 CA042777; United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / U10 CA035431; United States / NCI NIH HHS / CA / U10 CA035119; United States / NCI NIH HHS / CA / U10 CA046368; United States / NCI NIH HHS / CA / CA 45450; United States / NCI NIH HHS / CA / N01 CA067575; United States / NCI NIH HHS / CA / CA 42777; United States / NCI NIH HHS / CA / U10 CA052654; United States / NCI NIH HHS / CA / CA 58882; United States / NCI NIH HHS / CA / CA 30206; United States / NCI NIH HHS / CA / U10 CA035176; United States / NCI NIH HHS / CA / P01 CA030206; United States / NCI NIH HHS / CA / U10 CA035090; United States / NCI NIH HHS / CA / CA 14028; United States / NCI NIH HHS / CA / U10 CA063844; United States / NCI NIH HHS / CA / CA 45377; United States / NCI NIH HHS / CA / CA 35261; United States / NCI NIH HHS / CA / CA 46282
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2254550
  •  go-up   go-down


33. Biswas SK, Jiang JX, Lo WK: Gap junction remodeling associated with cholesterol redistribution during fiber cell maturation in the adult chicken lens. Mol Vis; 2009 Aug 04;15:1492-508
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gap junction remodeling associated with cholesterol redistribution during fiber cell maturation in the adult chicken lens.
  • PURPOSE: To investigate the structural remodeling in gap junctions associated with cholesterol redistribution during fiber cell maturation in the adult chicken lens.
  • We also evaluated the hypothesis that the cleavage of the COOH-terminus of chick Cx50 (formerly Cx45.6) during fiber cell maturation would affect the gap junction remodeling.
  • METHODS: Freeze-fracture TEM and filipin cytochemistry were applied to visualize structural remodeling of gap junction connexons associated with cholesterol redistribution during fiber cell maturation in adult leghorn chickens (42-62 weeks old).
  • RESULTS: Cortical fiber cells of the adult lenses contained three subtypes of cholesterol-containing gap junctions (i.e., cholesterol-rich, cholesterol-intermediate, and cholesterol-poor or -free) in both outer and inner cortical zones.
  • CONCLUSIONS: Gap junctions undergo significant structural remodeling during fiber cell maturation in the adult chicken lens.
  • In addition, the loss of the COOH-terminus of Cx50 seems to contribute equally to the transformation of the loosely-packed connexons to the crystalline-packed connexons during fiber cell maturation.
  • As a result, it compensates considerably for the large decrease in the percentage of membrane area specialized as gap junctions in the mature inner fibers in the adult chicken lens.

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Biochem. 1996;65:475-502 [8811187.001]
  • [Cites] Curr Eye Res. 1996 Mar;15(3):307-14 [8654111.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15303-8 [9860964.001]
  • [Cites] J Biol Chem. 1999 Mar 26;274(13):8678-85 [10085106.001]
  • [Cites] Novartis Found Symp. 1999;219:44-54; discussion 54-9 [10207897.001]
  • [Cites] Biochem J. 2006 Mar 15;394(Pt 3):527-43 [16492141.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Oct;47(10):4474-81 [17003442.001]
  • [Cites] J Membr Biol. 2006;211(3):163-71 [17091216.001]
  • [Cites] Mol Vis. 2007;13:345-59 [17392685.001]
  • [Cites] Cell Commun Adhes. 2008 May;15(1):1-11 [18649174.001]
  • [Cites] J Cell Biol. 1978 Feb;76(2):532-44 [10605455.001]
  • [Cites] Methods. 2000 Feb;20(2):180-7 [10671311.001]
  • [Cites] J Biol Chem. 2000 Mar 10;275(10):6850-6 [10702244.001]
  • [Cites] Cell Tissue Res. 2000 Mar;299(3):347-62 [10772249.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2658-64 [10937579.001]
  • [Cites] Exp Eye Res. 2000 Oct;71(4):415-35 [10995562.001]
  • [Cites] Exp Eye Res. 2001 Mar;72(3):199-214 [11180969.001]
  • [Cites] J Cell Sci. 2001 Feb;114(Pt 4):763-73 [11171382.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):34567-72 [11448971.001]
  • [Cites] J Gen Physiol. 2001 Nov;118(5):447-56 [11696604.001]
  • [Cites] Pflugers Arch. 2002 Mar;443(5-6):843-51 [11889584.001]
  • [Cites] J Membr Biol. 2002 Mar 15;186(2):101-12 [11944087.001]
  • [Cites] Science. 2002 Apr 19;296(5567):503-7 [11964472.001]
  • [Cites] Cell Commun Adhes. 2001;8(4-6):373-6 [12064621.001]
  • [Cites] Mol Membr Biol. 2002 Apr-Jun;19(2):121-36 [12126230.001]
  • [Cites] Curr Drug Targets. 2002 Dec;3(6):441-53 [12448696.001]
  • [Cites] Biol Cell. 2002 Nov;94(7-8):445-56 [12566219.001]
  • [Cites] Cardiovasc Res. 2004 May 1;62(2):378-87 [15094357.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2004 Oct;45(10):3629-37 [15452070.001]
  • [Cites] Biochim Biophys Acta. 1976 Dec 14;457(3-4):353-84 [793636.001]
  • [Cites] Exp Eye Res. 1978 Oct;27(4):495-8 [729657.001]
  • [Cites] J Cell Biol. 1979 Apr;81(1):215-28 [314450.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1979 Nov;18(11):1104-22 [511455.001]
  • [Cites] J Cell Biol. 1980 Oct;87(1):273-9 [7419595.001]
  • [Cites] Am J Anat. 1980 Dec;159(4):395-410 [7223675.001]
  • [Cites] Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1981;216(4):275-89 [6910997.001]
  • [Cites] Exp Eye Res. 1982 Mar;34(3):455-66 [7067751.001]
  • [Cites] J Lipid Res. 1982 May;23(4):619-26 [6808071.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1982;219(3):112-20 [7173625.001]
  • [Cites] J Cell Biol. 1983 Sep;97(3):749-55 [6411740.001]
  • [Cites] Exp Eye Res. 1984 Jan;38(1):95-9 [6705848.001]
  • [Cites] Curr Eye Res. 1984 Nov;3(11):1337-59 [6391828.001]
  • [Cites] J Cell Biol. 1985 Jul;101(1):28-35 [3891760.001]
  • [Cites] Tissue Cell. 1985;17(3):359-77 [4012767.001]
  • [Cites] J Lipid Res. 1985 May;26(5):600-9 [4020298.001]
  • [Cites] J Ultrastruct Res. 1984 Mar;86(3):228-45 [6544861.001]
  • [Cites] Cell Tissue Res. 1986;244(2):253-63 [3487382.001]
  • [Cites] Biochim Biophys Acta. 1987 Jan 13;917(1):112-20 [3790601.001]
  • [Cites] Curr Eye Res. 1987 Apr;6(4):599-605 [3581878.001]
  • [Cites] J Cell Sci. 1990 Jun;96 ( Pt 2):231-8 [1698798.001]
  • [Cites] Lipids. 1990 Aug;25(8):419-27 [2215085.001]
  • [Cites] Lens Eye Toxic Res. 1989;6(4):703-24 [2487279.001]
  • [Cites] Exp Cell Res. 1991 Sep;196(1):72-81 [1652451.001]
  • [Cites] J Cell Biol. 1991 Nov;115(4):1077-89 [1659572.001]
  • [Cites] J Gen Physiol. 1991 Dec;98(6):1085-103 [1783895.001]
  • [Cites] Mol Biol Cell. 1992 Jul;3(7):711-20 [1325220.001]
  • [Cites] J Biol Chem. 1993 Jan 5;268(1):706-12 [7678009.001]
  • [Cites] Mol Biol Cell. 1994 Mar;5(3):363-73 [8049527.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1994 Nov;35(12):4109-17 [7960593.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1996 Jun;37(7):1396-410 [8641842.001]
  • [Cites] Eur J Cell Biol. 1998 Aug;76(4):246-50 [9765054.001]
  • (PMID = 19657477.001).
  • [ISSN] 1090-0535
  • [Journal-full-title] Molecular vision
  • [ISO-abbreviation] Mol. Vis.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / G12 RR003034; United States / NEI NIH HHS / EY / R01 EY005314; United States / NEI NIH HHS / EY / R01 EY012085; United States / NEI NIH HHS / EY / R29 EY012085; United States / NEI NIH HHS / EY / EY12085; United States / NCRR NIH HHS / RR / RR03034; United States / NEI NIH HHS / EY / EY05314
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Connexins; 0 / Eye Proteins; 0 / connexin 50; 87Z59R7D14 / Filipin; 97C5T2UQ7J / Cholesterol
  • [Other-IDs] NLM/ PMC2720993
  •  go-up   go-down


34. Stiblar-Martincic D: Morphometrical evaluation of germ cell apoptosis in infertile men. Folia Biol (Praha); 2009;55(6):233-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphometrical evaluation of germ cell apoptosis in infertile men.
  • Apoptosis associated with programmed cell death plays an essential role in the control of germ cell number in the testes.
  • Although male germ cell apoptosis has been well characterized in different animal models, only a few studies of apoptosis in human testes are presently available.
  • Terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling-positive cells were found in the testicular tissue of all patients with azoospermia, except in Sertoli cell-only syndrome.
  • The apoptotic index was higher in germ cell hypoplasia and in normal spermatogenesis in comparison with germ cell arrest.
  • [MeSH-minor] Adult. Humans. In Situ Nick-End Labeling. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Male Infertility.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20163772.001).
  • [ISSN] 0015-5500
  • [Journal-full-title] Folia biologica
  • [ISO-abbreviation] Folia Biol. (Praha)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


35. Lü HZ, Xu L, Zou J, Wang YX, Ma ZW, Xu XM, Lu PH: Effects of autoimmunity on recovery of function in adult rats following spinal cord injury. Brain Behav Immun; 2008 Nov;22(8):1217-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of autoimmunity on recovery of function in adult rats following spinal cord injury.
  • [MeSH-minor] Analysis of Variance. Animals. Cell Survival / immunology. Cytoprotection. Flow Cytometry. Fluorescent Antibody Technique. Immunization, Passive. Lymphocyte Activation / immunology. Microscopy, Electron. Motor Activity / immunology. Myelin Basic Protein / immunology. Rats. Rats, Sprague-Dawley. Reverse Transcriptase Polymerase Chain Reaction. Spinal Cord / immunology. Staining and Labeling. Thoracic Vertebrae / immunology. Thymectomy. Time Factors

  • MedlinePlus Health Information. consumer health - Spinal Cord Injuries.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18625299.001).
  • [ISSN] 1090-2139
  • [Journal-full-title] Brain, behavior, and immunity
  • [ISO-abbreviation] Brain Behav. Immun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myelin Basic Protein
  •  go-up   go-down


36. Lyngbaek S, Schneider M, Hansen JL, Sheikh SP: Cardiac regeneration by resident stem and progenitor cells in the adult heart. Basic Res Cardiol; 2007 Mar;102(2):101-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac regeneration by resident stem and progenitor cells in the adult heart.
  • First, the traditional view on the heart as a postmitotic organ has been challenged by the finding of small dividing cells in the heart expressing cardiac contractile proteins with stem cell properties and, second, cellular therapy of the diseased heart using a variety of different cells has shown encouraging effects on cardiac function.
  • Emerging evidence suggests that several subpopulations of cardiac stem or progenitor cells (CPCs) reside within the adult heart.
  • CPCs with the ability to differentiate into all the constituent cells in the adult heart including cardiac myocytes, vascular smooth muscle and endothelial cells have been identified.
  • Valuable knowledge has been obtained from the large number of animal studies and a number of small clinical trials that have utilized a variety of adult stem cells for regenerating infarcted hearts.
  • [MeSH-major] Adult Stem Cells / physiology. Heart / physiology. Myocardium / cytology. Regeneration / physiology
  • [MeSH-minor] Animals. Cell Differentiation / physiology. Humans. Myocardial Ischemia / therapy. Stem Cell Transplantation

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17216393.001).
  • [ISSN] 0300-8428
  • [Journal-full-title] Basic research in cardiology
  • [ISO-abbreviation] Basic Res. Cardiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Number-of-references] 97
  •  go-up   go-down


37. Bader V, Ran Zhu X, Lübbert H, Stichel CC: Expression of DJ-1 in the adult mouse CNS. Brain Res; 2005 Apr 11;1041(1):102-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of DJ-1 in the adult mouse CNS.
  • In the present study, we mapped the distribution of DJ-1 transcript and protein by non-radioactive in situ hybridization and immunohistochemistry in adult mouse CNS.
  • Colocalization experiments revealed expression in neurons of different neurotransmitter phenotypes and in all glial cell types, such as astrocytes, microglia and oligodendrocytes.
  • The high expression of DJ-1 in neuronal and glial cells, that is not confined to a single functional system or any anatomical area, supports the view of a basic physiological role in cell biology.

  • COS Scholar Universe. author profiles.
  • SciCrunch. The Antibody Registry: Reagent: Antibodies .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15804505.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Oncogene Proteins; 0 / PARK7 protein, human; 0 / RNA, Messenger; EC 1.11.1.15 / DJ-1 protein, mouse; EC 1.11.1.15 / Peroxiredoxins
  •  go-up   go-down


38. Goffredo D, Conti L, Di Febo F, Biella G, Tosoni A, Vago G, Biunno I, Moiana A, Bolognini D, Toselli M, Cattaneo E: Setting the conditions for efficient, robust and reproducible generation of functionally active neurons from adult subventricular zone-derived neural stem cells. Cell Death Differ; 2008 Dec;15(12):1847-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Setting the conditions for efficient, robust and reproducible generation of functionally active neurons from adult subventricular zone-derived neural stem cells.
  • We demonstrate that NS cells derived from adult mouse subventricular zone robustly develop properties of mature neurons when exposed to an optimized neuronal differentiation protocol.
  • A high degree of cell viability was preserved.
  • Antigenic and functional properties were efficiently and reliably reproduced across experiments and cell passages (up to 68).
  • This is the first report showing a consistent and reproducible generation of large amounts of neurons from long-term passaged adult neural stem cells.
  • Remarkably, the neuronal progeny carries a defined set of antigenic, biochemical and functional characteristics that make this system suitable for studies of NS cell biology as well as for genetic and chemical screenings.
  • [MeSH-major] Cell Division. Cerebral Ventricles / cytology. Neurons / cytology. Stem Cells / cytology
  • [MeSH-minor] Action Potentials. Animals. Astrocytes / cytology. Cell Differentiation. Cell Line. Cell Proliferation. Cell Shape. Ion Channel Gating. Mice. Potassium Channels / metabolism. Receptors, GABA / metabolism. Receptors, Glutamate / metabolism. Reproducibility of Results. Sodium Channels / metabolism. Time Factors. gamma-Aminobutyric Acid / metabolism

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011641.001).
  • [ISSN] 1476-5403
  • [Journal-full-title] Cell death and differentiation
  • [ISO-abbreviation] Cell Death Differ.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Potassium Channels; 0 / Receptors, GABA; 0 / Receptors, Glutamate; 0 / Sodium Channels; 56-12-2 / gamma-Aminobutyric Acid
  •  go-up   go-down


39. Acosta ML, Kalloniatis M, Christie DL: Creatine transporter localization in developing and adult retina: importance of creatine to retinal function. Am J Physiol Cell Physiol; 2005 Oct;289(4):C1015-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Creatine transporter localization in developing and adult retina: importance of creatine to retinal function.
  • An affinity-purified antibody raised against the CRT was applied to adult vertebrate retinas and to mouse retina during development.
  • The lack of labeling of Müller cells suggests that neurons are independent of this glial cell in accumulating creatine.

  • Hazardous Substances Data Bank. CREATINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15930147.001).
  • [ISSN] 0363-6143
  • [Journal-full-title] American journal of physiology. Cell physiology
  • [ISO-abbreviation] Am. J. Physiol., Cell Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Transport Proteins; 0 / creatine transporter; MU72812GK0 / Creatine
  •  go-up   go-down


40. Wada T, Stepniak E, Hui L, Leibbrandt A, Katada T, Nishina H, Wagner EF, Penninger JM: Antagonistic control of cell fates by JNK and p38-MAPK signaling. Cell Death Differ; 2008 Jan;15(1):89-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antagonistic control of cell fates by JNK and p38-MAPK signaling.
  • During the development and organogenesis of all multicellular organisms, cell fate decisions determine whether cells undergo proliferation, differentiation, or aging.
  • Two independent stress kinase signaling pathways, p38-MAPK, and JNKs, have evolved that relay developmental and environmental cues to determine cell responses.
  • Similarly, genetic inactivation of the JNK pathway results in impaired proliferation of fetal hepatoblasts in vitro and defective adult liver regeneration in vivo, which is rescued by inhibition of the p38-MAPK pathway.
  • Thus, the balance between the two stress-signaling pathways, MKK7-JNK and MKK3/6-p38-MAPK, determines cell fate and links environmental and developmental stress to cell cycle arrest, senescence, oncogenic transformation, and adult tissue regeneration.
  • [MeSH-major] Cell Aging. Cell Proliferation. Cell Transformation, Neoplastic. JNK Mitogen-Activated Protein Kinases / metabolism. Liver Regeneration. MAP Kinase Signaling System. p38 Mitogen-Activated Protein Kinases / metabolism

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762881.001).
  • [ISSN] 1350-9047
  • [Journal-full-title] Cell death and differentiation
  • [ISO-abbreviation] Cell Death Differ.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.11.22 / CDC2 Protein Kinase; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


41. Tan H, Ye J, Luo X, Chen S, Yin Q, Yang L, Li Y: Clonal expanded TRA and TRB subfamily T cells in peripheral blood from patients with diffuse large B-cell lymphoma. Hematology; 2010 Apr;15(2):81-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonal expanded TRA and TRB subfamily T cells in peripheral blood from patients with diffuse large B-cell lymphoma.
  • T cell immunodeficiency is a common feature in cancer patients and may be a contributing factor to the initiation and development of the tumor.
  • In order to characterize the immune status in a group of patients with diffuse large B-cell lymphoma (DLBL), the repertoires of T cell receptor alpha and beta variable regions (TRAV and TRBV) were analyzed.
  • [MeSH-major] Clone Cells / pathology. Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor. Gene Rearrangement, beta-Chain T-Cell Antigen Receptor. Genes, T-Cell Receptor alpha. Genes, T-Cell Receptor beta. Lymphoma, Large B-Cell, Diffuse / blood. T-Lymphocyte Subsets / pathology
  • [MeSH-minor] Adult. Aged, 80 and over. Antigens, Neoplasm / immunology. DNA, Complementary / genetics. Gene Expression Profiling. Humans. Male. Middle Aged. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Receptors, Antigen, T-Cell, alpha-beta / analysis. T-Cell Antigen Receptor Specificity

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20423568.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA, Complementary; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, Antigen, T-Cell, alpha-beta
  •  go-up   go-down


42. Kimbi GC, Kramvis A, Kew MC: Integration of hepatitis B virus DNA into chromosomal DNA during acute hepatitis B. World J Gastroenterol; 2005 Nov 7;11(41):6416-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integration of hepatitis B virus DNA into chromosomal DNA during acute hepatitis B.
  • AIM: To examine the serum from black African patients with acute hepatitis B to ascertain if integrants of viral DNA can be detected in fragments of cellular DNA leaking from damaged hepatocytes into the circulation.
  • METHODS: DNA was extracted from the sera of five patients with uncomplicated acute hepatitis B and one with fulminant disease.
  • CONCLUSION: Integration of viral DNA into chromosomal DNA may occur rarely during acute hepatitis B and, with clonal propagation of the integrant, might play a role in hepatocarcinogenesis.
  • [MeSH-minor] Acute Disease. Adolescent. Adult. DNA, Viral / blood. DNA, Viral / genetics. Female. Humans. Male. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425409.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC4355779
  •  go-up   go-down


43. Goehring LS, van Maanen C, Berendsen M, Cullinane A, de Groot RJ, Rottier PJ, Wesselingh JJ, Sloet van Oldruitenborgh-Oosterbaan MM: Experimental infection with neuropathogenic equid herpesvirus type 1 (EHV-1) in adult horses. Vet J; 2010 Nov;186(2):180-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experimental infection with neuropathogenic equid herpesvirus type 1 (EHV-1) in adult horses.
  • (1) a large inhaled dose of a neuropathogenic EHV-1 strain would induce a cell-associated viraemia in all infected horses;.
  • This study showed that cell-associated viraemia was not guaranteed, despite a large-dose inoculation with EHV-1, yet viraemia was probably a pre-requisite for subsequent development of EHM.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19726209.001).
  • [ISSN] 1532-2971
  • [Journal-full-title] Veterinary journal (London, England : 1997)
  • [ISO-abbreviation] Vet. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Albumins
  •  go-up   go-down


44. Silberstein J, Grabowski J, Saltzstein SL, Kane CJ: Renal cell carcinoma in the pediatric population: Results from the California Cancer Registry. Pediatr Blood Cancer; 2009 Feb;52(2):237-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cell carcinoma in the pediatric population: Results from the California Cancer Registry.
  • BACKGROUND: Renal cell carcinoma (RCC) is a rare disease in children and adolescents.
  • The epidemiological characteristics of this tumor differ from adult RCC and Wilms tumor, suggesting its distinctive biology and potential need for alternative treatment strategies.
  • [MeSH-major] Carcinoma, Renal Cell / epidemiology
  • [MeSH-minor] Adolescent. Age Distribution. California / epidemiology. Child. Child, Preschool. Ethnic Groups. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Neoplasm Staging. Registries. Sex Factors. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18937317.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Murdoch B, DelConte C, García-Castro MI: Embryonic Pax7-expressing progenitors contribute multiple cell types to the postnatal olfactory epithelium. J Neurosci; 2010 Jul 14;30(28):9523-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Embryonic Pax7-expressing progenitors contribute multiple cell types to the postnatal olfactory epithelium.
  • Prolonged neurogenesis driven by stem/progenitor cells is a hallmark of the olfactory epithelium (OE), beginning at the placodal stages in the embryo and continuing throughout adult life.
  • Despite the progress made to identify and study the regulation of adult OE progenitors, our knowledge of embryonic OE precursors and their cellular contributions to the adult OE has been stalled by the lack of markers able to distinguish individual candidate progenitors.

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Biol. 2009 Feb 1;326(1):75-85 [19027001.001]
  • [Cites] Stem Cells. 2008 Dec;26(12):3194-204 [18802040.001]
  • [Cites] Neurosci Lett. 2009 Jun 12;456(3):137-42 [19429149.001]
  • [Cites] Brain Behav Evol. 2004;64(3):126-40 [15353905.001]
  • [Cites] J Neurocytol. 1979 Apr;8(2):197-213 [469573.001]
  • [Cites] Science. 1983 Jun 3;220(4601):1059-61 [6844926.001]
  • [Cites] Prog Neurobiol. 1984;23(4):317-45 [6398455.001]
  • [Cites] Dev Biol. 1985 Aug;110(2):422-39 [4018406.001]
  • [Cites] Mech Dev. 1990 Dec;33(1):27-37 [1982921.001]
  • [Cites] J Neurosci. 1994 Mar;14(3 Pt 2):1395-412 [8126546.001]
  • [Cites] Mol Cell Neurosci. 1995 Aug;6(4):363-79 [8846005.001]
  • [Cites] Development. 1996 Mar;122(3):831-8 [8631261.001]
  • [Cites] J Neurosci. 1996 Jun 15;16(12):4005-16 [8656294.001]
  • [Cites] J Neurosci. 1996 Aug 15;16(16):5082-94 [8756438.001]
  • [Cites] Development. 1997 Apr;124(8):1611-21 [9108377.001]
  • [Cites] Neuroreport. 1998 May 11;9(7):1611-7 [9631475.001]
  • [Cites] J Comp Neurol. 1998 Nov 2;400(4):469-86 [9786409.001]
  • [Cites] Int J Dev Biol. 1998;42(7):909-16 [9853821.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):70-1 [9916792.001]
  • [Cites] Nat Neurosci. 1999 Apr;2(4):339-45 [10204540.001]
  • [Cites] Genes Dev. 2004 Nov 1;18(21):2608-13 [15520281.001]
  • [Cites] Dev Neurosci. 2004 Mar-Aug;26(2-4):166-80 [15711058.001]
  • [Cites] Exp Cell Res. 2005 Jun 10;306(2):309-16 [15925585.001]
  • [Cites] Cell. 2005 Jul 29;122(2):289-301 [16051152.001]
  • [Cites] Development. 2005 Dec;132(23):5211-23 [16267092.001]
  • [Cites] Nature. 2006 May 11;441(7090):218-22 [16688176.001]
  • [Cites] Circ Res. 2006 Jun 23;98(12):1547-54 [16709902.001]
  • [Cites] Anat Embryol (Berl). 2006 Aug;211(4):293-310 [16506066.001]
  • [Cites] Dev Dyn. 2006 Sep;235(9):2376-85 [16871622.001]
  • [Cites] Biochem Pharmacol. 2007 Jan 1;73(1):1-14 [16904651.001]
  • [Cites] Nat Rev Neurosci. 2007 Apr;8(4):312-9 [17342173.001]
  • [Cites] Dev Biol. 2007 May 15;305(2):659-73 [17399698.001]
  • [Cites] Nat Neurosci. 2007 Jun;10(6):720-6 [17468753.001]
  • [Cites] Cell. 2007 Jun 1;129(5):999-1010 [17540178.001]
  • [Cites] J Mol Histol. 2007 Dec;38(6):581-99 [17851769.001]
  • [Cites] Nat Cell Biol. 2008 Jan;10(1):77-84 [18066051.001]
  • [Cites] Exp Neurol. 2008 Feb;209(2):353-67 [17643431.001]
  • [Cites] J Neurosci. 2008 Apr 16;28(16):4271-82 [18417707.001]
  • [Cites] Development. 2000 Apr;127(8):1607-16 [10725237.001]
  • [Cites] Development. 2000 Apr;127(8):1671-9 [10725243.001]
  • [Cites] Cell. 2000 May 12;101(4):435-45 [10830170.001]
  • [Cites] Curr Opin Neurobiol. 2000 Aug;10(4):511-8 [10981622.001]
  • [Cites] Neuron. 2000 Nov;28(2):411-25 [11144352.001]
  • [Cites] Annu Rev Cell Dev Biol. 2001;17:387-403 [11687494.001]
  • [Cites] Anat Rec. 2002 Feb 15;269(1):33-49 [11891623.001]
  • [Cites] Genomics. 2003 Nov;82(5):553-60 [14559212.001]
  • [Cites] BMC Dev Biol. 2001;1:4 [11299042.001]
  • [Cites] Physiol Rev. 2004 Jan;84(1):209-38 [14715915.001]
  • [Cites] J Comp Neurol. 2004 Feb 16;469(4):457-74 [14755529.001]
  • [Cites] Genes Dev. 2004 May 1;18(9):1088-105 [15132998.001]
  • [Cites] J Neurosci. 2004 Jun 23;24(25):5670-83 [15215289.001]
  • [Cites] J Neurosci. 2008 May 14;28(20):5229-39 [18480279.001]
  • [Cites] Stem Cells. 2008 May;26(5):1298-306 [18308944.001]
  • [Cites] Dev Dyn. 2008 Oct;237(10):2791-803 [18816860.001]
  • [Cites] Development. 2008 Dec;135(24):4165-77 [19029046.001]
  • [Cites] Dev Dyn. 2009 Mar;238(3):716-23 [19235729.001]
  • (PMID = 20631180.001).
  • [ISSN] 1529-2401
  • [Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience
  • [ISO-abbreviation] J. Neurosci.
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / DE017914-01A1; United States / NIDCR NIH HHS / DE / R01 DE017914; United States / NIDCR NIH HHS / DE / R56 DE017914; United States / NIDCR NIH HHS / DE / R01 DE017914-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / PAX7 Transcription Factor; 0 / Pax7 protein, mouse
  • [Other-IDs] NLM/ NIHMS221258; NLM/ PMC2920205
  •  go-up   go-down


46. Li R, Johnson AB, Salomons G, Goldman JE, Naidu S, Quinlan R, Cree B, Ruyle SZ, Banwell B, D'Hooghe M, Siebert JR, Rolf CM, Cox H, Reddy A, Gutiérrez-Solana LG, Collins A, Weller RO, Messing A, van der Knaap MS, Brenner M: Glial fibrillary acidic protein mutations in infantile, juvenile, and adult forms of Alexander disease. Ann Neurol; 2005 Mar;57(3):310-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glial fibrillary acidic protein mutations in infantile, juvenile, and adult forms of Alexander disease.
  • [MeSH-minor] Adolescent. Adrenocortical Carcinoma. Adult. Age Factors. Age of Onset. Cell Line, Tumor. Child. Child, Preschool. DNA Mutational Analysis / methods. Female. Humans. Infant. Magnetic Resonance Imaging / methods. Male. Middle Aged. Models, Molecular. Mutagenesis / physiology. Transfection / methods

  • Genetic Alliance. consumer health - Alexander Disease.
  • Genetics Home Reference. consumer health - Alexander disease.
  • Genetics Home Reference. consumer health - GFAP gene.
  • COS Scholar Universe. author profiles.
  • SciCrunch. OMIM: Data: Gene Annotation .
  • SciCrunch. Clinical Genomic Database: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Neurol. 2005 Mar;57(3):307-8 [15732119.001]
  • (PMID = 15732097.001).
  • [ISSN] 0364-5134
  • [Journal-full-title] Annals of neurology
  • [ISO-abbreviation] Ann. Neurol.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / N01 HD 43368; United States / NICHD NIH HHS / HD / N01 HD 83284; United States / NINDS NIH HHS / NS / P01 NS 42803; United States / NICHD NIH HHS / HD / P30 HD 38985; United States / NINDS NIH HHS / NS / R01 NS 39055
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


47. Hashemian MN, Moghimi S, Fard MA, Fallah MR, Mansouri MR: Corneal endothelial cell density and morphology in normal Iranian eyes. BMC Ophthalmol; 2006;6:9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Corneal endothelial cell density and morphology in normal Iranian eyes.
  • BACKGROUND: We describe corneal endothelial cell density and morphology in normal Iranian eyes and compare endothelial cell characteristics in the Iranian population with data available in the literature for American and Indian populations.
  • The studied parameters including mean endothelial cell density (MCD), mean cell area (MCA) and coefficient of variation (CV) in cell area were analyzed in all of the 525 eyes.
  • RESULTS: MCD was 1961 +/- 457 cell/mm2 and MCA was 537.0 +/- 137.4 microm2.
  • The rate of cell loss was 0.6% per year.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aging. Cell Count. Cell Size. Female. Humans. Iran. Male. Middle Aged. Reference Values. Regression Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 2004 Feb;111(2):309-17 [15019381.001]
  • [Cites] Trans Am Ophthalmol Soc. 1953;51:669-786 [13216798.001]
  • [Cites] Br J Ophthalmol. 2000 Jul;84(7):692-6 [10873975.001]
  • [Cites] Cornea. 2000 Nov;19(6):820-3 [11095057.001]
  • [Cites] Cornea. 2001 Jan;20(1):55-8 [11189005.001]
  • [Cites] Cornea. 2002 May;21(4):360-3 [11973383.001]
  • [Cites] Cornea. 2004 Mar;23(2):129-35 [15075881.001]
  • [Cites] Exp Eye Res. 1976 Jun;22(6):587-94 [776638.001]
  • [Cites] Arch Ophthalmol. 1978 Nov;96(11):2031-5 [718491.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1980 Jan;19(1):2-4 [7350130.001]
  • [Cites] Acta Ophthalmol (Copenh). 1979 Oct;57(5):860-7 [525309.001]
  • [Cites] Ophthalmology. 1980 Sep;87(9):861-6 [7413150.001]
  • [Cites] Ophthalmology. 1982 Jun;89(6):525-30 [6750487.001]
  • [Cites] Ophthalmology. 1982 Jun;89(6):531-90 [7122038.001]
  • [Cites] Arch Ophthalmol. 1985 Jan;103(1):68-70 [3977679.001]
  • [Cites] Curr Eye Res. 1985 Jun;4(6):671-8 [4028790.001]
  • [Cites] Arch Ophthalmol. 1985 Oct;103(10):1478-81 [4051849.001]
  • [Cites] Exp Eye Res. 1988 Jul;47(1):27-41 [3409985.001]
  • [Cites] Ophthalmology. 1991 Sep;98(9):1464-8 [1945326.001]
  • [Cites] Ophthalmology. 1994 Jun;101(6):1014-22; discussion 1022-3 [8008341.001]
  • [Cites] J Cataract Refract Surg. 1995 Jul;21(4):409-16 [8523285.001]
  • [Cites] Ophthalmology. 1997 Aug;104(8):1360-5 [9261327.001]
  • [Cites] J Cataract Refract Surg. 2000 May;26(5):727-32 [10831904.001]
  • (PMID = 16519812.001).
  • [ISSN] 1471-2415
  • [Journal-full-title] BMC ophthalmology
  • [ISO-abbreviation] BMC Ophthalmol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1456995
  •  go-up   go-down


48. Faderl S, O'Brien S, Pui CH, Stock W, Wetzler M, Hoelzer D, Kantarjian HM: Adult acute lymphoblastic leukemia: concepts and strategies. Cancer; 2010 Mar 01;116(5):1165-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult acute lymphoblastic leukemia: concepts and strategies.
  • Acute lymphoblastic leukemia (ALL), a clonal expansion of hematopoietic blasts, is a highly heterogeneous disease comprising many entities for which distinct treatment strategies are pursued.
  • An expansion of new drugs, more reliable immunologic and molecular techniques for the assessment of minimal residual disease, and efforts at more precise risk stratification are generating new aspects of adult ALL therapy.
  • For this review, the authors summarized pertinent and recent literature on ALL biology and therapy, and they discuss current strategies and potential implications of novel approaches to the management of adult ALL.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adult. Chromosome Aberrations. Hematopoietic Stem Cell Transplantation. Humans. Philadelphia Chromosome. Prognosis. Recurrence

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2007 May;92(5):612-8 [17488684.001]
  • [Cites] Curr Opin Pediatr. 2008 Feb;20(1):17-22 [18197034.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] Blood. 2007 May 1;109(9):3676-8 [17213285.001]
  • [Cites] Blood. 2007 Apr 1;109 (7):2744-50 [17132721.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1634-7 [17363514.001]
  • [Cites] Blood. 2005 May 1;105(9):3434-41 [15650057.001]
  • [Cites] Blood. 1999 Mar 1;93(5):1643-50 [10029593.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):7-10 [19147069.001]
  • [Cites] Bone Marrow Transplant. 2008 Apr;41(7):635-42 [18084335.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1267-88 [11147223.001]
  • [Cites] Blood. 2006 Jul 15;108(2):465-72 [16556888.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3739-45 [17646667.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2788-801 [15481055.001]
  • [Cites] Bone Marrow Transplant. 2005 Oct;36(8):683-9 [16113673.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3931-9 [10339502.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3768-73 [9850020.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3376-82 [15908649.001]
  • [Cites] Blood. 2007 May 15;109 (10 ):4164-7 [17264295.001]
  • [Cites] Nat Rev Drug Discov. 2007 Feb;6(2):149-65 [17268486.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2580-7 [7989932.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6341-8 [15322509.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):911-8 [19124805.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2097-101 [18720356.001]
  • [Cites] Bone Marrow Transplant. 1994 Sep;14(3):383-8 [7994259.001]
  • [Cites] Bone Marrow Transplant. 2008 Mar;41(5):447-53 [17968326.001]
  • [Cites] Adv Drug Deliv Rev. 2003 Sep 26;55(10 ):1293-302 [14499708.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):11-6 [19147070.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Blood. 2002 Feb 1;99(3):863-71 [11806988.001]
  • [Cites] J Clin Invest. 2007 Apr;117(4):1049-57 [17380207.001]
  • [Cites] Semin Hematol. 2009 Jan;46(1):100-6 [19100372.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1917-23 [16622268.001]
  • [Cites] Blood. 2007 Jan 15;109(2):683-92 [17008550.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1270-6 [12406912.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5136-42 [17344466.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14 (6):1327-52 [11147226.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] Best Pract Res Clin Haematol. 2002 Dec;15(4):741-56 [12617874.001]
  • [Cites] Blood. 2009 Feb 19;113(8):1615-6 [19228927.001]
  • [Cites] Blood. 2009 Feb 19;113(8):1689-98 [19001083.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7161-7 [16192600.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1337-54 [14508819.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2309-15 [17496201.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1469-77 [16638934.001]
  • [Cites] Pediatr Blood Cancer. 2007 Mar;48(3):254-61 [16421910.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4752-8 [15713801.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1569-80 [16502413.001]
  • [Cites] Blood. 1988 Jan;71(1):123-31 [3422030.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):552-9 [15295048.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):193-203 [16467884.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1316-22 [19164206.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1043-9 [14525776.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Semin Hematol. 2009 Jan;46(1):24-32 [19100365.001]
  • [Cites] Blood. 2000 Aug 1;96(3):1094-9 [10910927.001]
  • [Cites] Nat Rev Cancer. 2001 Nov;1(2):99-108 [11905809.001]
  • [Cites] Br J Haematol. 2002 Sep;118(3):748-54 [12181041.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Blood. 2009 Mar 5;113(10):2284-9 [19020309.001]
  • [Cites] Blood. 2009 Apr 30;113(18):4153-62 [19141862.001]
  • [Cites] Bone Marrow Transplant. 2006 Oct;38(7):467-75 [16892073.001]
  • [Cites] Ann Intern Med. 1991 Jul 1;115(1):13-8 [2048858.001]
  • [Cites] N Engl J Med. 2009 Jan 29;360(5):470-80 [19129520.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3072-8 [15637138.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6306-15 [16155013.001]
  • [Cites] Eur J Haematol. 2006 Dec;77(6):471-9 [16978239.001]
  • [Cites] Blood. 2009 Mar 26;113(13):2902-5 [19179301.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2542-51 [16775235.001]
  • [Cites] Blood. 1998 Jun 1;91(11):3995-4019 [9596644.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2464-71 [12011123.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1408-13 [17062730.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1646-54 [18502832.001]
  • [Cites] Blood. 2004 Aug 15;104(4):923-32 [15155462.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):774-80 [12610173.001]
  • [Cites] Nature. 2004 May 27;429(6990):464-8 [15164072.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1259-66 [12094249.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Sep;13(9):1083-94 [17697971.001]
  • [Cites] Leuk Lymphoma. 2007 Jul;48(7):1269-82 [17613754.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Semin Hematol. 2009 Jan;46(1):64-75 [19100369.001]
  • (PMID = 20101737.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 103
  •  go-up   go-down


49. Wang WR, Yang SS, Lin JX, Zeng ZY, Liu DM, Liu HT: [Expression of Aurora-B in non-small cell lung cancer and its clinical significance]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Sep;29(9):1853-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of Aurora-B in non-small cell lung cancer and its clinical significance].
  • OBJECTIVE: To study the expression of Aurora-B in non-small cell lung cancer (NSCLC) tissues and NSCLC cell lines.
  • The mRNA and protein expressions of Aurora-B in NSCLC cell lines (A549, H460 and H1299) were examined by RT-PCR and Western blotting, respectively.
  • Aurora-B was expressed in all the NSCLC cell lines (A549, H460 and H1299) at both mRNA and protein levels.
  • CONCLUSION: Aurora-B protein is highly expressed in NSCLC tissues and cell lines, and may play a crucial role in the invasion, metastasis and development of NSCLC.
  • The mRNA and protein expression levels of Aurora-B differ significantly between different NSCLC cell lines.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Protein-Serine-Threonine Kinases / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aurora Kinase B. Aurora Kinases. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19778810.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.11.1 / AURKB protein, human; EC 2.7.11.1 / Aurora Kinase B; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


50. Trosko JE: Dietary modulation of the multistage, multimechanisms of human carcinogenesis: effects on initiated stem cells and cell-cell communication. Nutr Cancer; 2006;54(1):102-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary modulation of the multistage, multimechanisms of human carcinogenesis: effects on initiated stem cells and cell-cell communication.
  • The mechanism affecting the promotion process appears to be the inhibition of cell-cell communication between normal and initiated cells.
  • Most, if not all, tumor-promoting agents and conditions, reversibly, inhibit cell-cell communication, whereas antipromoters, antioxidants, and anti-inflammatory agents have been shown to ameliorate the effects of tumor promoters on cell-cell communication.
  • Additionally, adult stem cells are hypothesized to be the target cells for initiating the carcinogenic process.
  • A new paradigm has been presented that postulates the first function of the carcinogenic process is to block the "mortalization" of a normal, "immortal" adult stem cell rather than the induction of "immortalization" of a normal mortal cell.
  • [MeSH-major] Cell Communication. Diet. Neoplasms / prevention & control. Stem Cells / pathology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16800778.001).
  • [ISSN] 0163-5581
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / P42 ES04911
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antineoplastic Agents; 0 / Antioxidants
  • [Number-of-references] 107
  •  go-up   go-down


51. Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD: IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol; 2010 May 10;28(14):2348-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
  • PURPOSE To analyze the frequency and associations with prognostic markers and outcome of mutations in IDH genes encoding isocitrate dehydrogenases in adult de novo cytogenetically normal acute myeloid leukemia (CN-AML).
  • The highest expressed gene and microRNAs in R172 IDH2-mutated patients compared with the IDH1/IDH2wt patients were APP (previously associated with complex karyotype AML) and miR-1 and miR-133 (involved in embryonal stem-cell differentiation), respectively.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1995 Jun 22;332(25):1671-7 [7760868.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4290-301 [15514371.001]
  • [Cites] Genomics. 1996 Oct 1;37(1):140-1 [8921382.001]
  • [Cites] Cancer Res. 1998 Jan 1;58(1):55-9 [9426057.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):482-93 [15534356.001]
  • [Cites] N Engl J Med. 2005 Jan 20;352(3):254-66 [15659725.001]
  • [Cites] Nat Cell Biol. 2005 Mar;7(3):255-61 [15723050.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3740-6 [16051734.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9234-42 [16275934.001]
  • [Cites] Leukemia. 2006 Mar;20(3):426-32 [16424866.001]
  • [Cites] Blood. 2006 May 1;107(9):3481-5 [16455952.001]
  • [Cites] J Immunol. 2006 Jul 15;177(2):1078-84 [16818764.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1677-83 [16670265.001]
  • [Cites] Am J Hematol. 2006 Oct;81(10):779-86 [16838325.001]
  • [Cites] J Clin Oncol. 2009 Oct 20;27(30):5031-8 [19752345.001]
  • [Cites] Inflamm Res. 2009 Dec;58(12):909-19 [19603257.001]
  • [Cites] Nature. 2009 Dec 10;462(7274):739-44 [19935646.001]
  • [Cites] Blood. 2010 Jan 21;115(3):453-74 [19880497.001]
  • [Cites] J Clin Oncol. 2010 Feb 1;28(4):596-604 [20026798.001]
  • [Cites] J Inherit Metab Dis. 2008 Apr;31(2):226-9 [18392745.001]
  • [Cites] N Engl J Med. 1994 Oct 6;331(14):896-903 [8078551.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3898-905 [16912223.001]
  • [Cites] Lancet. 2006 Nov 25;368(9550):1894-907 [17126723.001]
  • [Cites] Blood. 2007 Jan 15;109(2):431-48 [16960150.001]
  • [Cites] J Clin Oncol. 2007 May 10;25(14):1908-15 [17488990.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5164-7 [17341662.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3337-43 [17577018.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1552-9 [17940205.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5371-9 [18378853.001]
  • [Cites] Int J Oncol. 2008 Aug;33(2):239-44 [18636143.001]
  • [Cites] Semin Oncol. 2008 Aug;35(4):336-45 [18692684.001]
  • [Cites] Semin Oncol. 2008 Aug;35(4):346-55 [18692685.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4595-602 [18559874.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4934-9 [18591543.001]
  • [Cites] J Exp Med. 2008 Oct 27;205(11):2499-506 [18936236.001]
  • [Cites] J Clin Oncol. 2008 Nov 1;26(31):5078-87 [18809607.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5429-35 [18591546.001]
  • [Cites] Hum Mutat. 2009 Jan;30(1):7-11 [19117336.001]
  • [Cites] N Engl J Med. 2009 Feb 19;360(8):765-73 [19228619.001]
  • [Cites] N Engl J Med. 2009 Feb 19;360(8):813-5 [19228626.001]
  • [Cites] Blood. 2009 Jun 11;113(24):6215-24 [18955566.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3198-204 [19451432.001]
  • [Cites] Circ J. 2009 Aug;73(8):1492-7 [19521018.001]
  • [Cites] Best Pract Res Clin Haematol. 2009 Jun;22(2):239-48 [19698931.001]
  • [Cites] N Engl J Med. 2009 Sep 10;361(11):1058-66 [19657110.001]
  • [Cites] Blood. 2009 Oct 1;114(14):2993-3000 [19643984.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2831-9 [10561359.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7233-9 [11585760.001]
  • [Cites] Hypertens Res. 2002 Jan;25(1):135-40 [11924719.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4326-35 [12036858.001]
  • [Cites] J Immunol. 2002 Jul 1;169(1):415-23 [12077272.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1613-8 [12750167.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):624-33 [14726504.001]
  • [Cites] Blood Rev. 2004 Jun;18(2):115-36 [15010150.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3915-20 [15007164.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1940-51 [15217827.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1418-25 [8640834.001]
  • (PMID = 20368543.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / P50 CA140158; United States / NCI NIH HHS / CA / CA140158; United States / NCI NIH HHS / CA / CA16058; United States / NCI NIH HHS / CA / CA101140; United States / NCI NIH HHS / CA / U10 CA077658; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / R21 CA129657; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / U24 CA114725; United States / NCI NIH HHS / CA / U10 CA101140; United States / NCI NIH HHS / CA / P30 CA016058; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / CA129657; United States / NCI NIH HHS / CA / CA114725; United States / NCI NIH HHS / CA / CA31946
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.41 / isocitrate dehydrogenase 2, human; EC 1.1.1.42. / IDH1 protein, human
  • [Other-IDs] NLM/ PMC2881719
  •  go-up   go-down


52. Ashouri N, Singh J, Arrieta A: Micafungin in pediatrics: when one size does not fit all. Expert Opin Drug Metab Toxicol; 2008 Apr;4(4):463-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Micafungin is one of three FDA-approved echinocandins, a novel class of antifungal agents that target 1,3-beta-D-glucan in the fungal cell wall.
  • As with many drugs, the pharmacokinetic profiles observed in the pediatric population differ from those seen in adult studies.

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18433348.001).
  • [ISSN] 1742-5255
  • [Journal-full-title] Expert opinion on drug metabolism & toxicology
  • [ISO-abbreviation] Expert Opin Drug Metab Toxicol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / Lipopeptides; 0 / Lipoproteins; R10H71BSWG / micafungin
  • [Number-of-references] 30
  •  go-up   go-down


53. Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, Candon S, Le Guern V, Aouba A, Sibilia J, Gottenberg JE, Mariette X: Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis; 2007 Mar;66(3):351-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.
  • OBJECTIVE: To investigate the safety and efficacy of rituximab (RTX) for systemic symptoms in patients with primary Sjögren's syndrome (pSS), and changes in B cell biomarkers.
  • RTX induced decreased rheumatoid factor, gamma-globulin and beta2-microglobulin levels, and the level of B cell activating factor of the tumour necrosis factor family (BAFF) increased concomitantly with B cell depletion.
  • Except for BAFF, the level of which increases, serum B cell biomarker levels decrease after taking RTX.
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Biomarkers / blood. Drug Administration Schedule. Drug Therapy, Combination. Female. Glucocorticoids / administration & dosage. Humans. Lymphoma, B-Cell / drug therapy. Middle Aged. Retrospective Studies. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Sjogren's Syndrome.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 2001 Jul;44(7):1717-8 [11465726.001]
  • [Cites] Clin Rheumatol. 2006 Nov;25(6):891-4 [16283417.001]
  • [Cites] Clin Nucl Med. 2002 Feb;27(2):142-3 [11786752.001]
  • [Cites] Ann Rheum Dis. 2002 Jun;61(6):554-8 [12006334.001]
  • [Cites] Am J Hematol. 2002 Aug;70(4):329 [12214584.001]
  • [Cites] Blood. 2003 May 15;101(10):3818-26 [12506023.001]
  • [Cites] Blood. 2003 May 15;101(10):3827-34 [12560225.001]
  • [Cites] Arthritis Rheum. 2003 Jun 15;49(3):394-8 [12794796.001]
  • [Cites] Curr Opin Rheumatol. 2003 Sep;15(5):563-70 [12960481.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1792 [14630688.001]
  • [Cites] J Pathol. 2004 Apr;202(4):496-502 [15095277.001]
  • [Cites] N Engl J Med. 2004 Jun 17;350(25):2572-81 [15201414.001]
  • [Cites] J Immunol Methods. 2004 Jun;289(1-2):97-109 [15251416.001]
  • [Cites] Rheumatology (Oxford). 2004 Aug;43(8):1050-3 [15187246.001]
  • [Cites] Rheumatology (Oxford). 2004 Oct;43(10):1309-10 [15448217.001]
  • [Cites] Lupus. 2004;13(12):969-71 [15645755.001]
  • [Cites] Rheumatology (Oxford). 2005 Mar;44(3):406 [15637037.001]
  • [Cites] Ann Rheum Dis. 2005 Jun;64(6):913-20 [15550531.001]
  • [Cites] Ann Rheum Dis. 2005 Jun;64(6):958-60 [15576414.001]
  • [Cites] Ann Rheum Dis. 2005 Jul;64(7):1050-5 [15640273.001]
  • [Cites] Ann Rheum Dis. 2005 Jul;64(7):1087-8 [15958765.001]
  • [Cites] Curr Opin Rheumatol. 2005 Sep;17(5):550-7 [16093832.001]
  • [Cites] Arthritis Rheum. 2005 Sep;52(9):2740-50 [16142737.001]
  • [Cites] Arch Intern Med. 2005 Nov 14;165(20):2337-44 [16287762.001]
  • [Cites] Arthritis Rheum. 2006 Mar;54(3):723-32 [16508933.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2770-5 [16477017.001]
  • [Cites] Ann Rheum Dis. 2006 Jun;65(6):796-803 [16284097.001]
  • [Cites] Ann Rheum Dis. 2006 Aug;65(8):1033-7 [16322082.001]
  • [Cites] J Immunol. 2001 Oct 1;167(7):3610-8 [11564773.001]
  • (PMID = 16950808.001).
  • [ISSN] 0003-4967
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Antirheumatic Agents; 0 / Biomarkers; 0 / Glucocorticoids; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ PMC1856024
  •  go-up   go-down


54. Pestina TI, Hargrove PW, Jay D, Gray JT, Boyd KM, Persons DA: Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin. Mol Ther; 2009 Feb;17(2):245-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin.
  • Increased levels of red cell fetal hemogloblin, whether due to hereditary persistence of expression or from induction with hydroxyurea therapy, effectively ameliorate sickle cell disease (SCD).
  • Therefore, we developed erythroid-specific, gamma-globin lentiviral vectors for hematopoietic stem cell (HSC)-targeted gene therapy with the goal of permanently increasing fetal hemoglobin (HbF) production in sickle red cells.
  • We evaluated two different gamma-globin lentiviral vectors for therapeutic efficacy in the BERK sickle cell mouse model.
  • Adult erythroid cells have beta-globin mRNA 3'-UTR-binding proteins that enhance beta-globin mRNA stability and we postulated this design might enhance gamma-globin expression.
  • Stem cell gene transfer was efficient and nearly all red cells in transplanted mice expressed human gamma-globin.
  • [MeSH-major] Anemia, Sickle Cell / therapy. Fetal Hemoglobin / physiology. Genetic Therapy / methods. Genetic Vectors / genetics. Lentivirus / genetics. gamma-Globins / genetics
  • [MeSH-minor] Animals. Blotting, Southern. Cells, Cultured. Electrophoresis. Flow Cytometry. Hematopoietic Stem Cell Transplantation. Mice. Models, Genetic. Reverse Transcriptase Polymerase Chain Reaction. Spleen / metabolism. Spleen / pathology

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Sickle Cell Anemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gene Ther. 2004 Jun;11(11):879-81 [15057265.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4312-9 [12933581.001]
  • [Cites] Semin Hematol. 2004 Oct;41(4):279-86 [15508113.001]
  • [Cites] Blood. 1975 Nov;46(5):683-92 [1174703.001]
  • [Cites] Lancet. 1977 Apr 9;1(8015):795-6 [66587.001]
  • [Cites] J Biol Chem. 1977 May 25;252(10):3414-21 [16902.001]
  • [Cites] Ann Intern Med. 1978 Jan;88(1):1-6 [619731.001]
  • [Cites] Blood. 1984 Apr;63(4):921-6 [6200161.001]
  • [Cites] N Engl J Med. 1994 Jun 9;330(23):1639-44 [7993409.001]
  • [Cites] N Engl J Med. 1995 May 18;332(20):1317-22 [7715639.001]
  • [Cites] Science. 1996 Apr 12;272(5259):263-7 [8602510.001]
  • [Cites] J Exp Med. 1996 Mar 1;183(3):1185-92 [8642260.001]
  • [Cites] Science. 1997 Oct 31;278(5339):876-8 [9346488.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):2173-83 [9528789.001]
  • [Cites] Blood. 1999 Mar 15;93(6):1790-7 [10068649.001]
  • [Cites] Mol Cell Biol. 1999 Jul;19(7):4572-81 [10373506.001]
  • [Cites] Science. 1949 Nov 25;110(2865):543-8 [15395398.001]
  • [Cites] Blood. 2005 Mar 1;105(5):2154-60 [15536151.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2269-75 [16172253.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16013-8 [16247014.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:66-73 [16304361.001]
  • [Cites] Ann N Y Acad Sci. 2005;1054:238-49 [16339671.001]
  • [Cites] Nat Biotechnol. 2006 Jan;24(1):89-94 [16378095.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1651-8 [16166585.001]
  • [Cites] Mol Cell Biol. 2006 Mar;26(6):2419-29 [16508016.001]
  • [Cites] Expert Rev Mol Med. 2006;8(9):1-23 [16690007.001]
  • [Cites] Hum Gene Ther. 2007 Apr;18(4):333-43 [17411365.001]
  • [Cites] Mol Ther. 2007 Oct;15(10):1863-71 [17622240.001]
  • [Cites] Eur J Haematol. 2007 Dec;79(6):516-25 [17976188.001]
  • [Cites] Pediatr Blood Cancer. 2008 Feb;50(2):293-7 [17554794.001]
  • [Cites] Mol Ther. 2008 Mar;16(3):525-33 [18195719.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5785-92 [10582700.001]
  • [Cites] Nat Med. 2000 Feb;6(2):177-82 [10655106.001]
  • [Cites] Nature. 2000 Jul 6;406(6791):82-6 [10894546.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13294-9 [11069298.001]
  • [Cites] Blood. 2001 Jan 15;97(2):410-8 [11154217.001]
  • [Cites] Lancet. 2001 Mar 3;357(9257):680-3 [11247552.001]
  • [Cites] Mol Cell Biol. 2001 Sep;21(17):5879-88 [11486027.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2001;:31-46 [11722977.001]
  • [Cites] Science. 2001 Dec 14;294(5550):2368-71 [11743206.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14380-5 [12391330.001]
  • [Cites] Semin Nephrol. 2003 Jan;23(1):66-76 [12563602.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2175-83 [12411297.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Mar;24(3):382-9 [12637286.001]
  • [Cites] Blood. 2003 Apr 15;101(8):2932-9 [12480689.001]
  • [Cites] JAMA. 2003 Apr 2;289(13):1645-51 [12672732.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Aug;9(8):519-28 [12931121.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2281-90 [15198957.001]
  • (PMID = 19050697.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / U54 HL070590-060006; United States / NHLBI NIH HHS / HL / U54 HL070590-06; United States / NHLBI NIH HHS / HL / U54 HL070590; United States / NHLBI NIH HHS / HL / P01 HL053749; United States / NCI NIH HHS / CA / P30 CA021765-30; United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / P30 CA021765; United States / NHLBI NIH HHS / HL / P01HL053749
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / gamma-Globins; 9034-63-3 / Fetal Hemoglobin
  • [Other-IDs] NLM/ NIHMS83240; NLM/ PMC2670570
  •  go-up   go-down


55. Szeszko JS, Healy B, Stevens H, Balabanova Y, Drobniewski F, Todd JA, Nejentsev S: Resequencing and association analysis of the SP110 gene in adult pulmonary tuberculosis. Hum Genet; 2007 Apr;121(2):155-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resequencing and association analysis of the SP110 gene in adult pulmonary tuberculosis.
  • We genotyped 29 single nucleotide polymorphisms including seven amino-acid changing variants in 1,912 HIV-negative culture-confirmed adult pulmonary tuberculosis patients and 2,104 adult healthy controls from Russia and found no evidence of association.


56. Ratajczak MZ, Zuba-Surma EK, Machalinski B, Ratajczak J, Kucia M: Very small embryonic-like (VSEL) stem cells: purification from adult organs, characterization, and biological significance. Stem Cell Rev; 2008;4(2):89-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Very small embryonic-like (VSEL) stem cells: purification from adult organs, characterization, and biological significance.
  • In this review, we discuss current views of the bone marrow (BM) stem cell (SC) compartment and present data showing that BM contains heterogeneous populations of hematopoietic (H)SCs and non-HSCs.
  • These cells are variously described in the literature as: endothelial progenitor cells (EPCs); mesenchymal (M)SCs; multipotent adult progenitor cells (MAPCs); marrow-isolated adult multilineage inducible (MIAMI) cells; and multipotent adult (MA)SCs.
  • [MeSH-minor] Adult. Animals. Antigens, CD15. Biomarkers. Cell Differentiation. Cell Separation / methods. Flow Cytometry. Hematopoietic Stem Cells / cytology. Hematopoietic Stem Cells / physiology. Humans. Mesenchymal Stromal Cells / cytology. Mesenchymal Stromal Cells / physiology. Multipotent Stem Cells / cytology. Multipotent Stem Cells / physiology. Octamer Transcription Factor-3. Organ Specificity. Pluripotent Stem Cells / cytology. Pluripotent Stem Cells / physiology. Receptors, CXCR4

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2004 Apr 8;428(6983):664-8 [15034593.001]
  • [Cites] Science. 2004 Jul 2;305(5680):90-3 [15232107.001]
  • [Cites] Nat Med. 2003 Jun;9(6):702-12 [12778169.001]
  • [Cites] Leukemia. 2006 May;20(5):847-56 [16453000.001]
  • [Cites] Circ Res. 1999 Aug 6;85(3):221-8 [10436164.001]
  • [Cites] Curr Opin Hematol. 2004 May;11(3):156-64 [15257014.001]
  • [Cites] Science. 1997 Feb 14;275(5302):964-7 [9020076.001]
  • [Cites] Blood. 1998 Jul 15;92(2):362-7 [9657732.001]
  • [Cites] Cell Stem Cell. 2007 Oct 11;1(4):403-15 [18159219.001]
  • [Cites] Int J Hematol. 2000 Dec;72(4):408-11 [11197205.001]
  • [Cites] Nat Med. 2000 Nov;6(11):1229-34 [11062533.001]
  • [Cites] Circ Res. 2004 Dec 10;95(12):1191-9 [15550692.001]
  • [Cites] Science. 1997 Apr 4;276(5309):71-4 [9082988.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 2006 Mar-Apr;54(2):121-35 [16648972.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1487-95 [16791265.001]
  • [Cites] Dig Liver Dis. 2004 Sep;36(9):603-13 [15460845.001]
  • [Cites] Lab Invest. 2006 Jul;86(7):654-63 [16652109.001]
  • [Cites] Nat Immunol. 2002 Apr;3(4):323-8 [11919568.001]
  • [Cites] Leukemia. 2006 May;20(5):857-69 [16498386.001]
  • [Cites] Stem Cells. 2007 Sep;25(9):2245-56 [17556595.001]
  • [Cites] J Embryol Exp Morphol. 1966 Dec;16(3):381-90 [5336210.001]
  • [Cites] Science. 2000 Dec 1;290(5497):1779-82 [11099419.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1662-8 [14592819.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3438-46 [17525288.001]
  • [Cites] Leukemia. 2007 May;21(5):860-7 [17344915.001]
  • [Cites] J Neurosci Res. 2002 Dec 15;70(6):721-33 [12444594.001]
  • [Cites] J Clin Invest. 2003 Jul;112(2):160-9 [12865405.001]
  • [Cites] Ann N Y Acad Sci. 2007 Jun;1106:20-9 [17360803.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1118-27 [15902288.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1525-31 [15905185.001]
  • [Cites] Leukemia. 2006 Jan;20(1):18-28 [16270036.001]
  • [Cites] Science. 1999 May 14;284(5417):1168-70 [10325227.001]
  • [Cites] Leukemia. 2004 Jan;18(1):29-40 [14586476.001]
  • [Cites] Exp Neurol. 2004 Apr;186(2):134-44 [15026252.001]
  • [Cites] Nature. 2001 Apr 5;410(6829):701-5 [11287958.001]
  • [Cites] Nat Med. 2002 Mar;8(3):268-73 [11875498.001]
  • [Cites] Nature. 2002 Apr 4;416(6880):542-5 [11932747.001]
  • [Cites] Science. 2002 Sep 27;297(5590):2256-9 [12215650.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13156-61 [16920790.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2440-8 [17536014.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3483-93 [12893756.001]
  • [Cites] Transplantation. 1968 Mar;6(2):230-47 [5654088.001]
  • [Cites] Cell. 2005 Jul 29;122(2):303-15 [16051153.001]
  • [Cites] Science. 2002 Aug 23;297(5585):1299 [12193778.001]
  • [Cites] J Cell Sci. 2004 Jun 15;117(Pt 14):2971-81 [15173316.001]
  • (PMID = 18459073.001).
  • [ISSN] 1550-8943
  • [Journal-full-title] Stem cell reviews
  • [ISO-abbreviation] Stem Cell Rev
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA106281-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Biomarkers; 0 / Octamer Transcription Factor-3; 0 / Receptors, CXCR4
  • [Number-of-references] 60
  •  go-up   go-down


57. Zucchetto A, Bomben R, Dal Bo M, Sonego P, Nanni P, Rupolo M, Bulian P, Dal Maso L, Del Poeta G, Del Principe MI, Degan M, Gattei V: A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia. J Cell Physiol; 2006 May;207(2):354-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia.
  • We have previously identified 12 surface antigens whose differential expression represented the signature of B-cell chronic lymphocytic leukemia (B-CLL) subsets with different prognosis.
  • [MeSH-major] Antigens, CD / analysis. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD19 / analysis. Antigens, CD38 / analysis. Antigens, CD79 / analysis. Female. Flow Cytometry. Humans. Immunophenotyping / statistics & numerical data. Integrin alpha3 / analysis. Integrin alpha4 / analysis. Intercellular Adhesion Molecule-1 / analysis. L-Selectin / analysis. Male. Middle Aged. Multivariate Analysis. Prognosis. Proportional Hazards Models. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16331666.001).
  • [ISSN] 0021-9541
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD19; 0 / Antigens, CD79; 0 / Integrin alpha3; 126547-89-5 / Intercellular Adhesion Molecule-1; 126880-86-2 / L-Selectin; 143198-26-9 / Integrin alpha4; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


58. Subbarao G, Haut PR, Johnson CS, Gowan D, Molleston JP: Incidence, etiology, and risk factors for liver dysfunction in children following hematopoietic stem cell transplantation. Pediatr Transplant; 2006 Sep;10(6):682-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence, etiology, and risk factors for liver dysfunction in children following hematopoietic stem cell transplantation.
  • AIMS: To identify risk factors which predispose children to develop liver dysfunction (LD) during the initial 100 days following hematopoietic stem cell transplantation (HSCT).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Liver Diseases / etiology
  • [MeSH-minor] Adolescent. Adult. Alanine Transaminase / blood. Chi-Square Distribution. Child. Child, Preschool. Female. Humans. Immunosuppressive Agents / adverse effects. Immunosuppressive Agents / therapeutic use. Incidence. Infant. Jaundice / enzymology. Jaundice / etiology. Liver Function Tests. Logistic Models. Male. Retrospective Studies. Risk Factors. Statistics, Nonparametric. Survival Rate. Transplantation Conditioning / adverse effects. Transplantation Conditioning / methods. gamma-Glutamyltransferase / blood

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16911491.001).
  • [ISSN] 1397-3142
  • [Journal-full-title] Pediatric transplantation
  • [ISO-abbreviation] Pediatr Transplant
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; EC 2.3.2.2 / gamma-Glutamyltransferase; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


59. Otto A, Collins-Hooper H, Patel K: The origin, molecular regulation and therapeutic potential of myogenic stem cell populations. J Anat; 2009 Nov;215(5):477-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The origin, molecular regulation and therapeutic potential of myogenic stem cell populations.
  • Satellite cells, originating in the embryonic dermamyotome, reside beneath the myofibre of mature adult skeletal muscle and constitute the tissue-specific stem cell population.
  • In response to muscle damage, satellite cells harbour the ability both to form myogenic precursors and to self-renew to repopulate the stem cell niche following myofibre damage.
  • More recently, other stem cell populations including bone marrow stem cells, skeletal muscle side population cells and mesoangioblasts have also been shown to have myogenic potential in culture, and to be able to form skeletal muscle myofibres in vivo and engraft into the satellite cell niche.
  • These cell types, along with satellite cells, have shown potential when used as a therapy for skeletal muscle wasting disorders where the intrinsic stem cell population is genetically unable to repair non-functioning muscle tissue.
  • Accurate understanding of the mechanisms controlling satellite cell lineage progression and self-renewal as well as the recruitment of other stem cell types towards the myogenic lineage is crucial if we are to exploit the power of these cells in combating myopathic conditions.
  • Here we highlight the origin, molecular regulation and therapeutic potential of all the major cell types capable of undergoing myogenic differentiation and discuss their potential therapeutic application.
  • [MeSH-minor] Animals. Cell Differentiation / genetics. Cell Proliferation. Hematopoietic Stem Cells / cytology. Humans. Muscle, Skeletal / embryology. Muscular Diseases / therapy. Paired Box Transcription Factors / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 1990 Aug;109(4):943-52 [2226207.001]
  • [Cites] J Cell Sci. 1990 Nov;97 ( Pt 3):449-61 [2074265.001]
  • [Cites] Genes Dev. 1991 Apr;5(4):594-604 [1672661.001]
  • [Cites] EMBO J. 1991 May;10(5):1135-47 [2022185.001]
  • [Cites] Mech Dev. 1990 Dec;33(1):27-37 [1982921.001]
  • [Cites] Genomics. 1991 Oct;11(2):424-34 [1685142.001]
  • [Cites] Dev Biol. 1992 Oct;153(2):217-26 [1397679.001]
  • [Cites] J Exp Med. 1996 Apr 1;183(4):1797-806 [8666936.001]
  • [Cites] Mol Biol Cell. 1996 May;7(5):719-29 [8744946.001]
  • [Cites] Curr Opin Cell Biol. 1996 Dec;8(6):851-7 [8939674.001]
  • [Cites] Science. 1997 Apr 4;276(5309):71-4 [9082988.001]
  • [Cites] Cell. 1997 Apr 4;89(1):127-38 [9094721.001]
  • [Cites] Nature. 1997 May 1;387(6628):83-90 [9139826.001]
  • [Cites] Diabetes. 1997 Nov;46(11):1691-700 [9356014.001]
  • [Cites] Dev Biol. 1997 Nov 15;191(2):270-83 [9398440.001]
  • [Cites] Dev Biol. 1998 Feb 1;194(1):114-28 [9473336.001]
  • [Cites] Science. 1998 Mar 6;279(5356):1528-30 [9488650.001]
  • [Cites] J Bone Miner Res. 1998 May;13(5):828-38 [9610747.001]
  • [Cites] Mol Biol Cell. 1998 Jul;9(7):1891-902 [9658178.001]
  • [Cites] J Cell Biol. 1998 Sep 7;142(5):1257-67 [9732286.001]
  • [Cites] Dev Biol. 1998 Nov 1;203(1):49-61 [9806772.001]
  • [Cites] Exp Neurol. 1999 Jan;155(1):22-30 [9918701.001]
  • [Cites] J Cell Biol. 1999 Mar 22;144(6):1113-22 [10087257.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7 Suppl):1707s-1709s; discussion 1709s-1710s [10197584.001]
  • [Cites] Nature. 1999 Sep 23;401(6751):390-4 [10517639.001]
  • [Cites] J Biophys Biochem Cytol. 1961 Feb;9:493-5 [13768451.001]
  • [Cites] Cell. 2004 Nov 12;119(4):543-54 [15537543.001]
  • [Cites] J Clin Invest. 2004 Dec;114(11):1577-85 [15578090.001]
  • [Cites] Blood. 2004 Dec 15;104(13):4311-8 [15328150.001]
  • [Cites] Stem Cells. 2004;22(7):1292-304 [15579647.001]
  • [Cites] FASEB J. 2005 Feb;19(2):237-9 [15545301.001]
  • [Cites] Dev Biol. 2005 Mar 15;279(2):336-44 [15733662.001]
  • [Cites] Stem Cells. 2005 May;23(5):610-8 [15849168.001]
  • [Cites] Exp Cell Res. 2005 Jul 1;307(1):174-82 [15922737.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):948-53 [15843801.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):954-8 [15843802.001]
  • [Cites] Genes Dev. 2005 Jun 15;19(12):1426-31 [15964993.001]
  • [Cites] J Histochem Cytochem. 2005 Jul;53(7):861-73 [15995145.001]
  • [Cites] Science. 2005 Jul 8;309(5732):314-7 [16002622.001]
  • [Cites] Pigment Cell Res. 2005 Aug;18(4):243-51 [16029418.001]
  • [Cites] Cell. 2005 Jul 29;122(2):289-301 [16051152.001]
  • [Cites] Cell Tissue Res. 2005 Sep;321(3):391-400 [15988617.001]
  • [Cites] J Cell Sci. 2005 Oct 1;118(Pt 19):4343-52 [16144866.001]
  • [Cites] Science. 2005 Sep 23;309(5743):2064-7 [16141372.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(21):9509-19 [16227601.001]
  • [Cites] J Cell Biol. 2005 Nov 7;171(3):483-92 [16275752.001]
  • [Cites] J Cell Biol. 2006 Jan 2;172(1):91-102 [16380438.001]
  • [Cites] J Cell Biol. 2006 Jan 2;172(1):103-13 [16391000.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):945-50 [16418263.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Mar 17;341(3):882-8 [16442498.001]
  • [Cites] J Cell Sci. 2006 May 1;119(Pt 9):1824-32 [16608873.001]
  • [Cites] Am J Physiol Cell Physiol. 2006 Jun;290(6):C1487-94 [16684931.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Apr;65(4):371-86 [16691118.001]
  • [Cites] Nat Cell Biol. 2006 Jul;8(7):677-87 [16799552.001]
  • [Cites] Cell. 2007 Jun 1;129(5):999-1010 [17540178.001]
  • [Cites] Dev Biol. 2003 Oct 1;262(1):64-74 [14512018.001]
  • [Cites] Mol Biol Cell. 2003 May;14(5):2151-62 [12802082.001]
  • [Cites] Nat Cell Biol. 2003 Jul;5(7):640-6 [12792651.001]
  • [Cites] Cell. 2003 Jun 27;113(7):841-52 [12837243.001]
  • [Cites] Science. 2003 Jul 25;301(5632):487-92 [12855815.001]
  • [Cites] J Cell Biol. 2007 Jun 4;177(5):769-79 [17548510.001]
  • [Cites] Cell Metab. 2007 Jul;6(1):38-54 [17618855.001]
  • [Cites] J Cell Sci. 2007 Sep 1;120(Pt 17):3086-98 [17684061.001]
  • [Cites] J Cell Sci. 2006 Jul 15;119(Pt 14):2945-52 [16825428.001]
  • [Cites] J Cell Biol. 2006 Jul 17;174(2):231-43 [16831885.001]
  • [Cites] Dev Biol. 2006 Aug 1;296(1):164-76 [16730693.001]
  • [Cites] Anat Embryol (Berl). 2006 Aug;211(4):293-310 [16506066.001]
  • [Cites] Muscle Nerve. 2006 Sep;34(3):313-9 [16810685.001]
  • [Cites] Genes Dev. 2006 Sep 1;20(17):2450-64 [16951257.001]
  • [Cites] Hepatology. 2006 Oct;44(4):992-1002 [17006939.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16995-7000 [17077152.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):574-9 [17108972.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Dec;7(12):885-96 [17139329.001]
  • [Cites] Exp Cell Res. 2006 Nov 15;312(19):3872-9 [16982052.001]
  • [Cites] J Cell Sci. 2006 Dec 15;119(Pt 24):5114-23 [17158915.001]
  • [Cites] Neuromuscul Disord. 2007 Jan;17(1):38-46 [17142039.001]
  • [Cites] Nat Cell Biol. 2007 Mar;9(3):255-67 [17293855.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4401-6 [17360536.001]
  • [Cites] Mol Ther. 2007 May;15(5):867-77 [17387336.001]
  • [Cites] Mol Biol Cell. 2007 Jun;18(6):1992-2001 [17377068.001]
  • [Cites] Dev Biol. 2009 Mar 15;327(2):273-9 [19162003.001]
  • [Cites] Cell Stem Cell. 2009 Mar 6;4(3):217-25 [19265661.001]
  • [Cites] Cell. 2009 Mar 6;136(5):913-25 [19269368.001]
  • [Cites] Microvasc Res. 2009 May;77(3):235-46 [19323975.001]
  • [Cites] Stem Cells. 2009 Jan;27(1):157-64 [18845762.001]
  • [Cites] Dev Cell. 2009 Jun;16(6):822-32 [19531353.001]
  • [Cites] Nat Med. 2003 Dec;9(12):1528-32 [14625543.001]
  • [Cites] Nat Med. 2003 Dec;9(12):1520-7 [14625546.001]
  • [Cites] Exp Hematol. 2003 Dec;31(12):1323-30 [14662341.001]
  • [Cites] J Cell Biol. 2004 Feb 2;164(3):441-9 [14744997.001]
  • [Cites] Am J Pathol. 2004 Mar;164(3):773-9 [14982831.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3581-6 [14993597.001]
  • [Cites] Exp Cell Res. 2004 Apr 15;295(1):66-78 [15051491.001]
  • [Cites] J Cell Sci. 2004 Apr 15;117(Pt 10):1979-88 [15054107.001]
  • [Cites] Genes Dev. 2004 May 1;18(9):1088-105 [15132998.001]
  • [Cites] PLoS Biol. 2004 May;2(5):E130 [15138500.001]
  • [Cites] Exp Hematol. 2004 May;32(5):426-34 [15145210.001]
  • [Cites] Blood. 2004 Jul 1;104(1):290-4 [15010375.001]
  • [Cites] Exp Cell Res. 2004 Aug 1;298(1):144-54 [15242769.001]
  • [Cites] J Cell Biol. 2004 Aug 2;166(3):347-57 [15277541.001]
  • [Cites] EMBO J. 2004 Aug 18;23(16):3430-9 [15282552.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Sep 3;321(4):1050-61 [15358135.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13507-12 [15353585.001]
  • [Cites] Anat Embryol (Berl). 2004 Sep;208(6):411-24 [15338303.001]
  • [Cites] Exp Cell Res. 2004 Nov 1;300(2):418-26 [15475006.001]
  • [Cites] Circulation. 2004 Oct 12;110(15):2226-32 [15466630.001]
  • [Cites] Dev Biol. 2004 Nov 15;275(2):375-88 [15501225.001]
  • [Cites] J Cell Biol. 1969 Feb;40(2):568-71 [5812478.001]
  • [Cites] J Cell Biol. 1970 Feb;44(2):459-62 [5411085.001]
  • [Cites] Anat Rec. 1971 Aug;170(4):421-35 [5118594.001]
  • [Cites] Nature. 1975 May 15;255(5505):197-200 [1143315.001]
  • [Cites] Anat Rec. 1975 Jun;182(2):215-35 [168794.001]
  • [Cites] Anat Rec. 1977 Jun;188(2):181-99 [869237.001]
  • [Cites] Anat Rec. 1977 Jun;188(2):201-17 [869238.001]
  • [Cites] Arch Anat Microsc Morphol Exp. 1983;72(2):163-81 [6651304.001]
  • [Cites] Dev Biol. 1986 May;115(1):140-7 [3699242.001]
  • [Cites] Cell. 1986 Dec 26;47(6):1033-40 [2877747.001]
  • [Cites] J Cell Physiol. 1987 Dec;133(3):567-72 [3480289.001]
  • [Cites] J Cell Physiol. 1989 Feb;138(2):311-5 [2918032.001]
  • [Cites] Nature. 1990 May 24;345(6273):350-3 [2111464.001]
  • [Cites] Hum Reprod. 2007 Nov;22(11):2903-11 [17872908.001]
  • [Cites] Stem Cells. 2007 Dec;25(12):3173-82 [17761758.001]
  • [Cites] Dev Biol. 2008 Mar 15;315(2):437-47 [18255054.001]
  • [Cites] Biol Cell. 2008 Apr;100(4):231-41 [17997718.001]
  • [Cites] Cell Stem Cell. 2008 Jan 10;2(1):50-9 [18371421.001]
  • [Cites] J Cell Sci. 2008 May 1;121(Pt 9):1373-82 [18397993.001]
  • [Cites] J Cell Sci. 2008 May 1;121(Pt 9):1426-34 [18397996.001]
  • [Cites] Genes Dev. 2008 May 15;22(10):1397-409 [18483224.001]
  • [Cites] Gene Ther. 2008 Aug;15(15):1116-25 [18509381.001]
  • [Cites] Int J Biochem Cell Biol. 2008;40(10):2183-91 [18403250.001]
  • [Cites] J Cell Sci. 2008 Sep 1;121(Pt 17):2939-50 [18697834.001]
  • [Cites] Nature. 2008 Aug 21;454(7207):961-7 [18719582.001]
  • [Cites] Cell Stem Cell. 2008 Sep 11;3(3):301-13 [18786417.001]
  • [Cites] Stem Cells. 2008 Sep;26(9):2425-33 [18617684.001]
  • [Cites] Exp Cell Res. 2008 Oct 1;314(16):2951-64 [18647602.001]
  • [Cites] J Cell Physiol. 2009 Feb;218(2):444-9 [18937285.001]
  • [Cites] FASEB J. 2009 Feb;23(2):382-95 [18827026.001]
  • [Cites] Trends Biochem Sci. 1992 Aug;17(8):289-92 [1412702.001]
  • [Cites] FEBS Lett. 1993 Jan 25;316(2):175-80 [7678401.001]
  • [Cites] Neurology. 1993 Jul;43(7):1432-4 [8093118.001]
  • [Cites] Cell. 1993 Dec 31;75(7):1351-9 [8269513.001]
  • [Cites] J Cell Biol. 1994 Jun;125(6):1275-87 [8207057.001]
  • [Cites] Dev Dyn. 1994 Apr;199(4):326-37 [8075434.001]
  • [Cites] Dev Dyn. 1995 Mar;202(3):244-54 [7780174.001]
  • [Cites] Development. 1994 Apr;120(4):957-71 [7600971.001]
  • [Cites] Nature. 1995 Aug 31;376(6543):768-71 [7651534.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9856-60 [7568232.001]
  • [Cites] J Cell Physiol. 1995 Nov;165(2):307-12 [7593208.001]
  • [Cites] Muscle Nerve. 1995 Dec;18(12):1417-26 [7477065.001]
  • [Cites] Genes Dev. 1995 Dec 1;9(23):2911-22 [7498788.001]
  • [Cites] Development. 1995 Nov;121(11):3675-86 [8582280.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4213-8 [8633043.001]
  • [Cites] Genes Dev. 1996 May 15;10(10):1173-83 [8675005.001]
  • [Cites] Muscle Nerve. 1996 Jul;19(7):853-60 [8965839.001]
  • [Cites] J Cell Biol. 1999 Nov 15;147(4):869-78 [10562287.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14482-6 [10588731.001]
  • [Cites] Muscle Nerve. 2000 Feb;23(2):239-45 [10639617.001]
  • [Cites] J Cell Biol. 2000 Sep 4;150(5):1085-100 [10973997.001]
  • [Cites] Cell. 2000 Sep 15;102(6):777-86 [11030621.001]
  • [Cites] Nature. 2000 Nov 2;408(6808):92-6 [11081514.001]
  • [Cites] Dev Biol. 2000 Dec 1;228(1):86-94 [11087628.001]
  • [Cites] J Cell Biol. 2000 Dec 11;151(6):1221-34 [11121437.001]
  • [Cites] FEBS Lett. 2001 Feb 16;490(3):171-8 [11223032.001]
  • [Cites] J Cell Biol. 2001 Jan 22;152(2):335-48 [11266450.001]
  • [Cites] Tissue Eng. 2001 Apr;7(2):211-28 [11304456.001]
  • [Cites] Blood Cells Mol Dis. 2001 May-Jun;27(3):605-9 [11482874.001]
  • [Cites] Blood. 2001 Oct 1;98(7):2008-13 [11567983.001]
  • [Cites] Dev Dyn. 2001 Nov;222(3):506-21 [11747084.001]
  • [Cites] Differentiation. 2001 Oct;68(4-5):245-53 [11776477.001]
  • [Cites] Dev Biol. 2001 Nov 1;239(1):79-94 [11784020.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1341-6 [11830662.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2064-71 [11929826.001]
  • [Cites] Development. 2002 Jun;129(11):2773-83 [12015303.001]
  • [Cites] J Cell Biol. 2002 May 27;157(5):851-64 [12021255.001]
  • [Cites] Exp Cell Res. 2002 Jul 1;277(1):74-85 [12061818.001]
  • [Cites] Nature. 2002 Jul 4;418(6893):41-9 [12077603.001]
  • [Cites] Dev Cell. 2002 Sep;3(3):397-409 [12361602.001]
  • [Cites] J Cell Biol. 2002 Oct 14;159(1):123-34 [12379804.001]
  • [Cites] Cell. 2002 Nov 15;111(4):589-601 [12437931.001]
  • [Cites] J Anat. 2003 Jan;202(1):59-68 [12587921.001]
  • [Cites] Genesis. 2003 Mar;35(3):153-9 [12640619.001]
  • [Cites] J Cell Biol. 2003 Mar 17;160(6):909-18 [12629053.001]
  • [Cites] Stem Cells. 2003;21(3):363-71 [12743331.001]
  • [Cites] Int J Biochem Cell Biol. 2003 Aug;35(8):1151-6 [12757751.001]
  • (PMID = 19702867.001).
  • [ISSN] 1469-7580
  • [Journal-full-title] Journal of anatomy
  • [ISO-abbreviation] J. Anat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Paired Box Transcription Factors
  • [Number-of-references] 185
  • [Other-IDs] NLM/ PMC2780567
  •  go-up   go-down


60. Roethig HJ, Feng S, Liang Q, Liu J, Rees WA, Zedler BK: A 12-month, randomized, controlled study to evaluate exposure and cardiovascular risk factors in adult smokers switching from conventional cigarettes to a second-generation electrically heated cigarette smoking system. J Clin Pharmacol; 2008 May;48(5):580-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 12-month, randomized, controlled study to evaluate exposure and cardiovascular risk factors in adult smokers switching from conventional cigarettes to a second-generation electrically heated cigarette smoking system.
  • This randomized, controlled, forced-switching, open-label, parallel-group study in 97 adult male and female smokers of conventional cigarettes evaluated biomarkers of tobacco smoke exposure and cardiovascular risk factors.
  • These reductions in exposure in the EHCSS group were associated with statistically significant and pathophysiologically favorable changes in several cardiovascular risk factors, including white blood cell count (-0.78 x 10(3)/microL), hemoglobin (-0.16 g/dL), hematocrit (-0.44%), urine 11-dehydrothromboxane B2 (-374 ng/24 h), and high-density lipoprotein cholesterol (+5 mg/dL).
  • [MeSH-minor] Adult. Carboxyhemoglobin / urine. Cholesterol, HDL / blood. Cotinine / blood. Female. Follow-Up Studies. Humans. Male. Middle Aged. Mutagens / analysis. Nicotine / urine. Nicotinic Agonists. Risk Factors. Thromboxane B2 / analogs & derivatives. Thromboxane B2 / urine

  • MedlinePlus Health Information. consumer health - Smoking.
  • Hazardous Substances Data Bank. Cotinine .
  • Hazardous Substances Data Bank. NICOTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18319361.001).
  • [ISSN] 0091-2700
  • [Journal-full-title] Journal of clinical pharmacology
  • [ISO-abbreviation] J Clin Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cholesterol, HDL; 0 / Mutagens; 0 / Nicotinic Agonists; 54397-85-2 / Thromboxane B2; 67910-12-7 / 11-dehydro-thromboxane B2; 6M3C89ZY6R / Nicotine; 9061-29-4 / Carboxyhemoglobin; K5161X06LL / Cotinine
  •  go-up   go-down


61. Tsai WH, Hsu HC, Lin CC, Ho CK, Kou YR: Role of interleukin-8 and growth-regulated oncogene-alpha in the chemotactic migration of all-trans retinoic acid-treated promyelocytic leukemic cells toward alveolar epithelial cells. Crit Care Med; 2007 Mar;35(3):879-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Although all-trans retinoic acid (ATRA) can treat acute promyelocytic leukemia (APL), it also causes retinoic acid syndrome with presentations similar to acute respiratory distress syndrome.
  • DESIGN: An in vitro human cell culture study.
  • CONCLUSIONS: IL-8 and GRO-alpha secreted from alveolar epithelial cells play an important role in the cell-cell interaction involved in the chemotactic transmigration of ATRA-treated APL cells toward alveolar epithelial cells.
  • [MeSH-major] Antineoplastic Agents / toxicity. Chemokines, CXC / physiology. Chemotaxis, Leukocyte / drug effects. Interleukin-8 / physiology. Leukemia, Promyelocytic, Acute / drug therapy. Pulmonary Alveoli / drug effects. Respiratory Distress Syndrome, Adult / chemically induced. Tretinoin / toxicity
  • [MeSH-minor] Cell Line, Tumor. Cell Movement / drug effects. Chemokine CXCL1. Epithelial Cells / drug effects. Epithelial Cells / immunology. Flow Cytometry. Humans. In Vitro Techniques

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Crit Care Med. 2007 Mar;35(3):974-5 [17421102.001]
  • (PMID = 17235257.001).
  • [ISSN] 0090-3493
  • [Journal-full-title] Critical care medicine
  • [ISO-abbreviation] Crit. Care Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CXCL1 protein, human; 0 / Chemokine CXCL1; 0 / Chemokines, CXC; 0 / Interleukin-8; 5688UTC01R / Tretinoin
  •  go-up   go-down


62. Stepanichev MY, Moiseeva YV, Lazareva NA, Onufriev MV, Gulyaeva NV: Changes in cell proliferation in the subventricular zone of the brain in adult rats given beta-amyloid peptide (25-35). Neurosci Behav Physiol; 2010 Feb;40(2):123-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in cell proliferation in the subventricular zone of the brain in adult rats given beta-amyloid peptide (25-35).
  • The effects of intracerebroventricular administration of fragment (25-35) of beta-amyloid peptide [Abeta(25-35)] on cell proliferation in the subventricular zone of the dentate gyrus of the hippocampus in adult rats were analyzed.
  • Thus, Abeta(25-35) significantly increased cell proliferation in the subventricular zone after intracerebroventricular administration.
  • [MeSH-major] Amyloid beta-Peptides / metabolism. Cell Proliferation. Dentate Gyrus / physiology. Peptide Fragments / metabolism. Stem Cell Niche / physiology

  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Physiol Behav. 2004 Feb;80(5):647-55 [14984798.001]
  • [Cites] Neuromolecular Med. 2002;1(2):125-35 [12025858.001]
  • [Cites] J Neurosci. 2002 Feb 1;22(3):612-3 [11826087.001]
  • [Cites] Neuropathology. 2004 Sep;24(3):194-200 [15484697.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10417-22 [12925731.001]
  • [Cites] J Neurosci. 2004 Jun 9;24(23):5439-44 [15190117.001]
  • [Cites] Physiol Rev. 2001 Apr;81(2):741-66 [11274343.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):343-7 [14660786.001]
  • [Cites] J Neurochem. 2002 Dec;83(6):1509-24 [12472904.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13363-7 [15340159.001]
  • (PMID = 20033317.001).
  • [ISSN] 1573-899X
  • [Journal-full-title] Neuroscience and behavioral physiology
  • [ISO-abbreviation] Neurosci. Behav. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amyloid beta-Peptides; 0 / Peptide Fragments; 0 / amyloid beta-protein (25-35); G34N38R2N1 / Bromodeoxyuridine
  •  go-up   go-down


63. Corn CM, Hauser-Kronberger C, Moser M, Tews G, Ebner T: Predictive value of cumulus cell apoptosis with regard to blastocyst development of corresponding gametes. Fertil Steril; 2005 Sep;84(3):627-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of cumulus cell apoptosis with regard to blastocyst development of corresponding gametes.
  • INTERVENTION(S): Cumulus-oocyte complexes were denuded separately and the resulting cumulus cell suspensions were analyzed for presence of apoptosis using a terminal deoxynucleotidyl transferase-mediated digoxigenin-dUTP nick-end labeling (TUNEL) assay detection kit.
  • At zygote and cleavage stages (days 1 to 4) no morphologic features were related to the degree of programmed cell death.
  • [MeSH-minor] Adult. Cells, Cultured. Female. Germ Cells / cytology. Germ Cells / physiology. Humans. Predictive Value of Tests. Pregnancy. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16169395.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Bidaut G, Stoeckert CJ Jr: Large scale transcriptome data integration across multiple tissues to decipher stem cell signatures. Methods Enzymol; 2009;467:229-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large scale transcriptome data integration across multiple tissues to decipher stem cell signatures.
  • A wide variety of stem cells has been reported to exist and renew several adult tissues, raising the question of the existence of a stemness signature-that is, a common molecular program of differentiation.
  • To detect such a signature, we applied a data integration algorithm on several DNA microarray datasets generated by the Stem Cell Genome Anatomy Project (SCGAP) Consortium on several mouse and human tissues, to generate a cross-organism compendium that we submitted to a single layer artificial neural network (ANN) trained to attribute differentiation labels-from totipotent stem cells to differentiated ones (five labels in total were used).
  • This chapter presents technological details on DNA microarray integration, ANN training through leave-one-out cross-validation, and independent testing on uncharacterized adult tissues by automated detection of differentiation capabilities on human prostate and mouse stomach progenitors.
  • All scripts of the Stem Cell Analysis and characterization by Neural Networks (SCANN) project are available on the SourceForge Web site: http://scann.sourceforge.net.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Data and Code Repositories. supplemental materials - Supporting Code at SourceForge .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19897095.001).
  • [ISSN] 1557-7988
  • [Journal-full-title] Methods in enzymology
  • [ISO-abbreviation] Meth. Enzymol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / U01 DK63481
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


65. Magomedova AU, Vorob'ev AI: [International prognostic index in diffuse B large cell lymphosarcoma]. Ter Arkh; 2008;80(3):71-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [International prognostic index in diffuse B large cell lymphosarcoma].
  • AIM: To evaluate efficacy of the International Prognostic Index (IPI) in relation to diffuse B-large cell lymphosarcoma (BLCLS), to identify significant prognostic factors.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Morbidity / trends. Prognosis. Remission Induction / methods. Retrospective Studies. Survival Rate / trends

  • Genetic Alliance. consumer health - Lymphosarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18441690.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


66. Carageorgiou H, Pantos C, Zarros A, Stolakis V, Mourouzis I, Cokkinos D, Tsakiris S: Effects of hyper- and hypothyroidism on acetylcholinesterase, (Na(+), K (+))- and Mg ( 2+ )-ATPase activities of adult rat hypothalamus and cerebellum. Metab Brain Dis; 2007 Mar;22(1):31-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of hyper- and hypothyroidism on acetylcholinesterase, (Na(+), K (+))- and Mg ( 2+ )-ATPase activities of adult rat hypothalamus and cerebellum.
  • The aim of this work was to investigate how changes in metabolism induced by THs could affect the activities of acetylcholinesterase (AChE), (Na(+), K(+))- and Mg(2+)-ATPase in the hypothalamus and the cerebellum of adult rats.

  • MedlinePlus Health Information. consumer health - Hyperthyroidism.
  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Res. 1987 Apr 7;408(1-2):399-402 [3036307.001]
  • [Cites] Mech Ageing Dev. 2001 Apr 30;122(5):491-501 [11292514.001]
  • [Cites] Brain Res. 1980 Oct 6;198(2):389-402 [7407604.001]
  • [Cites] Z Naturforsch C. 2000 Mar-Apr;55(3-4):271-7 [10817219.001]
  • [Cites] Dev Neurosci. 1989;11(3):188-204 [2766963.001]
  • [Cites] Endocr Rev. 1997 Aug;18(4):462-75 [9267760.001]
  • [Cites] Metab Brain Dis. 2005 Jun;20(2):129-39 [15938131.001]
  • [Cites] J Pharmacol Exp Ther. 1984 Feb;228(2):304-11 [6141282.001]
  • [Cites] Basic Res Cardiol. 1999 Aug;94(4):254-60 [10505425.001]
  • [Cites] Can J Physiol Pharmacol. 1977 Apr;55(2):170-9 [141320.001]
  • [Cites] Jpn J Physiol. 1989;39(3):429-40 [2552204.001]
  • [Cites] J Neurochem. 1981 Feb;36(2):467-75 [6257854.001]
  • [Cites] Endocrinology. 1992 Feb;130(2):1077-9 [1733708.001]
  • [Cites] Brain Res. 1977 Mar 4;123(1):188-92 [843918.001]
  • [Cites] Neurosci Lett. 1990 Dec 11;120(2):159-62 [1705675.001]
  • [Cites] Endocrinology. 1987 Jan;120(1):325-31 [3780566.001]
  • [Cites] J Endocrinol. 1993 Aug;138(2):299-305 [7901316.001]
  • [Cites] Med Hypotheses. 1989 Nov;30(3):195-202 [2689848.001]
  • [Cites] Exp Brain Res. 1991;83(3):555-61 [1851100.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Sep;86(18):7250-4 [2780568.001]
  • [Cites] J Endocrinol. 2003 Sep;178(3):427-35 [12967335.001]
  • [Cites] Eur J Endocrinol. 1995 Oct;133(4):390-8 [7581959.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Life Sci. 1968 Apr 1;7(7):419-28 [5652184.001]
  • [Cites] J Neurochem. 1980 Jan;34(1):213-5 [7452237.001]
  • [Cites] J Neurochem. 1974 Sep;23(3):611-3 [4279007.001]
  • [Cites] Mol Cell Endocrinol. 1985 May;40(2-3):149-58 [2989030.001]
  • [Cites] Free Radic Biol Med. 1995 Feb;18(2):223-30 [7744305.001]
  • [Cites] Zhonghua Yu Fang Yi Xue Za Zhi. 1996 Nov;30(6):337-9 [9388907.001]
  • [Cites] Mol Endocrinol. 1991 Sep;5(9):1339-50 [1663215.001]
  • [Cites] Biochem Pharmacol. 1961 Jul;7:88-95 [13726518.001]
  • (PMID = 17165152.001).
  • [ISSN] 0885-7490
  • [Journal-full-title] Metabolic brain disease
  • [ISO-abbreviation] Metab Brain Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.- / Hydrolases; EC 3.1.1.7 / Acetylcholinesterase; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.1.- / magnesium sodium ATPase; EC 3.6.3.9 / Sodium-Potassium-Exchanging ATPase
  •  go-up   go-down


67. Hougeir FG, Yiannias JA, Hinni ML, Hentz JG, el-Azhary RA: Oral metal contact allergy: a pilot study on the cause of oral squamous cell carcinoma. Int J Dermatol; 2006 Mar;45(3):265-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral metal contact allergy: a pilot study on the cause of oral squamous cell carcinoma.
  • BACKGROUND: Intraoral metal contact allergy may result in mucositis that mimics lichen planus and the pathogenesis of squamous cell carcinoma.
  • METHODS: Clinical records of all patients examined in the departments of dermatology and otorhinolaryngology at a tertiary-care academic medical center between June 1994 and June 2000 who had a diagnosis of intraoral squamous cell carcinoma adjacent to a metal dental restoration and who were patch tested with our metal series were reviewed retrospectively.
  • CONCLUSION: Contact allergy to metal dental restorations may be a risk factor for development of intraoral squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / etiology. Dental Restoration, Permanent / adverse effects. Dermatitis, Contact / etiology. Metals / adverse effects. Mouth Neoplasms / etiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Patch Tests. Pilot Projects. Retrospective Studies


68. Scharnhorst V, Wals J, Beverloo HB, Langerak AW, van der Velden VH: Mutation of FLT3 is not a general phenomenon in CD117-positive T-ALL. Leuk Res; 2006 Feb;30(2):245-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / genetics. Mutation. Proto-Oncogene Proteins c-kit / analysis. fms-Like Tyrosine Kinase 3 / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16081157.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


69. Crupi R, Cambiaghi M, Spatz L, Hen R, Thorn M, Friedman E, Vita G, Battaglia F: Reduced adult neurogenesis and altered emotional behaviors in autoimmune-prone B-cell activating factor transgenic mice. Biol Psychiatry; 2010 Mar 15;67(6):558-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced adult neurogenesis and altered emotional behaviors in autoimmune-prone B-cell activating factor transgenic mice.
  • Accordingly, we examined emotional behaviors in autoimmune-prone cytokine B-cell-activating factor (BAFF) transgenic mice, a model of systemic lupus erythematosus, rheumatoid arthritis, and Sjögren's syndrome.
  • Mice were also tested for brain inflammation, stress-induced c-Fos expression, hippocampal progenitor cell proliferation, and hippocampal neurogenesis-dependent and neurogenesis-independent long-term potentiation (LTP).
  • Proliferation of newly formed neurons in the subgranular zone of adult hippocampus was significantly decreased in anxious BAFF transgenic mice that also showed impaired neurogenesis-dependent and neurogenesis-independent dentate gyrus LTP.
  • [MeSH-major] Anxiety. B-Cell Activating Factor / genetics. Emotions / physiology. Encephalitis. Gene Expression Regulation / genetics. Neurogenesis / genetics
  • [MeSH-minor] Age Factors. Animals. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Behavior, Animal / physiology. Cell Proliferation. Disease Models, Animal. Electric Stimulation / methods. Enzyme-Linked Immunosorbent Assay / methods. Exploratory Behavior / physiology. Glial Fibrillary Acidic Protein / metabolism. Hindlimb Suspension / methods. Hippocampus / cytology. Immunoglobulin G / blood. In Vitro Techniques. Long-Term Potentiation / genetics. Male. Maze Learning / physiology. Mice. Mice, Inbred C57BL. Mice, Transgenic. Microtubule-Associated Proteins / metabolism. Neurons / physiology. Neuropeptides / metabolism. Proto-Oncogene Proteins c-fos / metabolism. Stem Cells / physiology. Swimming / psychology

  • MedlinePlus Health Information. consumer health - Anxiety.
  • MedlinePlus Health Information. consumer health - Encephalitis.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20185032.001).
  • [ISSN] 1873-2402
  • [Journal-full-title] Biological psychiatry
  • [ISO-abbreviation] Biol. Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / B-Cell Activating Factor; 0 / CD68 antigen, human; 0 / Glial Fibrillary Acidic Protein; 0 / Immunoglobulin G; 0 / Microtubule-Associated Proteins; 0 / Neuropeptides; 0 / Proto-Oncogene Proteins c-fos; 0 / doublecortin protein
  •  go-up   go-down


70. Pommey S, Galipeau J: [The use of mesenchymal stromal cells in oncology and cell therapy]. Bull Cancer; 2006 Sep;93(9):901-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The use of mesenchymal stromal cells in oncology and cell therapy].
  • Amongst these, adult mesenchymal stromal cells (MSCs) possess particularly attracting properties, as they are easily expanded in vitro and possess the potential to differentiate into multiple cell lineages.
  • In Canada, the activities within the field of progenitor and stem cell therapeutics has been consolidated within the National Canadian Stem Cell Network which groups researchers, clinicians, engineers and ethicists, all dedicated to study this new promising pharmaceutical avenue.
  • [MeSH-major] Antigen-Presenting Cells / physiology. Mesenchymal Stem Cell Transplantation. Mesenchymal Stromal Cells / physiology. Neoplasms / therapy
  • [MeSH-minor] Adult. Bone Diseases / therapy. Cell Differentiation. Gene Transfer Techniques. Graft vs Host Disease / therapy. Hematopoiesis / physiology. Humans. Immune Tolerance. Immunosuppression / methods. Interleukin-2 / biosynthesis. Myocardial Infarction / therapy. Neurodegenerative Diseases / therapy. Stroke / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16980233.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Interleukin-2
  • [Number-of-references] 34
  •  go-up   go-down


71. Meuleman N, Vanhaelen G, Tondreau T, Lewalle P, Kwan J, Bennani J, Martiat P, Lagneaux L, Bron D: Reduced intensity conditioning haematopoietic stem cell transplantation with mesenchymal stromal cells infusion for the treatment of metachromatic leukodystrophy: a case report. Haematologica; 2008 Jan;93(1):e11-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced intensity conditioning haematopoietic stem cell transplantation with mesenchymal stromal cells infusion for the treatment of metachromatic leukodystrophy: a case report.
  • We report the case of a 23-year-old woman who presented with an adult form of metachromatic leukodystrophy (MLD) evolving over one year with a progressive neurological deterioration.
  • A non-myeloablative matched related haematopoietic stem cell transplantation (HSCT) with concomitant mesenchymal stromal cells (MSCs) infusion was performed.
  • This case report suggests the feasibility and the potential efficacy of reduced intensity conditioning (RIC) allogeneic HSCT combined with MSC infusion for patients with the adult form of MLD.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukodystrophy, Metachromatic / blood. Leukodystrophy, Metachromatic / therapy. Mesoderm / metabolism. Stromal Cells / cytology. Stromal Cells / pathology. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Bone Marrow Cells / cytology. Bone Marrow Transplantation. Cerebroside-Sulfatase / biosynthesis. Female. Graft Survival. Humans. Magnetic Resonance Imaging. Treatment Outcome


72. Huang WC, Kuo WC, Hsu SH, Cheng CH, Liu JC, Cheng H: Gait analysis of spinal cord injured rats after delivery of chondroitinase ABC and adult olfactory mucosa progenitor cell transplantation. Neurosci Lett; 2010 Mar 19;472(2):79-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gait analysis of spinal cord injured rats after delivery of chondroitinase ABC and adult olfactory mucosa progenitor cell transplantation.
  • In this article, we show that ChABC administration combining olfactory mucosa progenitor cell (OMPC) transplantation can promote axonal re-growth across the lesion site and enhance the consistency of stepping in spinally transected rats.
  • These OMPCs generated NG2(+) cell lineages after transplanting into the spinal cord parenchyma, and OMPCs were found to spread and migrate toward the lesion region of spinal cord.
  • [MeSH-major] Adult Stem Cells / transplantation. Chondroitin ABC Lyase / therapeutic use. Gait. Olfactory Mucosa / cytology. Spinal Cord Injuries / therapy
  • [MeSH-minor] Animals. Axons / physiology. Cell Proliferation. Rats. Spinal Cord / drug effects. Spinal Cord / pathology. Spinal Cord / ultrastructure

  • MedlinePlus Health Information. consumer health - Spinal Cord Injuries.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20079803.001).
  • [ISSN] 1872-7972
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 4.2.2.20 / Chondroitin ABC Lyase
  •  go-up   go-down


73. Sanz J, Montesinos P, Saavedra S, Lorenzo I, Senent L, Planelles D, Larrea L, Martín G, Palau J, Jarque I, Martínez J, de la Rubia J, Moscardó F, Martinez D, Gómez I, López M, Sanz MA, Sanz GF: Single-unit umbilical cord blood transplantation from unrelated donors in adult patients with chronic myelogenous leukemia. Biol Blood Marrow Transplant; 2010 Nov;16(11):1589-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-unit umbilical cord blood transplantation from unrelated donors in adult patients with chronic myelogenous leukemia.
  • Clinical studies focused on outcomes of umbilical cord blood transplantation (UCBT) for patients with chronic myelogenous leukemia (CML) in need of allogeneic stem cell transplantation and lacking an HLA-matched adult donor are limited.
  • The CI of acute graft-versus-host disease (GVHD) grade II-IV was 61%, that of acute GVHD grade III-IV was 39%, and that of chronic extensive GVHD was 60%.
  • [MeSH-major] Blood Donors. Cord Blood Stem Cell Transplantation / methods. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
  • [MeSH-minor] Adolescent. Adult. Cause of Death. Disease-Free Survival. Female. Graft Rejection / epidemiology. Graft Survival. Graft vs Host Disease / diagnosis. Graft vs Host Disease / epidemiology. Histocompatibility. Humans. Leukocyte Count. Male. Middle Aged. Neutrophils / cytology. Platelet Count. Recurrence. Retrospective Studies. Transplantation Chimera. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20553927.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Zinzani PL, Broccoli A, Stefoni V, Musuraca G, Abruzzese E, De Renzo A, Cantonetti M, Bacci F, Baccarani M, Pileri SA: Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. Cancer; 2010 Dec 15;116(24):5667-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients.
  • BACKGROUND: The development of gene expression profiling and tissue microarray techniques have provided more information about the heterogeneity of diffuse large B-cell lymphoma (DLBCL), enabling categorization of DLBCL patients into 3 prognostic groups according to cell origin (but independently from the International Prognostic Index [IPI] score): germinal center (GCB), activated B-cell (ABC), and not classified (NC) diffuse large B-cell lymphoma.
  • GCB patients received 6 courses of rituximab, cyclophophosphamide, doxorubicin, vinicristine, and prednisone (R-CHOP) chemotherapy, with a subsequent, autologous stem cell transplantation in case of partial response.
  • All ABC and NC-DLBCL patients received 6 R-CHOP cycles and autologous stem cell transplantation.
  • CONCLUSIONS: The autologous stem cell transplantation consolidation in the ABC&NC-DLBCL subtypes induced the same rate of complete response (and similar progression-free survival rate) compared with GCB-DLBCL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunohistochemistry. Immunophenotyping. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived / administration & dosage. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Humans. Male. Middle Aged. Prednisone / therapeutic use. Prognosis. Rituximab. Stem Cell Transplantation. Transplantation, Autologous. Treatment Failure. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • (PMID = 20737566.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


75. Fabre CC, Casal J, Lawrence PA: Mechanosensilla in the adult abdomen of Drosophila: engrailed and slit help to corral the peripheral sensory axons into segmental bundles. Development; 2010 Sep 01;137(17):2885-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanosensilla in the adult abdomen of Drosophila: engrailed and slit help to corral the peripheral sensory axons into segmental bundles.
  • The abdomen of adult Drosophila bears mechanosensory bristles with axons that connect directly to the CNS, each hemisegment contributing a separate nerve bundle.
  • [MeSH-minor] Abdomen / physiology. Adaptor Proteins, Signal Transducing / genetics. Adaptor Proteins, Signal Transducing / physiology. Animals. Animals, Genetically Modified. Axons / physiology. Gene Expression Regulation, Developmental. Genes, Insect. Hedgehog Proteins / genetics. Hedgehog Proteins / physiology. Models, Neurological. RNA Interference. Receptors, Cell Surface / genetics. Receptors, Cell Surface / physiology. Receptors, G-Protein-Coupled / genetics. Receptors, G-Protein-Coupled / physiology. Receptors, Immunologic / antagonists & inhibitors. Receptors, Immunologic / genetics. Receptors, Immunologic / physiology. Smoothened Receptor

  • COS Scholar Universe. author profiles.
  • FlyBase. FlyBase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 2007 Jan;134(1):55-64 [17164414.001]
  • [Cites] Cell. 2010 Feb 5;140(3):409-20 [20144763.001]
  • [Cites] Curr Biol. 2008 Mar 25;18(6):R238-41 [18364223.001]
  • [Cites] Neural Dev. 2008;3:12 [18668998.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(Database issue):D555-9 [18948289.001]
  • [Cites] Curr Opin Neurobiol. 2000 Feb;10(1):95-102 [10679444.001]
  • [Cites] Development. 2000 Sep;127(18):3971-80 [10952895.001]
  • [Cites] J Neurophysiol. 2000 Nov;84(5):2651-7 [11068006.001]
  • [Cites] Cell. 2002 Apr 19;109(2):229-41 [12007409.001]
  • [Cites] Development. 2002 Jun;129(11):2749-60 [12015301.001]
  • [Cites] Bioessays. 2003 Jan;25(1):32-8 [12508280.001]
  • [Cites] J Neurosci. 2003 Aug 27;23(21):7854-62 [12944515.001]
  • [Cites] Neuron. 2003 Sep 25;40(1):113-27 [14527437.001]
  • [Cites] Dev Biol. 1971 Oct;26(2):264-76 [5158535.001]
  • [Cites] Nat New Biol. 1973 Oct 24;245(147):251-3 [4518369.001]
  • [Cites] Ciba Found Symp. 1975;0(29):3-23 [1039914.001]
  • [Cites] J Embryol Exp Morphol. 1976 Feb;35(1):107-23 [1270974.001]
  • [Cites] J Embryol Exp Morphol. 1980 Dec;60:1-31 [6796636.001]
  • [Cites] Nature. 1981 Dec 3;294(5840):447-9 [6796894.001]
  • [Cites] J Embryol Exp Morphol. 1981 Dec;66:57-80 [6802923.001]
  • [Cites] Nature. 1985 Feb 21-27;313(6004):639-42 [3919303.001]
  • [Cites] Cell. 1988 Dec 23;55(6):1047-59 [3144436.001]
  • [Cites] Development. 1988 Jul;103(3):413-29 [3073078.001]
  • [Cites] Nature. 1989 Sep 14;341(6238):156-9 [2571087.001]
  • [Cites] Nature. 1989 Oct 12;341(6242):508-13 [2797178.001]
  • [Cites] Cell. 1989 Nov 17;59(4):751-65 [2582494.001]
  • [Cites] Nature. 1990 Mar 29;344(6265):431-5 [2320110.001]
  • [Cites] Curr Opin Genet Dev. 1991 Aug;1(2):230-5 [1822271.001]
  • [Cites] Dev Biol. 1996 Apr 10;175(1):24-36 [8608866.001]
  • [Cites] Science. 1996 Nov 15;274(5290):1123-33 [8895455.001]
  • [Cites] Development. 1997 Jun;124(11):2143-54 [9187141.001]
  • [Cites] Development. 1997 Jun;124(11):2155-65 [9187142.001]
  • [Cites] Development. 1997 Oct;124(20):4053-63 [9374402.001]
  • [Cites] Neuron. 1999 Feb;22(2):265-76 [10069333.001]
  • [Cites] Development. 1999 Jun;126(11):2431-9 [10226002.001]
  • [Cites] Development. 1999 Jun;126(11):2441-9 [10226003.001]
  • [Cites] Curr Biol. 1999 Jun 17;9(12):R432-5 [10375520.001]
  • [Cites] Development. 1999 Aug;126(16):3573-84 [10409503.001]
  • [Cites] Development. 1999 Oct;126(19):4201-12 [10477289.001]
  • [Cites] Development. 2004 Dec;131(23):5935-45 [15525663.001]
  • [Cites] Development. 2005 May;132(10):2251-62 [15857918.001]
  • [Cites] Dev Biol. 2005 Jun 15;282(2):411-21 [15950606.001]
  • [Cites] Nat Rev Neurosci. 2005 Jul;6(7):553-64 [15959467.001]
  • [Cites] Development. 2005 Aug;132(16):3643-56 [16033800.001]
  • [Cites] Nature. 2005 Nov 3;438(7064):94-8 [16267555.001]
  • [Cites] Neuron. 2006 Jan 19;49(2):215-28 [16423696.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:651-75 [17029581.001]
  • [Cites] Neuron. 2009 Nov 12;64(3):355-66 [19914184.001]
  • [Cites] Dev Biol. 2007 Jan 15;301(2):542-54 [17126316.001]
  • (PMID = 20667917.001).
  • [ISSN] 1477-9129
  • [Journal-full-title] Development (Cambridge, England)
  • [ISO-abbreviation] Development
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105184283; United Kingdom / Wellcome Trust / / WD078889MA; United Kingdom / Wellcome Trust / / WD086986MA
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Drosophila Proteins; 0 / Hedgehog Proteins; 0 / Homeodomain Proteins; 0 / Nerve Tissue Proteins; 0 / Receptors, Cell Surface; 0 / Receptors, G-Protein-Coupled; 0 / Receptors, Immunologic; 0 / Smoothened Receptor; 0 / Transcription Factors; 0 / dreadlocks protein, Drosophila; 0 / engrail protein, Drosophila; 0 / ptc protein, Drosophila; 0 / roundabout protein; 0 / sli protein, Drosophila; 0 / smoothened protein, Drosophila; 149291-21-4 / hedgehog protein, Drosophila
  • [Other-IDs] NLM/ PMC2938919
  •  go-up   go-down


76. Kan H, Kataoka-Shirasugi N, Amakawa T: Transduction pathways mediated by second messengers including cAMP in the sugar receptor cell of the blow fly: study by the whole cell clamp method. J Insect Physiol; 2008 Jun;54(6):1028-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transduction pathways mediated by second messengers including cAMP in the sugar receptor cell of the blow fly: study by the whole cell clamp method.
  • The whole cell clamp method was directly applied to the sensory receptor neurons isolated from the adult labellar hair of the blow fly Phormia regina to locate the signal transduction pathways mediated by second messengers.
  • First, the cAMP-mediated transduction pathway was examined to specify its location in the sugar receptor cell.
  • Sugar receptor cell was identified by recording inward current flow under the voltage clamp applying sucrose solution to the surface of the taste neurons.
  • When cyclic nucleotides, such as cGMP and cAMP, were introduced into the sugar receptor cell, inward current was observed (cGMP, 70pA; cAMP, 300pA at 350microM).
  • The sugar receptor cell was activated when it was injected with IP3 or Ca2+.
  • All the obtained results suggest that the cAMP-mediated signal transduction pathway plays a major role in the sugar receptor cell.
  • [MeSH-minor] Animals. Calcium / metabolism. Cyclic GMP / metabolism. Electrophysiology. Inositol 1,4,5-Trisphosphate / metabolism. Ions / metabolism. Patch-Clamp Techniques. Receptors, Cell Surface

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501923.001).
  • [ISSN] 0022-1910
  • [Journal-full-title] Journal of insect physiology
  • [ISO-abbreviation] J. Insect Physiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ions; 0 / Receptors, Cell Surface; 85166-31-0 / Inositol 1,4,5-Trisphosphate; E0399OZS9N / Cyclic AMP; H2D2X058MU / Cyclic GMP; SY7Q814VUP / Calcium
  •  go-up   go-down


77. Hao SP, Tsang NM, Chang KP, Chen CK, Huang SS: Treatment of squamous cell carcinoma of the retromolar trigone. Laryngoscope; 2006 Jun;116(6):916-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of squamous cell carcinoma of the retromolar trigone.
  • OBJECTIVES: Retromolar trigone (RMT) squamous cell carcinoma is uncommon but notorious for poor prognosis.
  • METHODS: Fifty patients with RMT squamous cell carcinoma were treated with surgery and/or radiation or chemoradiation therapy between July 1993 and June 2004 at Chang Gung Memorial Hospital, Taiwan.
  • CONCLUSIONS: RMT squamous cell carcinomas are aggressive tumors.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Mouth Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Head and Neck Neoplasms / secondary. Humans. Male. Mandibular Neoplasms / therapy. Maxillary Neoplasms / therapy. Middle Aged. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Laryngoscope. 2006 Oct;116(10):1940; author reply 1941 [17003700.001]
  • (PMID = 16735888.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Korganow AS, Knapp AM, Nehme-Schuster H, Soulas-Sprauel P, Poindron V, Pasquali JL, Martin T: Peripheral B cell abnormalities in patients with systemic lupus erythematosus in quiescent phase: decreased memory B cells and membrane CD19 expression. J Autoimmun; 2010 Jun;34(4):426-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral B cell abnormalities in patients with systemic lupus erythematosus in quiescent phase: decreased memory B cells and membrane CD19 expression.
  • Several B cell phenotype characteristics such as the expansion of activated populations, and of a newly identified memory compartment have already been reported.
  • B cell surface marker expression was determined by flow cytometry.
  • We analysed the main B cell sub-populations.
  • Above all, we describe a lower membrane expression of the CD19 protein on all B cells in every patient compared to controls.
  • [MeSH-minor] Adult. Antigens, CD45 / analysis. Case-Control Studies. Down-Regulation. Flow Cytometry. Humans. Membrane Proteins. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Systemic lupus erythematosus.
  • MedlinePlus Health Information. consumer health - Lupus.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19963348.001).
  • [ISSN] 1095-9157
  • [Journal-full-title] Journal of autoimmunity
  • [ISO-abbreviation] J. Autoimmun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Membrane Proteins; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


79. Clever JL, Sakai Y, Wang RA, Schneider DB: Inefficient skeletal muscle repair in inhibitor of differentiation knockout mice suggests a crucial role for BMP signaling during adult muscle regeneration. Am J Physiol Cell Physiol; 2010 May;298(5):C1087-99
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inefficient skeletal muscle repair in inhibitor of differentiation knockout mice suggests a crucial role for BMP signaling during adult muscle regeneration.
  • We have found that adult inhibitor of differentiation (Id)-mutant (Id1(+/-)Id3(-/-)) mice display delayed and reduced skeletal muscle regeneration after injury compared with either wild-type littermates or Id3-null mice.
  • The mouse myoblast-derived cell line C2C12 also expressed Id1, Id3, BMP receptor type II, and pSmad1/5/8 during proliferation, but all were reduced upon differentiation into myotubes.
  • Although we did not observe differences in the numbers of quiescent Pax7(+) satellite cells in adult uninjured hindlimb muscles, we did observe a significant reduction in the number of proliferating Pax7(+) cells in the Id-mutant mice after muscle injury compared with either wild-type or Id3-null mice.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Cell Biol. 2003 Aug;13(8):410-8 [12888293.001]
  • [Cites] Circulation. 2002 Oct 22;106(17):2263-70 [12390958.001]
  • [Cites] Physiol Rev. 2004 Jan;84(1):209-38 [14715915.001]
  • [Cites] EMBO J. 2004 Aug 18;23(16):3430-9 [15282552.001]
  • [Cites] J Mol Med (Berl). 2004 Sep;82(9):592-9 [15184986.001]
  • [Cites] Circ Res. 2004 Sep 17;95(6):557-9 [15321928.001]
  • [Cites] Science. 2004 Oct 8;306(5694):247-52 [15472070.001]
  • [Cites] Immunity. 2004 Oct;21(4):551-60 [15485632.001]
  • [Cites] Med Sci Sports Exerc. 1983;15(3):187-98 [6353126.001]
  • [Cites] Science. 1985 Nov 15;230(4727):758-66 [2414846.001]
  • [Cites] Genes Dev. 1992 Aug;6(8):1466-79 [1644289.001]
  • [Cites] J Cell Biol. 1994 Dec;127(6 Pt 1):1755-66 [7798324.001]
  • [Cites] Cell Growth Differ. 1996 Aug;7(8):1059-66 [8853902.001]
  • [Cites] Dev Dyn. 1997 Jan;208(1):92-106 [8989524.001]
  • [Cites] J Biol Chem. 1997 Aug 8;272(32):19785-93 [9242638.001]
  • [Cites] Genes Dev. 1998 Feb 1;12(3):290-303 [9450925.001]
  • [Cites] J Biol Chem. 1999 Jul 9;274(28):19838-45 [10391928.001]
  • [Cites] Mol Cell Biol. 1999 Sep;19(9):5969-80 [10454544.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):2014-20 [15345510.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2005 Feb;288(2):R345-53 [15637171.001]
  • [Cites] Circ Res. 2005 Sep 2;97(5):496-504 [16100039.001]
  • [Cites] Trends Immunol. 2005 Oct;26(10):535-42 [16109502.001]
  • [Cites] Circulation. 2005 Nov 1;112(18):2840-50 [16267257.001]
  • [Cites] J Cell Biol. 2006 Jan 2;172(1):103-13 [16391000.001]
  • [Cites] Science. 2006 Mar 31;311(5769):1880-5 [16574858.001]
  • [Cites] Nat Genet. 2006 May;38(5):525-7 [16642017.001]
  • [Cites] Genes Dev. 2006 Jul 1;20(13):1692-708 [16818602.001]
  • [Cites] Cancer Sci. 2006 Jul;97(7):568-74 [16827795.001]
  • [Cites] Ann N Y Acad Sci. 2006 Apr;1068:54-65 [16831905.001]
  • [Cites] J Cell Biol. 2006 Oct 9;175(1):99-110 [17015616.001]
  • [Cites] Exp Cell Res. 2006 Dec 10;312(20):4162-80 [17054947.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2007 Jan;292(1):H1-18 [16980351.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Feb;292(2):C953-67 [17020936.001]
  • [Cites] J Leukoc Biol. 2007 Mar;81(3):775-85 [17135576.001]
  • [Cites] Mol Biol Cell. 2007 Apr;18(4):1397-409 [17287398.001]
  • [Cites] Cell. 2007 Jun 1;129(5):999-1010 [17540178.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2007 Aug;293(2):R651-61 [17522124.001]
  • [Cites] Stem Cells. 2007 Aug;25(8):2006-16 [17495111.001]
  • [Cites] Immunology. 2007 Sep;122(1):73-9 [17472721.001]
  • [Cites] Dev Biol. 2007 Dec 1;312(1):13-28 [17961534.001]
  • [Cites] Cell Stem Cell. 2008 Jan 10;2(1):22-31 [18371418.001]
  • [Cites] Gene. 2008 May 15;414(1-2):95-105 [18372118.001]
  • [Cites] Curr Opin Genet Dev. 2008 Aug;18(4):330-6 [18625314.001]
  • [Cites] FASEB J. 2009 Feb;23(2):382-95 [18827026.001]
  • [Cites] J Bone Joint Surg Am. 2009 Mar 1;91(3):652-63 [19255227.001]
  • [Cites] J Biol Chem. 2009 Mar 13;284(11):7149-56 [18684712.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2008;73:323-31 [19329572.001]
  • [Cites] J Bone Miner Metab. 2009;27(4):402-11 [19252814.001]
  • [Cites] Mol Biol Cell. 2009 Jul;20(14):3170-7 [19458195.001]
  • [Cites] Nature. 2009 Jul 30;460(7255):627-31 [19554048.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17475-80 [19805133.001]
  • [Cites] Nature. 1999 Oct 14;401(6754):670-7 [10537105.001]
  • [Cites] Immunity. 2000 Jan;12(1):17-26 [10661402.001]
  • [Cites] J Bone Miner Res. 2000 Jun;15(6):1056-65 [10841174.001]
  • [Cites] Nat Rev Mol Cell Biol. 2000 Dec;1(3):169-78 [11252892.001]
  • [Cites] Nat Med. 2001 Nov;7(11):1194-201 [11689883.001]
  • [Cites] Differentiation. 2001 Oct;68(4-5):245-53 [11776477.001]
  • [Cites] Development. 2002 Jun;129(12):2987-95 [12050145.001]
  • [Cites] Sci STKE. 2002 Sep 24;2002(151):pe40 [12297674.001]
  • [Cites] Development. 2003 Dec;130(24):6089-99 [14597575.001]
  • (PMID = 20181926.001).
  • [ISSN] 1522-1563
  • [Journal-full-title] American journal of physiology. Cell physiology
  • [ISO-abbreviation] Am. J. Physiol., Cell Physiol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL075033; United States / NHLBI NIH HHS / HL / K08 HL076390
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Morphogenetic Proteins; 0 / Idb1 protein, mouse; 0 / Inhibitor of Differentiation Protein 1; 0 / Inhibitor of Differentiation Proteins; 135845-89-5 / Idb3 protein, mouse; EC 2.7.11.30 / Bone Morphogenetic Protein Receptors
  • [Other-IDs] NLM/ PMC2867391
  •  go-up   go-down


80. Doney K, Loken M, Bryant E, Smith A, Appelbaum F: Lack of utility of chimerism studies obtained 2-3 months after myeloablative hematopoietic cell transplantation for ALL. Bone Marrow Transplant; 2008 Aug;42(4):271-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of utility of chimerism studies obtained 2-3 months after myeloablative hematopoietic cell transplantation for ALL.
  • Lineage-specific chimerism studies are commonly obtained at several time points after nonmyeloablative hematopoietic cell transplantation to assess the tempo and degree of engraftment, and to monitor graft rejection.
  • In this study, a retrospective analysis was performed to assess the transplant outcome of 89 adult patients with ALL who had chimerism studies of unfractionated BM cells or peripheral blood subsets performed approximately 80 days after transplantation.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Chimera / immunology
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Myeloablative Agonists / therapeutic use. Transplantation Conditioning / methods

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2001 Feb;15(2):293-302 [11236950.001]
  • [Cites] Rev Immunogenet. 1999;1(2):255-64 [11253951.001]
  • [Cites] Biol Blood Marrow Transplant. 2001;7(9):473-85 [11669214.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Jul;9(7):472-81 [12869961.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1690-700 [16871276.001]
  • [Cites] Blood. 1989 May 1;73(6):1729-34 [2653461.001]
  • [Cites] Bone Marrow Transplant. 1993 Aug;12(2):149-54 [8401362.001]
  • [Cites] Blood. 1995 Apr 1;85(7):1954-63 [7703498.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3515-20 [9808542.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1696-705 [15117992.001]
  • (PMID = 18500370.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA018029; United States / NCI NIH HHS / CA / P01 CA018029-36
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Myeloablative Agonists
  • [Other-IDs] NLM/ NIHMS262856; NLM/ PMC3044127
  •  go-up   go-down


81. Puglisi MA, Giuliani L, Fierabracci A: Identification and characterization of a novel expandable adult stem/progenitor cell population in the human exocrine pancreas. J Endocrinol Invest; 2008 Jun;31(6):563-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and characterization of a novel expandable adult stem/progenitor cell population in the human exocrine pancreas.
  • It is a general opinion that tissue-specific stem cells are present in adult tissues but their specific properties remain elusive.
  • We obtained evidence that most freshly isolated spheroids, when co-cultured with the c-kit positive neuroblastoma cell line LAN 5, produced a c-kit positive progeny of cells larger in their cytoplasmic content than the original spheroid population, with elongated morphology resembling the neuronal phenotype.
  • We identified a novel predominant functional type of stem/progenitor cell within the human exocrine pancreas, able to generate insulin-producing cells and potentially non-pancreatic cells.
  • [MeSH-major] Cell Proliferation. Pancreas, Exocrine / cytology. Stem Cells / cytology
  • [MeSH-minor] Adult. Cell Differentiation / physiology. Cell Line, Tumor. Cells, Cultured. Coculture Techniques / methods. Humans

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocrinology. 2002 Aug;143(8):3152-61 [12130581.001]
  • [Cites] Stem Cells Dev. 2007 Feb;16(1):75-89 [17348806.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7999-8004 [10884429.001]
  • [Cites] Science. 2003 Jan 17;299(5605):363 [12532008.001]
  • [Cites] Nat Rev Genet. 2004 Nov;5(11):873-8 [15520797.001]
  • [Cites] Thyroid. 2002 Apr;12(4):281-6 [12034051.001]
  • [Cites] Adv Exp Med Biol. 1992;321:85-9; discussion 91-3 [1449085.001]
  • [Cites] Pancreas. 2005 Aug;31(2):108-18 [16024996.001]
  • [Cites] Int J Biochem Cell Biol. 2006;38(5-6):973-84 [16431150.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10733-8 [11535818.001]
  • [Cites] Diabetes Metab Res Rev. 2004 Jan-Feb;20(1):13-27 [14737742.001]
  • [Cites] Diabetes. 1993 Dec;42(12):1715-20 [8243817.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3024-9 [11867737.001]
  • [Cites] Nat Med. 2006 Mar;12 (3):310-6 [16491084.001]
  • [Cites] Lancet. 2004 Nov 20-26;364(9448):1872-83 [15555667.001]
  • [Cites] FEBS Lett. 2000 Jun 9;475(1):17-21 [10854849.001]
  • [Cites] Cell. 2000 Jan 7;100(1):157-68 [10647940.001]
  • [Cites] Nature. 2000 Oct 26;407(6807):963-70 [11069169.001]
  • [Cites] Science. 2004 Dec 24;306(5705):2261-4 [15564314.001]
  • [Cites] Hepatology. 2004 Jun;39(6):1499-507 [15185290.001]
  • [Cites] BMJ. 2002 Aug 17;325(7360):372-6 [12183311.001]
  • [Cites] J Neurosci. 1996 Feb 1;16(3):1091-100 [8558238.001]
  • [Cites] Diabetes. 1997 Jul;46(7):1120-3 [9200645.001]
  • [Cites] Diabetologia. 2006 Oct;49(10):2359-67 [16896938.001]
  • [Cites] J Endocrinol. 2004 Jul;182(1):113-22 [15225136.001]
  • [Cites] Cell. 2001 Jun 29;105(7):829-41 [11439179.001]
  • [Cites] Nature. 2004 May 6;429(6987):41-6 [15129273.001]
  • [Cites] J Cell Mol Med. 2005 Apr-Jun;9(2):331-44 [15963253.001]
  • [Cites] Pancreas. 1992;7(3):320-5 [1375749.001]
  • [Cites] Circ Res. 2004 Oct 29;95(9):911-21 [15472116.001]
  • [Cites] Diabetes. 2001 Mar;50(3):521-33 [11246871.001]
  • [Cites] Lab Invest. 2006 Feb;86(2):141-53 [16402034.001]
  • [Cites] Nature. 2003 Apr 17;422(6933):688-94 [12700753.001]
  • [Cites] N Engl J Med. 2003 Aug 7;349(6):570-82 [12904523.001]
  • [Cites] Methods Mol Biol. 2006;333:47-104 [16790847.001]
  • [Cites] Endocrinology. 2001 Nov;142(11):4956-68 [11606464.001]
  • [Cites] Pediatr Surg Int. 2007 Sep;23(9):837-9 [17619197.001]
  • [Cites] Circ Res. 2003 Apr 4;92(6):598-608 [12676811.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jun 21;294(4):906-11 [12061793.001]
  • [Cites] J Pathol. 2002 Jul;197(4):430-40 [12115860.001]
  • [Cites] JOP. 2003 Jul;4(4):137-45 [12853681.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Apr 16;316(4):1094-100 [15044097.001]
  • [Cites] Immunol Cell Biol. 1999 Dec;77(6):509-15 [10571671.001]
  • [Cites] Biochem Biophys Res Commun. 2002 May 3;293(2):670-4 [12054520.001]
  • [Cites] Cell. 2004 Mar 5;116(5):639-48 [15006347.001]
  • (PMID = 18591892.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


82. Li S, Juan YS, Kogan BA, Mannikarottu A, Leggett R, Schuler C, Levin RM: Effects of inosine on response to in vitro hypoxia in absence of substrate on bladder dysfunction in adult rats. Urology; 2009 Mar;73(3):661-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of inosine on response to in vitro hypoxia in absence of substrate on bladder dysfunction in adult rats.
  • OBJECTIVES: To investigate the effects of inosine on in vitro ischemia-reperfusion injury to urinary bladders in adult rats.
  • METHODS: A total of 18 adult male rats were used.
  • [MeSH-minor] Animals. Cell Hypoxia / drug effects. Electric Stimulation. In Vitro Techniques. Male. Rats. Rats, Sprague-Dawley

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19103461.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 5A614L51CT / Inosine
  •  go-up   go-down


83. Pan CC, Jong YJ, Chai CY, Huang SH, Chen YJ: Comparative genomic hybridization study of perivascular epithelioid cell tumor: molecular genetic evidence of perivascular epithelioid cell tumor as a distinctive neoplasm. Hum Pathol; 2006 May;37(5):606-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative genomic hybridization study of perivascular epithelioid cell tumor: molecular genetic evidence of perivascular epithelioid cell tumor as a distinctive neoplasm.
  • Perivascular epithelioid cell tumor (PEComa) is a neoplasm composed chiefly of HMB-45-positive epithelioid cells with clear to granular cytoplasm and a perivascular distribution.
  • [MeSH-minor] Adolescent. Adult. Angiomyolipoma / genetics. Angiomyolipoma / metabolism. Angiomyolipoma / pathology. Biomarkers, Tumor / metabolism. Child. DNA, Neoplasm / analysis. Female. Humans. Male. Middle Aged. Nucleic Acid Hybridization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16647959.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


84. Lin LM, Chen YK, Chen CH, Chen YW, Huang AH, Wang WC: VX2-induced rabbit buccal carcinoma: a potential cancer model for human buccal mucosa squamous cell carcinoma. Oral Oncol; 2009 Nov;45(11):e196-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VX2-induced rabbit buccal carcinoma: a potential cancer model for human buccal mucosa squamous cell carcinoma.
  • Of all oral squamous cell carcinomas (SCCs), those of the buccal mucosa are most associated with the poorest prognoses.
  • Ten adult male, New Zealand White outbred rabbits were randomly divided into two groups A (n=2) and B (n=8).
  • A 0.5 ml VX2 tumor cell suspension containing approximately 40 x 10(6) vital cells was injected intramuscularly into the right hind paw of the two rabbits of group A.
  • In conclusion, our findings indicated that VX2-induced rabbit buccal carcinomas could be a potential cancer model for human buccal mucosa squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Disease Models, Animal. Mouth Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19666238.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


85. Dengel DR, Ness KK, Glasser SP, Williamson EB, Baker KS, Gurney JG: Endothelial function in young adult survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2008 Jan;30(1):20-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endothelial function in young adult survivors of childhood acute lymphoblastic leukemia.
  • BACKGROUND: Adult survivors of childhood acute lymphoblastic leukemia (ALL) have an earlier than expected mortality from cardiovascular disease.
  • This study examined endothelial function in 75 young (age 30.2+/-7.1 y) adult survivors of childhood ALL who received chemotherapy without cranial radiation (n=25) or chemotherapy combined with cranial radiation (n=50) compared with a healthy control group of similar sex, age, and weight (n=59).
  • [MeSH-major] Brachial Artery / physiopathology. Endothelium, Vascular / physiopathology. Nitroglycerin / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology. Vasodilation / drug effects. Vasodilator Agents / administration & dosage
  • [MeSH-minor] Adult. Child. Child, Preschool. Cranial Irradiation. Female. Follow-Up Studies. Humans. Male. Sex Factors. Survivors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITROGLYCERIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18176175.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01-RR00400; United States / NCI NIH HHS / CA / R21-CA106778; United States / NCI NIH HHS / CA / U24-CA55727
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vasodilator Agents; G59M7S0WS3 / Nitroglycerin
  •  go-up   go-down


86. Bläuer M, Rovio PH, Ylikomi T, Heinonen PK: Vitamin D inhibits myometrial and leiomyoma cell proliferation in vitro. Fertil Steril; 2009 May;91(5):1919-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin D inhibits myometrial and leiomyoma cell proliferation in vitro.
  • SETTING: Cell biology research laboratory.
  • MAIN OUTCOME MEASURE(S): A colorimetric crystal violet assay to determine the effect of 1,25(OH)(2)D(3) and 25(OH)D(3) on cell growth.
  • The growth inhibition was concentration dependent; the highest concentration of 1,25(OH)(2)D(3) (100 nM) inhibited growth by 62% in both cell types.
  • A slight stimulation (<4%) of cell proliferation was observed with the lowest 25(OH)(2)D(3) concentrations.
  • When treated with either a 500 nM or 1000 nM concentration of the compound, the growth of both cell types fell to approximately 50% of that of the control cultures, and the level of inhibition with the latter concentration was statistically significant.
  • CONCLUSION(S): Both myometrial and leiomyoma cell growth in vitro was effectively inhibited by 1,25(OH)(2)D(3).
  • [MeSH-minor] Adult. Cell Proliferation / drug effects. Cells, Cultured. Dose-Response Relationship, Drug. Female. Humans. Immunohistochemistry. Middle Aged. Receptors, Calcitriol / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18423458.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Calcitriol; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; FXC9231JVH / Calcitriol; P6YZ13C99Q / Calcifediol
  •  go-up   go-down


87. Guillaume N, Alleaume C, Munfus D, Capiod JC, Touati G, Pautard B, Desablens B, Lefrère JJ, Gouilleux F, Lassoued K, Gouilleux-Gruart V: ZAP-70 tyrosine kinase is constitutively expressed and phosphorylated in B-lineage acute lymphoblastic leukemia cells. Haematologica; 2005 Jul;90(7):899-905
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ZAP-70 tyrosine kinase is constitutively expressed and phosphorylated in B-lineage acute lymphoblastic leukemia cells.
  • While little is known about ZAP-70 expression in normal human B cells, it has been reported that ZAP-70 is expressed in a subset of patients with chronic lymphocytic leukemia (CLL) with a poor prognosis.
  • In this study, we examined the expression and phosphorylation status of ZAP-70 in B-lineage acute lymphoblastic leukemia (Blin-ALL).
  • DESIGN AND METHODS: First, ZAP-70 protein expression was assessed by Western blotting and flow cytometry and ZAP-70 mRNA transcripts were analyzed by reverse transcription polymerase chain reaction (RT-PCR) on human precursor B cell lines.
  • RESULTS: ZAP-70 was constitutively expressed and phosphorylated on tyr319 in human precursor Blin-ALL cell lines as well as in primary B leukemic cells from all examined Blin-ALL patients with pro-B, pre-B and B phenotypes, but not in malignant myeloid cells.
  • Importantly, analysis of normal human bone marrow revealed expression of ZAP-70 transcripts only in the CD34+ cell fraction (either CD19-CD10- or CD19+CD10+) but not in the CD34- cell fraction (CD19+sIgM- pre-B cells or CD19+sIgM+ immature B cells).
  • INTERPRETATION AND CONCLUSIONS: ZAP-70 was found to be expressed in the CD34+ normal bone marrow compartment including earlier B-cell progenitors, but not in CD34- pre-B and immature B cells.
  • [MeSH-minor] Adult. Antigens, CD34 / biosynthesis. Bone Marrow / metabolism. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Phosphorylation

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2005 Jul;90(7):867 [15996917.001]
  • (PMID = 15996927.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD34; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase
  •  go-up   go-down


88. Martin P, Garcia-Cosio M, Santon A, Bellas C: Aberrant gene promoter methylation in plasma cell dyscrasias. Exp Mol Pathol; 2008 Jun;84(3):256-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant gene promoter methylation in plasma cell dyscrasias.
  • Our study demonstrates that methylation-mediated silencing is a frequent event in monoclonal gammopathies: 83% of MM, 46% of MGUS and 77% of plasmacytomas have at least one gene methylated, affecting different molecular pathways involved in cell cycle, DNA repair and apoptosis.
  • [MeSH-major] DNA Methylation. Leukemia, Plasma Cell / metabolism. Paraproteinemias / metabolism. Plasma Cells / metabolism. Plasmacytoma / metabolism. Promoter Regions, Genetic. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Genes, Tumor Suppressor. Humans. Male. Middle Aged. Multiple Myeloma / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18410922.001).
  • [ISSN] 1096-0945
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins
  •  go-up   go-down


89. Qiu JY, Zhu W, Zhang Y, Chen SS, Jiang B, Shi HL, Shi Y, He Q, Dang H, Wang DB, Lu DP: [Cytogenetic and clinical study of Philadelphia chromosome positive adult acute leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun;13(3):358-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytogenetic and clinical study of Philadelphia chromosome positive adult acute leukemia].
  • To explore the cytogenetics and related clinical characteristics of adult acute leukemia with Philadelphia chromosome positive (Ph(+)AL), MIC classification by morphology, immunology and cytogenetics was used to retrospectively study 79 patients with Ph(+)AL hospitalized in the Institute of Hematology, People Hospital in Beijing from October 1991 to September 2003.
  • The results showed that 6.9% cases were diagnosed as Ph(+)AL and classified into three subtypes: acute lymphoblastic leukemia (Ph(+)ALL) in 56 patients (18%), acute myeloid leukemia (Ph(+)AML) in 10 patients (1.2%) and mixed acute leukemia (Ph(+)MAL) in 13 patients.
  • B-cell antigen expression was found in 52 out of 56 patients with Ph(+)ALL.
  • Since the poor prognosis associated with this kind of AL, early diagnosis with MIC classification is a prerequisite to take more effective conditioning regimen and prospectively consideration of allogeneic stem cell transplantation to improve prognosis.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15972120.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


90. Lazar AJ, Fletcher CD: Primitive nonneural granular cell tumors of skin: clinicopathologic analysis of 13 cases. Am J Surg Pathol; 2005 Jul;29(7):927-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primitive nonneural granular cell tumors of skin: clinicopathologic analysis of 13 cases.
  • A rare subset of distinctive cutaneous nonneural granular cell tumors was described by LeBoit et al in 1991 and termed "primitive polypoid granular-cell tumor."
  • Herein, we report our experience with 13 similar, distinctive nonneural granular cell tumors.
  • [MeSH-major] Granular Cell Tumor / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Child. Female. Humans. Immunohistochemistry. Lymphatic Metastasis / pathology. Male. Middle Aged. Treatment Outcome